Developer / Researcher,Treatment vs. Vaccine,Product Category,Stage of Development,Anticipated Next Steps,Product Description,Clinical Trials for COVID-19,Funder,Published Results,Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only),FDA-Approved Indications,Sources,Date Last Updated
Roivant Sciences,Treatment,Antibodies,Clinical,Phase II study started in April 2020,"Gimsilumab, anti-granulocyte-macrophage colony stimulating factor monoclonal",NCT04351243,Unknown,Science (https://www.science.org/doi/10.1126/sciimmunol.abd0205),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/29/2021
Generation Bio/ Vir Biotechnology,Treatment,Antibodies,Clinical,Phase I trials for IN01 vaccine treatment in ex-COVID patients began Oct 2020,Non-viral gene therapy to produce monoclonal antibodies,NCT04537130,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/6/2020
Edesa Biotech/ Light Chain Bioscience (NovImmune),Treatment,Antibodies,Clinical,Phase I/II not yet recruiting July 2020,"EB05, non-steroidal anti-inflammatory molecule (sPLA2 inhibitor) ",Phase II trials FDA to begin Oct 2020; NCT04401475,Unknown,,ARDS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/20/2021
University of Hong Kong (BMS),Treatment,Antibodies,Clinical,Phase II study not yet recruiting,"Opdivo (nivolumab), PD-1 blocking antibody","NCT04356508, NCT04333914, NCT04405271, NCT04343144",Unknown,,,"FDA-approved since 2014, approved to treat melanoma and squamous non-small cell lung cancer",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/11/2020
Atreca / BeiGene / IGM Biosciences/ Singlomics,Treatment,Antibodies,Pre-clinical,Phase I/II trials to begin in Oct 2020,"Novel IgM and IgA antibodies 
", NCT04511949,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/8/2020
Ablexis / AlivaMab Discovery Services / Berkeley Lights Collaborate,Treatment,Antibodies,Pre-clinical,Unknown,Antibodies,,Unknown,,,"N/A
",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/26/2020
Implicit Bioscience,Treatment,Antibodies,Clinical,Phase II not yet recruiting July 2020; Expanded access protocols,"IC14, recombinant chimeric anti-CD14 monoclonal antibody","NCT04346277, NCT04391309",Unknown,,Acute Respiratory Distress Syndrome,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/7/2021
Numerous trials with Chinese research sponsors; Roche,Treatment,Antibodies,Clinical,Phase II/III studies recruiting April 2020,"Avastin (bevacizumab), vascular endothelial growth factor inhibitor","NCT04275414, NCT04305106, NCT04344782, EudraCT 2020-001246-18",Unknown,medRxiv (https://www.medrxiv.org/content/10.1101/2020.07.26.20159756v1.full.pdf),,"FDA-approved since 2004, approved to treat certain types of cancer",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/15/2021
Numerous trials with Chinese research sponsors,Treatment,Antibodies,Clinical,Phase II study not yet recruiting,PD-1 blocking antibody; Thymosin,"NCT04268537, ChiCTR2000030028 ",Unknown,"ScienceDirect (https://www.sciencedirect.com/science/article/pii/S1567576920336109), PubMed (https://pubmed.ncbi.nlm.nih.gov/33967626/), PubMed (https://pubmed.ncbi.nlm.nih.gov/34149679/)",,Unknown,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/28/2021
Centivax (Distributed Bio),Treatment,Antibodies,Pre-clinical,Released hamster study results in June 2020,Antibody,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/29/2020
Tang-Du Hospital,Treatment,Antibodies,Clinical,Results released July 2020; Phase II/III efficacy trials begin Oct 2020,"meplazumab, anti-CD147 antibody","NCT04275245, NCT04586153, NCT04586153",Chinese National Science and Technology Major Project,"medRxiv (https://doi.org/10.1101/2020.03.21.20040691), Nature (https://www.nature.com/articles/s41392-020-00426-x), Nature (https://www.nature.com/articles/s41392-021-00603-6), Nature (https://www.nature.com/articles/s41392-021-00760-8), PubMed (https://pubmed.ncbi.nlm.nih.gov/34829778/)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/29/2021
Regeneron/ NIAID,Treatment,Antibodies,Clinical,Joined Operation Warp Speed in July 2020; Phase III prevention trial with NIAID starts July 2020; Phase 2 stage of 1/2/3 treatment trial started July 2020; Phase 3 starts Aug 2020; compassionate use/expanded access requested Oct 2020. FDA Emergency Use Authorization Nov 2020.,Antibody combination REGN-COV2 (REGN10933+REGN10987) against the spike protein,"NCT04425629, NCT04426695, NCT04452318, NCT04617535, NCT04992273, NCT04852978",Biomedical Advanced Research and Development Authority (BARDA)/ US Department of Defense,"Science (https://science.sciencemag.org/content/370/6520/1110), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2035002), ACC (https://www.acc.org/latest-in-cardiology/clinical-trials/2020/12/23/16/01/regn-cov2), Practice Update (https://www.practiceupdate.com/content/regn-cov2-reduces-viral-load-in-covid-19-patients/111343), PubMed (https://pubmed.ncbi.nlm.nih.gov/33332778/), mdpi (https://www.mdpi.com/1999-4915/13/4/628), Regeneron (https://investor.regeneron.com/news-releases/news-release-details/phase-3-prevention-trial-showed-81-reduced-risk-symptomatic-sars), Regeneron (https://investor.regeneron.com/news-releases/news-release-details/phase-3-treatment-trial-recently-infected-asymptomatic-patients), Nature (https://www.nature.com/articles/s41577-021-00542-x), (https://assets.cureus.com/uploads/case_report/pdf/58662/20210527-11493-13a9a8r.pdf), Oxford Academic (https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofab335/6309029?searchresult=1), Springer (https://link.springer.com/article/10.1007/s15010-021-01657-y), Science Direct (https://www.sciencedirect.com/science/article/abs/pii/S0735675721006276), CDC (https://wwwnc.cdc.gov/eid/article/27/10/21-1538_article), ScienceDirect (https://www.sciencedirect.com/science/article/pii/S2590170221000261), Nature (https://www.nature.com/articles/s41423-021-00752-2), Lancet (https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00472-2/fulltext), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2109682), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2108163), MedRxiv (https://www.medrxiv.org/content/10.1101/2021.11.29.21266623v1), Science (https://www.science.org/doi/10.1126/science.abl6251), PubMed (https://pubmed.ncbi.nlm.nih.gov/34979607/), PubMed (https://pubmed.ncbi.nlm.nih.gov/35182277/), PubMed (https://pubmed.ncbi.nlm.nih.gov/35181864/)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/25/2022
AstraZeneca; ACCORD trial ,Treatment,Antibodies,Clinical,ACCORD Phase II trial to start May 2020,"MEDI3506, monoclonal antibody targeting interleukin 33",EudraCT 2020-001736-95 (ACCORD Trial),UK Government (ACCORD study),,Chronic Obstructive Pulmonary Diesase,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/15/2020
Ligand Pharmaceuticals,Treatment,Antibodies,Pre-clinical,Unknown,Antibodies (OmniChicken platform),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/13/2020
Kamada/ Kedrion Biopharma/ Columbia University Irving Medical Center,Treatment,Antibodies,Clinical,Individual Expanded Access use in Israel started in June 2020; Phase I/II in hospitalized patients in Israel to start 3Q 2020; Will talk to FDA in 3Q 2020; enrollment completed Sept 2020 in Israel,Antibodies from recovered COVID-19 patients,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/9/2020
Harbour BioMed / Erasmus MC / Utrecht University / Mount Sinai Health System / AbbVie,Treatment,Antibodies,Clinical,Phase I clinical trial initiated Dec 2020. Licensed for clinical development Dec 2020.,Antibody 47D11,NCT04644120,Unknown,"Science Advances (https://advances.sciencemag.org/content/early/2021/05/05/sciadv.abf5632.full), Science Advances (https://advances.sciencemag.org/content/7/23/eabf5632), Nature (https://www.nature.com/articles/s41586-021-03720-y), Nature (https://www.nature.com/articles/s41467-021-24874-3), Science (https://www.science.org/doi/10.1126/sciadv.abf5632)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/20/2021
Emergent BioSolutions/ National Institute of Allergy and Infectious Diseases (NIAID)/ Mt Sinai Health System/ ImmunoTek Bio Centers,Treatment,Antibodies,Clinical,Phase II trials begin ~August 2020,Polyclonal hyperimmune globulin (H-IG),NCT04661839,Biomedical Advanced Research and Development Authority (BARDA)/ US Department of Defense,,Same human hyperimmune platform as FDA-approved anthrax treatment (Anthrasil) and smallpox vaccine complications (VIGIV) were developed,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/25/2021
Eli Lilly/AbCellera (NIH Vaccines Research Center)/Takeda,Treatment,Antibodies,Clinical,"Phase II trial recruiting July 2020; Phase I started June 2020; results expected end of June 2020; FDA IND application for EUA requested Oct 2020; FDA EUA approved Nov 2020. Interim authorization from Health Canada Nov 2020. Doses purchased by US, Dec 2020.",LY-CoV555 antibody from recovered patients,"NCT04411628, NCT04427501, NCT04497987, NCT04441931",Defense Advanced Research Projects Agency/ Government of Canada (ISED Strategic Innovation Fund),"PubMed (https://www.nejm.org/doi/full/10.1056/NEJMoa2029849), Eli Lilly (https://investor.lilly.com/news-releases/news-release-details/lillys-neutralizing-antibody-bamlanivimab-ly-cov555-prevented), Eli Lilly (https://investor.lilly.com/news-releases/news-release-details/new-data-show-treatment-lillys-neutralizing-antibodies), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2033130?query=featured_infectious-disease), PRNewswire (https://www.prnewswire.com/news-releases/lilly-vir-biotechnology-and-gsk-announce-positive-topline-data-from-the-phase-2-blaze-4-trial-evaluating-bamlanivimab-with-vir-7831-in-low-risk-adults-with-covid-19-301257430.html), Cell (https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00071-9), mdpi (https://www.mdpi.com/1999-4915/13/4/628), Science Translational Medicine (https://stm.sciencemag.org/content/early/2021/04/05/scitranslmed.abf1906), Pharmaceutical Technology (https://www.pharmaceutical-technology.com/news/abcellera-abcl-bamlanivimab-potency/), Cureus (https://www.cureus.com/articles/58640-clinical-impact-of-the-early-use-of-monoclonal-antibody-ly-cov555-bamlanivimab-on-mortality-and-hospitalization-among-elderly-nursing-home-patients-a-multicenter-retrospective-study), Science Translational Medicine (https://stm.sciencemag.org/content/13/593/eabf1906), bioRxiv (https://www.biorxiv.org/content/10.1101/2021.05.18.444605v1.full), Nature (https://www.nature.com/articles/s41586-021-03720-y), Lancet (https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00189-0/fulltext), ScienceMag (https://stm.sciencemag.org/content/13/607/eabi4547), CDC (https://wwwnc.cdc.gov/eid/article/27/10/21-1509_article), PubMed (https://pubmed.ncbi.nlm.nih.gov/34835101/), Science (https://www.science.org/doi/10.1126/science.abl6251), BioRxiv (https://www.biorxiv.org/content/10.1101/2021.12.28.474369v1.full), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMc2119407)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/31/2022
"Chelsea and Westminster Hospital, Imperial College London",Treatment,Antibodies,Pre-clinical,Unknown,Antibodies,,UK Government,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/10/2020
GSK,Treatment,Antibodies,Clinical,Phase II recruiting June 2020,"otilimab, anti-granulocyte macrophase colony-stimulating factor (GM-CSF) antibody
",NCT04376684,Unknown,medRxiv (https://www.medrxiv.org/content/10.1101/2021.04.14.21255475v1),"To treat rheumatoid arthritis
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/1/2021
Eli Lilly,Treatment,Antibodies,Clinical,Phase II trial recruiting July 2020; Phase II study ended Oct 2020,"LY3127804, anti-Angiopoietin 2 (Ang2) antibody",NCT04342897,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/17/2020
Edesa Biotech / Light Chain Bioscience (NovImmune),Treatment,Antibodies,Pre-clinical,Unknown,"Monocloncal antibodies, CXC10 antagonist",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/28/2020
"CoVIg-19 Plasma Alliance (Takeda, CSL Behring, Biotest AG, Bio Products Laboratory, LFB, and Octapharma, ADMA Biologics, BioPharma Plasma, GC Pharma, Sanquin)/Gates Foundation/ NIAID/ Microsoft",Treatment,Antibodies,Pre-clinical,"Phase I trials start in summer 2020; To patients between December 2020 and December 2021; Phase III first patient enrolled, Oct 2020","Polyclonal hyperimmune globulin (H-IG), unbranded (TAK-888) ",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/14/2020
Multiple global research sponsors; Octapharma USA/ Sharp Memorial Hospital; Grifols,Treatment,Antibodies,Clinical,Octapharma released topline results from retrospective study July 2020; Phase III study ongoing July 2020; Phase 1/2 trials began ,Octagam; intravenous Immunoglobulin (IVIG),"NCT04261426, NCT04264858, NCT04350580, NCT04400058, NCT04411667, EudraCT 2020-002482-34, NCT04480424, NCT04432324, 2020-001890-56, NCT04521309",Unknown,"Open Forum Infectious Diseases (https://academic.oup.com/ofid/article/7/3/ofaa102/5810740), Business Wire (https://www.businesswire.com/news/home/20200603005130/en/Octapharma-USA-Extends-Funding-COVID-19-Study-Positive), medRxiv (https://doi.org/10.1101/2020.06.15.20132407), Business Wire (https://www.afp.com/en/news/1314/octapharma-reports-positive-data-octagamr-usage-critically-ill-covid-19-patients-202007150056321), medRxiv (https://doi.org/10.1101/2020.07.20.20157891), PubMed ( https://pubmed.ncbi.nlm.nih.gov/33236646/), Eureka (https://www.eurekalert.org/pub_releases/2020-12/ypr-opr112420.php)",,"FDA-approved since 2014, approved to treat chronic immune thrombocytopenic purpura (ITP)",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/23/2021
Abcore,Treatment,Antibodies,Pre-clinical,Unknown,"Single domain antibodies (sdAbs), engineered monoclonal antibody derived from camelids",,Unknown,Nature (https://www.nature.com/articles/s41467-020-18387-8),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/16/2021
Celltrion,Treatment,Antibodies,Pre-clinical,Unknown,Super-antibody or antibody cocktail to target potential mutations of SARS-CoV-2,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
University of Texas at Austin/ US National Institutes of Health/ Ghent University,Treatment,Antibodies,Pre-clinical,Unknown,Linked nanobody antibody,,Unknown,Nature (https://www.nature.com/articles/s41467-020-18174-5),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/28/2020
Xbiotech/ BioBridge Global,Treatment,Antibodies,Pre-clinical,Unknown,Antibodies from recovered COVID-19 patients,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/23/2020
Ligand Pharmaceuticals,Treatment,Antibodies,Pre-clinical,Unknown,Antibodies (OmniRat platform),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/23/2020
FairJourney Biologics / Iontas,Treatment,Antibodies,Pre-clinical,Unknown,Antibodies,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/28/2020
Assistance Publique - Hopitaux de Paris (Phase II); Alexion (Expanded Access Protocols),Treatment,Antibodies,Clinical,Phase II recruiting May 2020. Expanded access protocols,"Soliris (eculizumab), complement inhibitor","NCT04288713, NCT04346797, NCT04355494, EudraCT 2020-001246-18 ",Unknown,,,"FDA-approved since 2007, approved to treat Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis, and Neuromyelitis Optica Spectrum Disorder",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/15/2020
Celltrion,Treatment,Antibodies,Clinical,Phase I trial started July 2020; Celltrion beginning commercial production; Korean Ministry of Food and Drug Safety (MFDS)  IND application for a Phase II/III trials Sept 2020. Phase II enrollment complete Nov 2020. Approval for special-case use Dec 2020.,"CT-P59; Antibodies from recovered COVID-19 patients
","NCT04525079, NCT04602000, NCT04593641",The Korea Health Industry Development Institute,"Nature (https://www.nature.com/articles/s41467-020-20602-5), Korea BioMed (http://www.koreabiomed.com/news/articleView.html?idxno=10149), AFP (https://www.afp.com/en/news/1314/celltrion-group-announces-positive-top-line-efficacy-and-safety-data-global-phase-ii/iii-clinical-trial-covid-19-treatment-candidate-ct-p59-202101130053551), Business Wire (https://www.businesswire.com/news/home/20210429005477/en/Celltrion%E2%80%99s-anti-COVID-19-monoclonal-antibody-treatment-regdanvimab-CT-P59-demonstrates-neutralising-effect-against-the-South-African-variant-B.1.351), bioRxiv (https://www.biorxiv.org/content/10.1101/2021.04.27.441707v1), Business Wire (https://www.businesswire.com/news/home/20210517006051/en/Celltrion-Confirms-Neutralising-Potency-Against-Emerging-SARS-CoV-2-Variants-With-Anti-COVID-19-Monoclonal-Antibody-Treatment-regdanvimab-CT-P59), Science Direct (https://www.sciencedirect.com/science/article/pii/S0006291X21009311), Business Wire (https://www.businesswire.com/news/home/20210614005275/en/Celltrion-announces-positive-top-line-results-from-global-Phase-III-trial-of-regdanvimab-CT-P59-an-anti-COVID-19-monoclonal-antibody-treatment), BioRxiv (https://www.biorxiv.org/content/10.1101/2021.07.08.451696v1), Business Wire (https://www.businesswire.com/news/home/20210715006147/en/%C2%A0Celltrion%E2%80%99s-Monoclonal-Antibody-Treatment-for-COVID-19-regdanvimab-CT-P59-Demonstrates-Strong-Neutralising-Activity-Against-Delta-Variant), bioRxiv (https://www.biorxiv.org/content/10.1101/2021.07.23.453472v1.full.pdf), Europe PMC (https://europepmc.org/article/PMC/PMC8380488), Biochemical and Biophysical Research Communications (https://www.sciencedirect.com/science/article/pii/S0006291X21013176), BioRxiv (https://www.biorxiv.org/content/10.1101/2021.12.04.471200v1.full)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/11/2022
Alexion Pharmaceuticals. TACTIC-R trial ,Treatment,Antibodies,Clinical,Phase III recruiting July 2020,"Ultomiris (ravulizumab-cwvz), complement inhibitor","NCT04369469, EudraCT 2020-001354-22 (TACTIC-R), ISRCTN11188345, NCT04390464",Unknown,Science Direct (https://www.sciencedirect.com/science/article/pii/S0085253820314186),,"FDA-approved since 2018, aprpoved to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/26/2021
GigaGen,Treatment,Antibodies,Pre-clinical,Phase I trial expected to start early 2021,"rCIG (recombinant anti-coronavirus 19 hyperimmune gammaglobulin), polyclonal antibodies",,Unknown,,,N//A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/28/2020
Vir Biotechnology/ GSK/ Samsung/ WuXi Biologics/ Biogen,Treatment,Antibodies,Clinical,Start Phase II ~July-September 2020; Dosing began Aug 2020; Phase 3 results and endpoints expect Jan 2021; Submitted for EUA May 2021,"Sotrovimab (VIR-7831 and VIR-7832), antibodies from recovered SARS patients","NCT04545060, NCT04913675, NCT04913675, NCT04779879, NCT04746183, NCT04988152",Unknown,"Cell (https://www.cell.com/cell/fulltext/S0092-8674(20)31234-4), Pipeline Review (https://pipelinereview.com/index.php/2021031277633/Antibodies/Vir-Biotechnology-and-GSK-announce-VIR-7831-reduces-hospitalisation-and-risk-of-death-in-early-treatment-of-adults-with-COVID-19.html), bioRxiv (https://www.biorxiv.org/content/10.1101/2021.03.09.434607v1), GSK (https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-announce-vir-7831-reduces-hospitalisation-and-risk-of-death-in-early-treatment-of-adults-with-covid-19/), PRNewswire (https://www.prnewswire.com/news-releases/lilly-vir-biotechnology-and-gsk-announce-positive-topline-data-from-the-phase-2-blaze-4-trial-evaluating-bamlanivimab-with-vir-7831-in-low-risk-adults-with-covid-19-301257430.html), Globe Newswire (http://www.globenewswire.com/news-release/2021/04/05/2204240/0/en/Vir-Biotechnology-Announces-New-Preclinical-Research-Demonstrating-VIR-7831-Maintains-Neutralizing-Activity-Against-the-SARS-CoV-2-California-Variant.html), bioRxiv (https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1), Vir Biotechnology (https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-announces-new-research-demonstrating-novel), bioRxiv (https://www.biorxiv.org/content/10.1101/2021.03.09.434607v2), bioRxiv (https://www.biorxiv.org/content/10.1101/2021.03.09.434607v7), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2107934), MDPI (https://www.mdpi.com/2076-393X/9/12/1376/htm), BioRxiv (https://www.biorxiv.org/content/10.1101/2021.03.09.434607v9.full.pdf)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/6/2022
Swedish Orphan Biovitrum,Treatment,Antibodies,Clinical,Phase II/III recruiting April 2020,"Gamifant (emapalumab), anti-interferon gamma antibody",NCT04324021,Unknown,,,"FDA-approved since 2018, approved to treat primary hemophagocytic lymphohistiocytosis",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/18/2022
ImmunoPrecise Antibodies,Treatment,Antibodies,Pre-clinical,"Lead candidates identified June 2020, pre-clinical studies to start summer 2020",Monoclonal antibody cocktail,,North Dakota Bioscience Innovation Grant,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/16/2021
CytoDyn,Treatment,Antibodies,Clinical,Phase II trial interim results released July 2020; Phase II trial (mild/moderate) met enrollment in June 2020; Phase IIb/III trial (severe) ongoing June 2020; individual expanded access. Enrollment completed Dec 2020.,"leronlimab (PRO 140), a CCR5 antagonist","NCT04343651, NCT04347239, NCT04901676, NCT04901676, NCT040901689",Unknown,"CytoDyn (https://www.cytodyn.com/newsroom/press-releases/detail/415/southern-california-patients-treated-with-leronlimab-for), CytoDyn (https://www.cytodyn.com/newsroom/press-releases/detail/453/update---impressive-results-from-cytodyns-phase-2), CytoDyn (https://www.cytodyn.com/newsroom/press-releases/detail/512/cytodyns-leronlimab-decreased-mortality-at-14-days-by), CytoDyn (https://www.cytodyn.com/newsroom/press-releases/detail/513/cytodyn-files-new-protocol-with-u-s-fda-for-4-doses-of), CytoDyn (https://www.cytodyn.com/newsroom/press-releases/detail/515/first-compassionate-special-permit-csp-patient-in), Globe Newswire (https://www.globenewswire.com/fr/news-release/2021/06/21/2250254/0/en/CytoDyn-Inc-Announces-Positive-Preliminary-Results-of-Unblinded-Data-from-Long-Haulers-Trial-Showing-Greater-Improvement-in-Leronlimab-Group-over-Placebo-in-18-of-24-Symptoms.html), Globe Newswire(https://www.globenewswire.com/en/news-release/2021/06/21/2250254/19782/en/CytoDyn-Inc-Announces-Positive-Preliminary-Results-of-Unblinded-Data-from-Long-Haulers-Trial-Showing-Greater-Improvement-in-Leronlimab-Group-over-Placebo-in-18-of-24-Symptoms.html)","Treatment of HIV/AIDS, Graft versus Host Disease, Non-Alcoholic Steatohepatitis, and numerous cancers",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/27/2021
Grifols,Treatment,Antibodies,Clinical,Phase I trial expected to start July 2020,Polyclonal hyperimmune globulin (H-IG),"NCT04432324, NCT04480424",Biomedical Advanced Research and Development Authority (BARDA),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/30/2020
"EUSA Pharma / The Papa Giovanni XXII Hospital; University Hospital, Ghent; Fundacion Clinic per a la Recerca Biomédica",Treatment,Antibodies,Clinical,FDA approves Phase III trial in hospitalized patients in July 2020,"Sylvant (siltuximab), interleukin-6 targeted monoclonal","NCT04322188, NCT04330638, NCT04329650, EudraCT 2020-001500-41, EudraCT 2020-001854-23, EudraCT 2020-001413-20, NCT04486521",Unknown,"EUSA Pharma (https://www.eusapharma.com/news/interim-analysis-data-for-siltuximab-treated-covid-19-patients-from-the-sisco-study/), medRxiv (https://doi.org/10.1101/2020.04.01.20048561), medRxiv (https://doi.org/10.1101/2020.04.23.20076612), JACI (https://www.jaci-inpractice.org/article/S2213-2198(20)30611-5/fulltext)",,"FDA-approved since 2014, approved to treat multicentric Castleman disease",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/18/2020
Vanderbilt Vaccine Center/ AstraZeneca/ IDBiologics,Treatment,Antibodies,Clinical,Phase I trial began August 2020; Phase III trial began Nov 2020,"Evusheld, Combo of two antibodies tixagevimab and cilgavimab (formerly known as AZD7442)","NCT04507256, NCT04625725",Defense Advanced Research Projects Agency/ Dolly Parton/ Biomedical Advanced Research and Development Authority (BARDA),"Astrazeneca (https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-azd7442-storm-chaser-trial.html), Medrxiv (https://www.medrxiv.org/content/10.1101/2021.08.30.21262666v1), JAMA (https://jamanetwork.com/journals/jama/fullarticle/2785781), Lancet (https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00180-1/fulltext)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/15/2022
Numerous trials with global research sponsors; Roche; REMAP-CAP; RECOVERY,Treatment,Antibodies,Clinical,"Initial Roche studies could be completed May or June 2020; Phase II open-label study in Italy active (April 2020), Phase III Roche global trial enrolling May 2020, Roche trial (+ remdesivir) to start June 2020; ; Phase 3 EMPACTA Trial (tocilizumab + placebo); HEPMAB (Actemra + Heparin) Phase 3 trials begin Oct 2020","Actemra (tocilizumab), interleukin-6 receptor antagonist","NCT04317092, NCT04320615, NCT04310228, ChiCTR2000030894, NCT04306705, ChiCTR2000030442, ChiCTR2000029765, NCT04322773, NCT04345445, NCT04331795, NCT04332094, NCT04346355, NCT04359667, NCT04332913, NCT04335071, NCT04356937, NCT04361032, NCT04315480, NCT04339712, NCT04333914, NCT04361552, NCT04330638, NCT04331808, NCT02735707, NCT04349410, NCT04363736, NCT04372186, NCT04363853, EudraCT 2020-001754-21, EudraCT 2020-001500-41, EudraCT 2020-001246-18, EudraCT 2020-001039-29, EudraCT 2015-002340-14 (REMAP-CAP), EudraCT 2020-001854-23, NCT04381936 (RECOVERY), NCT04409262, EudraCT 2020-001903-17, NCT04560205, NCT04577534, NCT04600141",Biomedical Advanced Research and Development Authority (BARDA),"ChinaXiv (http://www.chinaxiv.org/abs/202003.00026), medRxiv (https://doi.org/10.1101/2020.04.20.20061861), medRxiv (https://doi.org/10.1101/2020.04.23.20076612), Assistance Publique Hopitaux De Paris (https://www.aphp.fr/contenu/le-tocilizumab-ameliore-significativement-le-pronostic-des-patients-avec-pneumonie-covid), PNAS (https://www.pnas.org/content/early/2020/04/27/2005615117#T1), medRxiv (https://doi.org/10.1101/2020.05.01.20078360), medRxiv (https://doi.org/10.1101/2020.05.07.20094599), medRxiv (https://doi.org/10.1101/2020.05.14.20099234), medRxiv (https://doi.org/10.1101/2020.05.13.20100404), medRxiv (https://doi.org/10.1101/2020.05.13.20100081), medRxiv (https://doi.org/10.1101/2020.05.21.20109207), medRxiv (https://doi.org/10.1101/2020.06.12.20122374), medRxiv (https://doi.org/10.1101/2020.06.08.20125245), medRxiv (https://doi.org/10.1101/2020.06.06.20122341), medRxiv (https://doi.org/10.1101/2020.06.05.20122622), medRxiv (https://doi.org/10.1101/2020.06.03.20121558), medRxiv (https://doi.org/10.1101/2020.06.05.20113738), medRxiv (https://doi.org/10.1101/2020.06.01.20119149), medRxiv (https://doi.org/10.1101/2020.05.29.20117358), medRxiv (https://doi.org/10.1101/2020.06.13.20130088), Italian Medicines Agency (https://www.aifa.gov.it/web/guest/-/covid-19-studio-randomizzato-italiano-nessun-beneficio-dal-tocilizumab), medRxiv (https://doi.org/10.1101/2020.06.15.20132407), EClinicalMed (https://doi.org/10.1016/j.eclinm.2020.100418), Lancet Rheumatology (https://doi.org/10.1016/S2665-9913(20)30173-9), medRxiv (https://doi.org/10.1101/2020.06.23.20134072), medRxiv (https://doi.org/10.1101/2020.06.22.20133413), medRxiv (https://doi.org/10.1101/2020.06.24.20134288), The Lancet (https://doi.org/10.1016/j.eclinm.2020.100410), The Lancet (https://doi.org/10.1016/j.eclinm.2020.100459), medRxiv (https://doi.org/10.1101/2020.07.20.20157503), medRxiv (https://doi.org/10.1101/2020.07.13.20149328), medRxiv (https://doi.org/10.1101/2020.07.10.20150938), medRxiv (https://doi.org/10.1101/2020.07.10.20150680), The Lancet (https://doi.org/10.1016/S2665-9913(20)30277-0), The Lancet (https://doi.org/10.1016/S2665-9913(20)30313-1), JAMA (doi:10.1001/jamainternmed.2020.6252), MedRxiv (https://www.medrxiv.org/content/10.1101/2020.10.21.20210203v1.full.pdf), EyeWire News (https://eyewire.news/articles/roches-actemra-reduces-deaths-in-hospitalized-covid-19-patients-study/), Science Direct (https://www.sciencedirect.com/science/article/pii/S1201971221002496)",,"FDA-approved since 2010; approved to treat various type of arthritis, including rheumatoid arthritis and cytokine release syndrome",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/5/2022
Tsinghua University/ Third People's Hospital of Shenzhen/ Brii Biosciences,Treatment,Antibodies,Clinical,Phase I trials recruiting July 2020,"BRII-196 and BRII-198, Antibodies from recovered COVID-19 patients","NCT04479644, NCT04479631, NCT04691180, NCT04770467",Unknown,"medRvxiv (https://www.medrxiv.org/content/10.1101/2021.07.21.21260964v1), medrxiv (https://www.medrxiv.org/content/10.1101/2021.07.21.21260964v2), Lancet (https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00751-9/fulltext), Nature (https://www.nature.com/articles/s41392-022-00880-9), Lancet (https://www.sciencedirect.com/science/article/pii/S0140673622001635)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/10/2022
Public Health England (Stuart Dowall),Treatment,Antibodies,Pre-clinical,Unknown,Purified ovine immunoglobulin from immunized sheep,,UK Government,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/23/2020
Grifols,Treatment,Antibodies,Pre-clinical,Unknown,Antibodies from recovered COVID-19 patients,,Biomedical Advanced Research and Development Authority (BARDA),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Humanigen Inc./ Catalent Biologics,Treatment,Antibodies,Clinical,Data on first clinical use released June 2020; Phase III trial ongoing July 2020/Dosing began Oct 2020,"lenzilumab, anti-granulocyte-macrophage colony stimulating factor antibody",NCT04351152,Unknown,"medRxiv (https://doi.org/10.1101/2020.06.08.20125369), Science Direct (https://www.sciencedirect.com/science/article/pii/S0025619620309897), BusinessWire (https://www.businesswire.com/news/home/20210329005301/en/Humanigen-Reports-Positive-Phase-3-Topline-Results-Demonstrating-That-Lenzilumab%E2%84%A2-Improves-Survival-Without-Need-for-Mechanical-Ventilation-in-Hospitalized-Patients-With-COVID-19), Evaluate (https://www.evaluate.com/vantage/articles/news/trial-results/humanigen-claims-covid-19-win-lenzilumab), (https://www.pharmaceutical-technology.com/news/humanigen-lenzilumab-improves-survival/), Humanigen (https://www.biospace.com/article/releases/humanigen-reports-positive-data-with-lenzilumab-in-the-zuma-19-car-t-phase-1b-study-in-dlbcl-and-plans-to-initiate-a-potential-registrational-study/), Businesswire (https://www.businesswire.com/news/home/20210505005845/en/Humanigen-Announces-Publication-of-Results-From-Phase-3-Randomized-Double-Blind-Placebo-Controlled-Study-Demonstrating-the-Efficacy-and-Safety-of-Lenzilumab%E2%84%A2-in-Hospitalized-COVID-19-Patients), Lancet (https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00494-X/fulltext), LWW (https://journals.lww.com/ccmjournal/_layouts/15/oaks.journals/downloadpdf.aspx?an=00003246-202201001-00025&pdfToken=aHR0cHM6Ly9wZGZzLmpvdXJuYWxzLmx3dy5jb20vY2Ntam91cm5hbC8yMDIyLzAxMDAxLzIzX19MRU5aSUxVTUFCX0lOX0hPU1BJVEFMSVpFRC4yNS5wZGY/dG9rZW49bWV0aG9kfEV4cGlyZUFic29sdXRlO3NvdXJjZXxKb3VybmFsczt0dGx8MTY0MDYyMzMyMTcwNjtwYXlsb2FkfG1ZOEQzdTFUQ0NzTnZQNUU0MjFKWUs2TjZYSUNEYW14Qnl5WXBhTnprN0ZLalRhYTFZejIyTWl2a0hacWpHUDRrZFMydjBKNzZXR0FuSEFDSDY5czIxQ3NrME9wUWkzWWJqRU1kU296MlVoVnliRnFReEE3bEt3U1VsQTUwMnpRWnI5NlRRUndoVmxvY0VwL3NKNTg2YVZiY0JGbGx0S05Lbyt0YnVNZkw3M2hpUHFKbGl1ZHFzMTdjSGVMY0xiVi9DcWpsUDNJTzBqR0hsSFF0SldjSUNEZEF5R0pNbnBpNlJsYkVKYVJoZUdlaDV6NXV2cXozRkxIZ1BLVlhKemQ5aWExL01KSlVGbVdwMWI5dXJ2MTNFaUZGN3hXbm00TjhmTHdDU2Zrd1EwPTtoYXNofC9rTW0vRmhjNFkwNzh4TUlvdEtMOUE9PQ==), MedRxiv (https://www.medrxiv.org/content/10.1101/2021.12.30.21267140v1), Medrxiv (https://www.medrxiv.org/content/10.1101/2022.02.11.22270859v1)",Prevent cytokine storm with CAR-T cancer therapy; prevention/treatment of acute graft versus host disease; chronic myelomonocytic leukemia; eosinophilic asthma,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/19/2022
"Novartis; other research sponsors
",Treatment,Antibodies,Clinical,Novartis Phase III to start and trial top-line results expected late summer 2020,"Ilaris (canakinumab), interleukin-1beta blocker","NCT04348448, NCT04362813, NCT04365153, EudraCT 2020-001854-23, NCT04476706",Unknown,The Lancet Rheumatology (https://doi.org/10.1016/S2665-9913(20)30167-3),,"FDA-approved since 2009, approved to treat periodic fever syndromes and systemic juvenile idiopathic arthritis",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/10/2020
Junshi Biosciences/ Eli Lilly/ Lonza/ AbCellera,Treatment,Antibodies,Clinical,Phase I trial in China started June 2020; trial in US to start 2H 2020   ,JS016 antibody candidate (LY-CoV016 + LY-CoV555) ,"NCT04441918, NCT04780321, NCT04931238",Unknown,"BioSpace (https://www.biospace.com/article/releases/new-data-show-treatment-with-etesevimab-js016-and-bamlanivimab-together-reduced-risk-of-covid-19-hospitalizations-and-death-by-70-percent/), Eli Lilly (https://investor.lilly.com/news-releases/news-release-details/lillys-bamlanivimab-and-etesevimab-together-reduced), mdpi (https://www.mdpi.com/1999-4915/13/4/628), PubMed (https://pubmed.ncbi.nlm.nih.gov/33972256/), ASM Journals (https://journals.asm.org/doi/abs/10.1128/AAC.02045-21?af=R), PubMed (https://pubmed.ncbi.nlm.nih.gov/35191746/)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/1/2022
Medicago / Laval University's Infectious Disease Research Centre,Treatment,Antibodies,Pre-clinical,Unknown,Antibodies,,Canadian Institutes for Health Research (CIHR),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
I-Mab Biopharma,Treatment,Antibodies,Clinical,"Interim Phase I/II data released June 2020, part 2 of the study to start June 2020","TJM2 (TJ003234), anti-granulocyte-macrophage colony stimulating factor antibody",NCT04341116,Unknown,PR Newswire (https://www.prnewswire.com/news-releases/i-mab-reports-interim-results-from-part-1-study-for-anti-gm-csf-antibody-tjm2-to-treat-covid-19-patients-with--cytokine-release-syndrome-301066451.html),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/2/2020
Innovent Biologics,Treatment,Antibodies,Pre-clinical,Unknown,Antibodies from recovered COVID-19 patients,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Sorrento Therapeutics/ Mount Sinai Health System/ Columbia University ,Treatment,Antibodies,Clinical,Start Phase II trial Q3 2020; FDA cleared for Phase I for COVI-GUARD (STI-1499) in hospitalized COVID-19 patients. WITHDRAWN.,COVI-SHIELD/COVI-TRACE/COVI-GUARD antibody cocktail that binds to three different epitopes,NCT04454398,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/18/2022
AstraZeneca / US Army Medical Research Institute of Infectious Diseases (USAMRIID)/ University of Maryland School of Medicine,Treatment,Antibodies,Pre-clinical,Phase I/II trials begin in summer 2020,"Antibodies targeting the S protein from convalescent serum, humanized mice, and phage display", ,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/6/2020
Costa Rican Social Security Fund (CCSS)/ The University of Costa Rica (UCR)/ Clodomiro Picado Institute,Treatment,Antibodies,Pre-clinical,Unknown,Antibodies from recovered COVID-19 patients,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/2/2020
Prellis Biologics,Treatment,Antibodies,Pre-clinical,Phase I trial could begin as early as Sept 2020,Antibodies,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/14/2020
Emergent BioSolutions,Treatment,Antibodies,Pre-clinical,Phase II trials begin ~August 2020,Horse plasma product (COVID-EIG),,Unknown,,Same equine hyperimmune platform as FDA-approved botulism anti-toxin (BAT) is produced,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
CSL Behring / SAb Biotherapeutics,Treatment,Antibodies,Phase III,"Phase I starts early summer 2020; Dosing to start August 2020. Data from the phase II study demonstrated the safety and efficacy of SAB-185, January 2022.","SAB-185, Polyclonal hyperimmune globulin (H-IG)","NCT04468958, NCT04469179",Biomedical Advanced Research and Development Authority (BARDA)/ US Department of Defense,"BioRxiv (https://www.biorxiv.org/content/10.1101/2021.02.06.430072v1.full.pdf), T and F (https://www.tandfonline.com/doi/abs/10.1080/21645515.2021.1940652?journalCode=khvi20&), Business Wire (https://www.businesswire.com/news/home/20210708005448/en/SAB-Biotherapeutics-Announces-Publication-of-Preclinical-Data-Demonstrating-SAB-185-Effectively-Neutralizes-SARS-CoV-2-Variants), BioRxiv (https://www.biorxiv.org/content/10.1101/2021.08.09.454215v1), Sab Therapeutics (https://www.sabbiotherapeutics.com/2021/08/11/sab-biotherapeutics-announces-nonclinical-data-demonstrating-sab-185-potently-neutralizes-delta-and-lambda-sars-cov-2-variants/)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/29/2022
CSL Behring Australia,Treatment,Antibodies,Clinical,Phase I/II trials began June 2020; recruitment began Aug 2020,"COVID-19 Immunoglobulin, plasma derived
",NCT04548557,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/27/2020
Amgen/ Adaptive Biotechnologies,Treatment,Antibodies,Pre-clinical,Phase I trial expected to start ~October 2020,Antibodies from recovered COVID-19 patients,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/17/2020
InflaRx N.V.,Treatment,Antibodies,Clinical,Phase III trial to begin fall 2020; Phase II topline results reported June 2020,"IFX-1, anti-C5a antibody","NCT04333420, EudraCT 2020-001335-28",Unknown,inflaRx (https://www.inflarx.de/Home/Investors/Press-Releases/06-2020-InflaRx-Reports-Encouraging-Topline-Results-from-the-Exploratory-Phase-II-Part-of-the-Adaptive-Randomized-Phase-II-III-Trial-of-IFX-1-in-COVID-19.html),"To treat various inflammatory conditions including hidradenitis suppurativa, ANCA-associated vasculitis, and pyoderma gangraenosum",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/9/2021
"Multiple global research sponsors, including: New York State Department of Health; Johns Hopkins University; the Feinstein Institutes; RECOVERY trial",Treatment,Antibodies,Clinical,"Mayo Clinic and Houston Methodist trial results published June 2020, other trials ongoing; FDA issued Emergency Use Authorization on Aug 23, 2020",Convalescent plasma (blood plasma from recovered patients),"Many expanded access, observational, patient registry, plasma collection, prevention, and other studies listed in clinicaltrials.gov, including: NCT04321421, NCT04292340, NCT04316728, NCT04338360, NCT04345289, NCT04349410, NCT04346589, NCT04333251, NCT04361253, NCT04323800, NCT04359810, NCT04362176, NCT04354831, NCT04360486, NCT04321421, NCT04441424, NCT04460547, NCT04381936 (RECOVERY), EudraCT 2020-001310-38, ISRCTN67000769 (REMAP-CAP), EudraCT 2015-002340-14 (REMAP-CAP), NCT02735707 (MJM Bonten), NCT04467151, NCT04442191, NCT04456413, NCT04438057, NCT04377568, NCT04418518, NCT04408040, NCT04397757, NCT04390503, NCT04385199, NCT04421404, NCT04364737, NCT04344535, NCT04355767, NCT04373460, NCT04377672, NCT04528368, NCT04497324","Bloomberg Philantropies and the State of Maryland (to Johns Hopkins University)/ Biomedical Advanced Research and Development Authority (BARDA) (to Mayo Clinic), Department of Defense (DoD)","medRxiv (https://doi.org/10.1101/2020.03.16.20036145), JAMA (https://jamanetwork.com/journals/jama/fullarticle/2763983), medRxiv (https://doi.org/10.1101/2020.04.07.20056440), JAMA Network (https://jamanetwork.com/journals/jama/fullarticle/2763982), medRxiv (https://doi.org/10.1101/2020.05.08.20095471), medRxiv (https://doi.org/10.1101/2020.05.12.20099879), Amer J Pathology (https://ajp.amjpathol.org/article/S0002-9440(20)30257-1/fulltext), medRxiv (https://doi.org/10.1101/2020.05.20.20102236), JAMA (https://jamanetwork.com/journals/jama/article-abstract/2766943), JAMA (https://jamanetwork.com/journals/jama/fullarticle/2766940), (https://ctmirror.org/2020/05/17/cautious-enthusiasm-for-plasma-treatment-in-covid-19-cases/), (https://www.wbtv.com/2020/06/11/novant-health-physicians-say-convalescent-plasma-therapy-is-showing-promising-results-covid-fight/), medRxiv (https://doi.org/10.1101/2020.06.05.20122820), medRxiv (https://doi.org/10.1101/2020.05.26.20113373), medRxiv (https://doi.org/10.1101/2020.05.21.20109512), medRxiv (https://doi.org/10.1101/2020.06.15.20132407), medRxiv (https://doi.org/10.1101/2020.06.19.20135830), medRxiv (https://doi.org/10.1101/2020.06.21.20132944), Mayo Clinic Proceedings (https://mayoclinicproceedings.org/pb/assets/raw/Health%20Advance/journals/jmcp/jmcp_ft95_6_8.pdf), medRxiv (https://doi.org/10.1101/2020.06.24.20121905), medRxiv (https://doi.org/10.1101/2020.07.20.20156398), medRxiv (https://doi.org/10.1101/2020.07.14.20144469), medRxiv (https://doi.org/10.1101/2020.07.01.20139857), medRxiv (doi: https://doi.org/10.1101/2020.09.03.20187252), BMJ (https://www.bmj.com/content/371/bmj.m3939), PlosOne (https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0243967), Medscape (https://www.medscape.com/viewarticle/945396), Penn State (https://news.psu.edu/story/648997/2021/02/25/research/study-finds-short-window-donating-convalescent-plasma-covid-19), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2031893), The Lancet (https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00060-4/fulltext), Nature (https://www.nature.com/articles/s41586-021-03471-w), The Lancet (https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00030-6/fulltext), PubMed (https://pubmed.ncbi.nlm.nih.gov/33784412/), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMc2104747), Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01064-3/fulltext), Science Daily (https://www.sciencedaily.com/releases/2021/05/210517125003.htm), The Lancet (https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00130-0/fulltext), Eureka Alert (https://www.eurekalert.org/pub_releases/2021-06/jhub-dic060721.php), Medscape (https://www.medscape.com/viewarticle/953463), AJMC (https://www.ajmc.com/view/convalescent-plasma-treatment-increases-odds-of-covid-19-survival-among-patients-with-hematologic-malignancies), PubMed (https://pubmed.ncbi.nlm.nih.gov/34227110/), medRxiv (https://www.medrxiv.org/content/10.1101/2021.06.29.21259427v1), medRxiv (https://www.medrxiv.org/content/10.1101/2021.07.13.21260414v1), Academic (https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofab385/6323155), Cureus (https://www.cureus.com/articles/58961-effectiveness-of-covid-19-convalescent-plasma-infusion-within-48-hours-of-hospitalization-with-sars-cov-2-infection), PLOS (https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0254453), Nature (https://www.nature.com/articles/s41467-021-25113-5), NIH (https://www.nih.gov/news-events/news-releases/nih-study-shows-no-significant-benefit-convalescent-plasma-covid-19-outpatients-early-symptoms), PubMed (https://pubmed.ncbi.nlm.nih.gov/34464352/), Pubmed (https://pubmed.ncbi.nlm.nih.gov/34579646/), PubMed (https://pubmed.ncbi.nlm.nih.gov/34695186/), Wiley (https://onlinelibrary.wiley.com/doi/10.1002/rcr2.858), PubMed (•	https://pubmed.ncbi.nlm.nih.gov/34767118/ ), Nature (https://www.nature.com/articles/s41467-021-27201-y), PubMed (https://pubmed.ncbi.nlm.nih.gov/34836825/), Pub Med (https://pubmed.ncbi.nlm.nih.gov/34814946/)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/29/2021
Cerecor,Treatment,Antibodies,Clinical,"Phase II recruiting July 2020, top line data expected 4Q 2020","CERC-002, anti-LIGHT monoclonal antibody",NCT04412057,Unknown,"mSphere (https://msphere.asm.org/content/5/4/e00699-20), Cerecor (https://ir.cerecor.com/press-releases/detail/114/cerecor-announces-successful-proof-of-concept-data-for), Cerecor (https://ir.cerecor.com/press-releases/detail/121/cerecor-announces-cerc-002-significantly-reduced), Cerecor (https://ir.cerecor.com/press-releases/detail/123/cerecor-reports-2020-financial-results-and-provides), medRxiv (https://www.medrxiv.org/content/10.1101/2021.04.03.21254748v1), JCI (https://www.jci.org/articles/view/153173)",Pediatric Crohn's Disease,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/20/2022
Celltrion/ University of Oxford/ University Hospitals Birmingham (CATALYST trial),Treatment,Antibodies,Clinical,Phase II trial to start in June 2020,"Remsima (infliximab), anti-TNF antibody","NCT04425538, NCT04734678, EudraCT 2020-001684-89, NCT04922827",Unknown,"Gut (https://gut.bmj.com/content/early/2021/03/19/gutjnl-2021-324388), medRxiv (https://www.medrxiv.org/content/10.1101/2021.03.25.21254335v2)",,"FDA-approved since 2016, approved to treat various autoimmune diseases",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/7/2021
Tychan/ SingHealth Investigational Medicine Unit,Treatment,Antibodies,Clinical,Phase I started June 2020; efficacy data expected 3Q 2020. Phase III began Dec 2020.,"TY027, monoclonal antibody targeting SARS-CoV-2","NCT04429529, NCT04649515",,Business Wire (https://www.businesswire.com/news/home/20201210006232/en/Tychan-to-Start-COVID-19-Phase-3-Clinical-Trial-For-Novel-Monoclonal-Antibody-TY027),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/17/2020
IGY Life Sciences/ MMS Holdings/ Canadian Government National Microbiology Lab,Treatment,Antibodies,Pre-clinical,,"IgY-110, anti-CoV-2 antibody (nasal spary application)",,,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
"Alliance - Proteona/ NMI/ NUS Enterprise/10X Genomics/ NovogeneAIT/ Twist Bioscience/ University Hospitals/ German Cancer Research Center, Heidelberg University Hospital/ Tübingen University Hospital/ NovogeneAIT",Treatment,Antibodies,Pre-clinical,,Antibody for immunocompromised patients,,,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/20/2020
Virna Therapeutics/ University of Toronto,Treatment,Antibodies,Pre-clinical,,Neutralizing antibodies,,,medRxiv (https://www.biorxiv.org/content/10.1101/2020.06.05.137349v2.full.pdf),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/9/2020
Kiniksa/ Cleveland Clinic/ Ospedale San Raffaele,Treatment,Antibodies,Clinical,Phase II trial recruiting June 2020; Case reports published June 2020,"mavrilimumab, anti-granulocyte-macrophase colony-stimunlating factor receptor-alpha monoclonal antibody","NCT04399980, NCT04397497, NCT04447469, NCT04463004, EudraCT 2020-001795-15",,"Lancet (https://doi.org/10.1016/S2665-9913(20)30170-3), Global Newswire (https://www.globenewswire.com/news-release/2020/12/22/2149342/0/en/Kiniksa-Announces-Data-from-U-S-Investigator-Initiated-Study-of-Mavrilimumab-in-Severe-COVID-19-Pneumonia-and-Hyperinflammation.html), PubMed (https://pubmed.ncbi.nlm.nih.gov/33754144/), Kiniksa (https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-announces-positive-results-mavrilimumab-phase-2-trial), Rheumatology Advisor (https://www.rheumatologyadvisor.com/home/conference-highlights/eular-2021/mavrilimumab-mechanical-ventilation-severe-covid19-pneumonia-hyperinflammation/)",Giant cell arteritis (GCA); rheumatoid arthritis; large B-cell lymphoma (with Yescarta),N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/5/2022
Staidson/ Pivotal,Treatment,Antibodies,Clinical,Phase II/III trials began Jul 2020,"BDB-001, monocloncal anti-C5a antibody","EudraCT 2020-001671-32, NCT04449588, NCT05075304",Unknown,The Lancet (DOI:https://doi.org/10.1016/S2665-9913(20)30341-6),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/19/2021
Tiziana Life Sciences,Treatment,Antibodies,Pre-clinical,Plan to initiate Phase I in Q1 2021,"TZLS-501, an anti-interleukin-6 receptor monoclonal antibody (inhalation technology in development-Foralumab anti-CD3 monoclonal antibody)",,Unknown,Tiziana Life Sciences (https://www.tizianalifesciences.com/news-item?s=2021-02-02-tiziana-reports-positive-data-from-the-clinical-study-of-nasal-administration-with-foralumab-its-proprietary-fully-human-anti-cd3-monoclonal-antibody-in-covid-19-patients-in-brazil),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/23/2021
BioCon/Equilium ,Treatment,Antibodies,Clinical,Phase II open label trial began July 2020; FDA IND cleared for Phase III trial (EQUINOX) Phase 3will not be initiated at this time Nov 2020.,"itolizumab, anti-CD6 IgG1 monoclonal antibody","NCT04475588, NCT04605926",Unknown,"Future Medicine (https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.futuremedicine.com%2Fdoi%2F10.2217%2Fimt-2020-0235%3Furl_ver%3DZ39.88-2003%26rfr_id%3Dori%253Arid%253Acrossref.org%26rfr_dat%3Dcr_pub%2B%2B0pubmed%26&data=04%7C01%7C%7Cd68092f3d7bd43b7d48b08d8b27c59b9%7C4f96fd4653b94a44b39518a615885a42%7C0%7C0%7C637455594453655348%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=dNYLQZZbd5W69pZyM0zQyNvRK5cuvlSOSXus3VPZ3Qs%3D&reserved=0), NCT04475588 (https://clinicaltrials.gov/ct2/show/results/NCT04475588?term=itolizumab&cond=COVID-19&draw=2&rank=1)",Graft versus host disease; Lupus nephritis; Plaque psoriasis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/8/2021
GC Pharma/ Korea National Institute of Health,Treatment,Antibodies,Clinical,Phase II/III to start in July 2020,"GC5131A, plasma derived therapy",,Unknown,Korea Herald (http://www.koreaherald.com/view.php?ud=20210120000827),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/11/2021
Cologne University Hospital/ German Center for Infection Research/ Boehringer Ingelheim,Treatment,Antibodies,Pre-clinical,Clinical trials to start in 2020,"BI 767551, Antibodies from recovered COVID-19 patients","NCT04631705, NCT04822701, NCT04894474, EudraCT 2020-005588, EudraCT 2021-000408-39-29, ",Unknown,mBio (https://mbio.asm.org/content/11/5/e02590-20),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/30/2021
Rosalind Franklin Institute/ Oxford University/ Diamond Light Source/ Public Health England,Treatment,Antibodies,Pre-clinical,,Nanobodies from Llamas,,Unknown,"BioRxiv (https://www.biorxiv.org/content/10.1101/2021.02.15.431198v1), Science (https://science.sciencemag.org/content/370/6523/1473), News Medical (https://www.news-medical.net/news/20210310/Research-demonstrates-multivalent-nanobodies-overcome-SARS-CoV-2-variant-mutations.aspx), Rosalind Franklin Institute (https://www.rfi.ac.uk/covid-19-update/), Rosalind Franklin Institute (https://www.rfi.ac.uk/engineered-llama-antibodies-neutralise-covid-19-virus/), PNAS (https://www.pnas.org/content/118/19/e2101918118.short?rss=1), Nature (https://www.nature.com/articles/s41586-021-03676-z)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/22/2021
Adagio Therapeutics,Treatment,Antibodies,Pre-clinical,Phase I trial expected to start by early 2021,"Antibodies binding to a piece of the spike protein found on multiple coronaviruses including SARS-CoV-2, ADG20","NCT04805671, NCT04859517",Unknown,"Adagio Therapeutics (https://adagiotx.com/wp-content/uploads/2021/01/adagio_Science-FINAL-1.25.2021-.pdf), Cell (https://www.cell.com/cell/fulltext/S0092-8674(21)00428-1), Lancet (https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00379-9/fulltext)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/17/2021
Fab'entech,Treatment,Antibodies,Pre-clinical,Expected to begin Phase I/II trials in early 2021,Polyclonal antibodies,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/20/2021
Columbia University Irving Medical Center; IAVI and Serum  Research Institute India,Treatment,Antibodies,Pre-clinical,Recruiting Dec 2020.,Mix of neutralizing antibodies isolated from recovered COVID-19 patients,"NCT04606407, NCT04390503, NCT04359810",Unknown,"Nature (https://www.nature.com/articles/s41586-020-2852-1), JCI (https://www.jci.org/articles/view/150646)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/25/2021
Eli Lilly/ Sanford Burnham Prebys Medical Discovery Institute,Treatment,Antibodies,Pre-clinical,Unknown,Neutralizing antibodies,,Unknown,"Science Daily (https://www.sciencedaily.com/releases/2021/01/210112125206.htm), Cell Reports (https://secure.jbs.elsevierhealth.com/action/getSharedSiteSession?redirect=https%3A%2F%2Fwww.cell.com%2Fcell-reports%2Fpdf%2FS2211-1247%2820%2931617-X.pdf&rc=0)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/13/2021
"Various global research sponsors/ Grifols/ Emergent BioSolutions, CSL Behring and Takeda",Treatment,Antibodies,Clinical,Phase II trial recruiting July 2020; Phase III trials began Oct 2020 (ITAC Trial),"Prolastin, alpha-1 anti-trypsin antibody","EudraCT  2020-001391-15, NCT04385836, NCT04495101, NCT04547140, NCT04799873","National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH)",,,"FDA approved since at least 2005, approved for chronic replacement therapy of individuals having congenital deficiency of alpha-antitrypsin deficinecy with emphysema",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/17/2021
Immunome,Treatment,Antibodies,Pre-clinical,Unknown,Novel biosynthetic convalescent plasma (BCP),,Department of Defense (DoD),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/17/2021
Grifols,Treatment,Antibodies,Clinical,Trial to begin Feb 2021 in Spain,"Gamunex-C, contains anti-SARS-CoV-2 polyclonal antibodies from recovered plasma donors",NCT04480424,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/9/2021
  Corvus Pharmaceuticals and Lewis Katz School of Medicine at Temple University,Treatment,Antibodies,Clinical,Phase III trial begun in hospitalized patients,CPI-006,"NCT04734873, NCT04464395",Unknown,Corvus Pharma (https://corvuspharma.gcs-web.com/news-releases/news-release-details/corvus-completes-enrollment-phase-1-study-cpi-006-patients-covid),,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/23/2021
Bristol Myers Squibb,Treatment,Antibodies,Clinical,Developer has intiated and begun to enroll participants in proof-of-concept trial with hospitalized COVID patients,abatacept (Orencia),"NCT04472494, NCT04477642",Operation Warp Speed,PubMed (https://pubmed.ncbi.nlm.nih.gov/34075090/),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/7/2021
CSL Behring,Treatment,Antibodies,Clinical,"A Phase II for safety and efficacy has completed enrollment, results expected Q2 2021",CSL312 (garadacimab),NCT04409509,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/5/2021
I-SPY COVID trial (Omeros),Treatment,Antibodies,Clinical,Data from compassionate use in Italy released Nov 2020; first patient dosed in I-SPY trial March 2021,Narsoplimab (IV administered mannan-binding lectin-associated serine protease-2 (MASP-2) pathway inhibitor IgG4 antibody),NCT04488081,Quantum Leap Healthcare Collaborative,Omeros (https://investor.omeros.com/news-releases/news-release-details/omeros-announces-preliminary-results-additional-critically-ill),hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) (pending FDA approval),N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/20/2021
"SCORE consortium (universities of Aix-Marseille, Leuven, Utrecht, Bern, and Lubeck), the Helmholtz Centre for Infection Research, and Janssen Pharmaceutica NV",Treatment,Antivirals,Pre-clinical,Unknown,Antiviral drug combinations,,EU Commission (Horizon 2020 Program),,,Unknown,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"Beech Tree Labs
",Treatment,Antivirals,Clinical,"FDA cleared trial July 2020, trial to start July/Aug 2020 with results available Fall 2020; Has been used in 36 patients anecdotally; Phase II trial started August 2020","BTL-tml
",NCT04522830,Unknown,,"Treatment of herpes virus infections
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/28/2020
BioCryst Pharmaceuticals,Treatment,Antivirals,Clinical,Phase Ib recruiting May 2020,galidesivir,NCT03891420,National Institute of Allergy and Infectious Diseases (NIAID),"PubMed (https://pubmed.ncbi.nlm.nih.gov/33765239/), PubMed (https://pubmed.ncbi.nlm.nih.gov/33818031/), Environmental Science and Pollution Research (https://link.springer.com/article/10.1007/s11356-021-16096-3), Antiviral Research (https://www.sciencedirect.com/science/article/abs/pii/S0166354221001704)",Treatment of yellow fever,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/21/2021
Acer Therapeutics / US National Center for Advancing Translational Sciences (NCATS),Treatment,Antivirals,Clinical,Phase II/III to start in Q3 2020,"emetine hydrochloride
",,Unknown,,"To treat viral hepatitis and varicella-virus
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/18/2020
Ansun Biopharma/ Renmin Hospital of Wuhan University,Treatment,Antivirals,Clinical,Individual patient expanded access finding released in May 2020; Phase II/III started enrolling in May 2020,"DAS181, recombinant sialidase (nebulized)
","NCT03808922, NCT04354389, NCT04298060, NCT04324489, NCT04460547",Unknown,"PR Newswire (https://www.prnewswire.com/news-releases/ansun-biopharma-announces-positive-results-from-investigator-initiated-trial-of-novel-covid-19-treatment-301033871.html), Nature (•	https://www.nature.com/articles/s41392-021-00809-8), LWW (https://journals.lww.com/pidj/_layouts/15/oaks.journals/downloadpdf.aspx?an=00006454-202106000-00021&pdfToken=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)",Treatment of lower respiratory tract parainfluenza virus infections and severe influenza infections,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/28/2021
"Fujifilm Toyama Chemical/ Zhejiang Hisun Pharmaceuticals/ numerous trials with global research sponsors/ Brigham and Women's Hospital, Massachusetts General Hospital, and the University of Massachusetts Medical School/ Glenmark Pharmaceuticals",Treatment,Antivirals,Clinical,Fuijfilm trial initial results released July 2020; Glenmark Phase III trial in India top-line results released July 2020 (Glenmark),"Favilavir/ Favipiravir/ T-705/ Avigan, licensed in Japan to treat influenza","NCT04303299, NCT04310228, ChiCTR2000029548, ChiCTR2000029496, ChiCTR2000029544, ChiCTR2000030254, NCT04336904, NCT04333589, NCT04345419, EudraCT 2020-001435-27, NCT04356495, NCT04425460, NCT04373733, EudraCT 2020-001449-38, EudraCT 2020-001528-32, EudraCT 2020-001904-41, NCT04468087, NCT04376814, NCT04411433, NCT04445467, NCT04402203, NCT04392973, NCT04349241, NCT04346628, NCT04448119, NCT04475991, NCT04358549, NCT04434248, NCT04359615, NCT04464408, NCT04387760, NCT04474457, NCT04351295, EudraCT Number: 2020-002106-68,  NCT04529499, NCT04558463",Life Arc (FLARE trial; PIONEER trial),"medRxiv (https://doi.org/10.1101/2020.03.17.20037432), medRxiv (https://doi.org/10.1101/2020.04.21.20066761), Kyodo News (https://english.kyodonews.net/news/2020/05/fce701d4d88d-antiflu-avigan-not-showing-apparent-efficacy-in-coronavirus-treatment.html), Critical Care (https://doi.org/10.1186/s13054-020-03078-z), (https://asia.nikkei.com/Business/Pharmaceuticals/Fujifilm-s-Avigan-inconclusive-as-COVID-19-treatment-in-Japan-trial), Glenmark (http://www.glenmarkpharma.com/sites/default/files/Glenmark-Announces-Top-Line-Results-From-Phase-3%20-Clinical.pdf), medRxiv (https://doi.org/10.1101/2020.06.24.20133249), PNAS (https://doi.org/10.1073/pnas.2014441117), ACS Pub (https://pubs.acs.org/doi/10.1021/acscentsci.0c01242#), ScienceDirect (https://www.sciencedirect.com/science/article/pii/S1201971220322736), PubMed (https://pubmed.ncbi.nlm.nih.gov/33765239/), PubMed (https://pubmed.ncbi.nlm.nih.gov/34276987/), Annals of Medicine and Surgery (https://www.sciencedirect.com/science/article/pii/S2049080121005100), Environmental Science and Pollution Research (https://link.springer.com/article/10.1007/s11356-021-16096-3), DovePress (https://www.dovepress.com/effectiveness-and-safety-of-favipiravir-compared-to-hydroxychloroquine-peer-reviewed-fulltext-article-IJGM), Indian Journal of Ophthalmology (https://journals.lww.com/ijo/_layouts/15/oaks.journals/downloadpdf.aspx?an=02223307-202112000-00089&pdfToken=aHR0cHM6Ly9wZGZzLmpvdXJuYWxzLmx3dy5jb20vaWpvLzIwMjEvMTIwMDAvQW5fdW51c3VhbF9jYXNlX29mX2JsdWlzaF9kaXNjb2xvcmF0aW9uX29mX3RoZS44OS5wZGY/dG9rZW49bWV0aG9kfEV4cGlyZUFic29sdXRlO3NvdXJjZXxKb3VybmFsczt0dGx8MTYzOTU1NzU2NzEyMztwYXlsb2FkfG1ZOEQzdTFUQ0NzTnZQNUU0MjFKWUs2TjZYSUNEYW14Qnl5WXBhTnprN0ZLalRhYTFZejIyTWl2a0hacWpHUDRrZFMydjBKNzZXR0FuSEFDSDY5czIxQ3NrME9wUWkzWWJqRU1kU296MlVoVnliRnFReEE3bEt3U1VsQTUwMnpRWnI5NlRRUndoVmxvY0VwL3NKNTg2YVZiY0JGbGx0S05Lbyt0YnVNZkw3M2hpUHFKbGl1ZHFzMTdjSGVMY0xiVi9DcWpsUDNJTzBqR0hsSFF0SldjSUNEZEF5R0pNbnBpNlJsYkVKYVJoZUdlaDV6NXV2cXozRkxIZ1BLVlhKemRvVUxObUMwN1pRQnpRQVpaemJUNWwwNWxnZUdGOFg4a2FHa1U0Qk1tMmlVPTtoYXNofFBseDRNRUgzaDJxcXY1QjdJQ0pxeHc9PQ==), Nature (https://www.nature.com/articles/s41598-022-05835-2), BMC (https://journals.lww.com/ijo/_layouts/15/oaks.journals/downloadpdf.aspx?an=02223307-202112000-00089&pdfToken=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)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/1/2021
ViralClear Pharmaceuticals,Treatment,Antivirals,Pre-clinical,Unknown,"Vicromax, broad spectrum antiviral",,Unknown,,,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/6/2020
ISR Immune System Regulation,Treatment,Antivirals,Pre-clinical,Unknown,ISR-50,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Bukwang Pharm,Treatment,Antivirals,Clinical,Phase II trial not yet recruiting,Levovir (clevudine),NCT04347915,Unknown,,,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/9/2021
Agastiya Biotech,Treatment,Antivirals,Pre-clinical,Phase I to start in 2020,AB001,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/24/2020
Cocrystal Pharma,Treatment,Antivirals,Pre-clinical,Unknown,Antiviral compounds,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/18/2020
Ridgeback Biotherapeutics / Drug Innovation Ventures at Emory (DRIVE)/ Merck,Treatment,Antivirals,Clinical,Phase III trial started August 2021. FDA EUA December 2021.,"Molnupiravir (MK-4482/EIDD-2801), oral ribonucleoside analog","NCT04405739, NCT04405570, NCT04392219",Unknown,"Nature (https://www.nature.com/articles/s41564-020-00835-2), Nature (https://www.nature.com/articles/s41586-021-03312-w), Eureka Alert (https://www.eurekalert.org/pub_releases/2021-02/uonc-ape020921.php), NIH (https://www.nih.gov/news-events/news-releases/experimental-antiviral-covid-19-effective-hamster-study), Merck (https://www.merck.com/news/interim-results-from-phase-2-3-studies-of-molnupiravir-an-investigational-oral-antiviral-therapeutic-for-mild-to-moderate-covid-19-presented-at-the-european-congress-of-clinical-microbiology-i/), BMC Journal (https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05538-5), ScienceDirect (https://www.sciencedirect.com/science/article/pii/S2211383521004032), Nature (https://www.nature.com/articles/d41586-021-03667-0), Nature (https://www.nature.com/articles/s41422-022-00618-w), Wiley (https://wchh.onlinelibrary.wiley.com/doi/10.1002/psb.1963), PubMed (https://pubmed.ncbi.nlm.nih.gov/35118917/), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2116044#:~:text=In%20this%20trial%2C%20oral%20molnupiravir,for%20progression%20to%20severe%20disease.)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/10/2022
Ascletis/ Chinese research sponsors,Treatment,Antivirals,Clinical,Phase III trial recruiting May 2020,"ASC09, HIV protease inhibitor","NCT04261907

NCT04261270",Unknown,,Treatment of HIV/AIDS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/4/2022
Roche; REMAP-CAP global trial,Treatment,Antivirals,Clinical,"REMAP-CAP trial recruiting May 2020
","Tamiflu (oseltamivir), neuraminidase inhibitor","NCT04303299, NCT04255017, NCT04261270, NCT02735707, NCT04338698, NCT04371601, EudraCT 2015-002340-14 (REMAP-CAP), NCT04457609",Unknown,"medRxiv (https://doi.org/10.1101/2020.03.28.20045955), medRxiv (https://doi.org/10.1101/2020.04.11.20056523), PubMed (https://pubmed.ncbi.nlm.nih.gov/33718494/)",,"FDA-approved since 1999, approved to treat and prevent influenza",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/16/2021
"Plan Nacional sobre el Sida
",Treatment,Antivirals,Clinical,Phase III trial recruiting May 2020,"Truvada (emtricitabine and tenofovir, both HIV-1 nucleoside analog reverse transcriptase inhibitors)","ChiCTR2000029468, NCT04334928, NCT04405271",Unknown,Annals of Internal Med (https://doi.org/10.7326/M20-3689),,FDA-approved since 2004; approved to treat and prevent HIV-1 infection,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/4/2020
Bausch Health,Treatment,Antivirals,Clinical,Phase II recruiting May 2020; Individual patient expanded access,Virazole (ribavirin for inhalation solution),"NCT04356677, NCT04460443, NCT04392427, NCT04276688, NCT04551768",Unknown,"PubMed (https://pubmed.ncbi.nlm.nih.gov/33765239/), PubMed (https://pubmed.ncbi.nlm.nih.gov/33818031/), Environmental Science and Pollution Research (https://link.springer.com/article/10.1007/s11356-021-16096-3)",,"FDA-approved since 1985, approved to treat lower respiratory tract infections due to RSV",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/14/2021
Atea Pharmaceuticals/ Roche,Treatment,Antivirals,Clinical,Phase II trial to start May 2020,"AT-527, oral purine nucleotide prodrug","NCT04396106, NCT05059080",Unknown,"Oxford Academic (https://academic.oup.com/ofid/article/7/Supplement_1/S649/6057903), BioSpace (https://www.biospace.com/article/releases/atea-pharmaceuticals-announces-publication-of-preclinical-data-highlighting-potent-activity-of-at-527-against-sars-cov-2data-underscore-key-mechanistic-features-enabling-at-527-to-inhibit-sars-cov-2-viral-replication/), PubMed (https://pubmed.ncbi.nlm.nih.gov/33558299/), AP News (https://apnews.com/press-release/globenewswire-mobile/science-business-products-and-services-coronavirus-pandemic-product-testing-ec17ff40e106f91f40f9c6a7045a8eca), Globe Newswire (https://www.globenewswire.com/news-release/2021/06/30/2255518/0/en/Atea-s-AT-527-an-Oral-Antiviral-Drug-Candidate-Reduces-Viral-Replication-in-Hospitalized-Patients-with-COVID-19-in-Phase-2-Interim-Analysis.html), Lancet (https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00278-0/fulltext), Nature (https://www.nature.com/articles/s41467-022-28113-1)",Treatment of Hepatitis C infections,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/11/2022
Ascletis / Chinese research sponsors,Treatment,Antivirals,Clinical,Small open label trial completed and results released in March 2020; Larger open label trial recruiting May 2020,"Ganovo (danoprevir), hepatitis C virus NS3 protease inhibitor; ritonavir; interferon, approved in China to treat Hepatitis C","NCT04291729

NCT04345276",Unknown,medRxiv (https://doi.org/10.1101/2020.03.22.20034041),"Treatment of Hepatitis C
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/7/2020
Cidara Therapeutics,Treatment,Antivirals,Pre-clinical,Unknown,antiviral Fc conjugates,,Unknown,Nature (https://www.nature.com/articles/s41467-021-21609-2),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/16/2021
Gilead; World Health Organization SOLIDARITY trial; National Institute of Allergy and Infectious Diseases (NIAID)'s Adaptive COVID-19 Treatment Trial; Feinstein Institutes; I-SPY COVID,Treatment,Antivirals,Clinical,"Gilead releases additional data Phase III trial on July 10, 2020; Gilead's Phase Ia trial of inhalant version started July 2020; EU grants conditional authorization July 3, 2020; Gilead starting Phase II/III trial in pediatric patients in June 2020; FDA issued an Emergency Use Authorization on May 1, 2020; Expanded EUA access Aug 2020, Phase I trial in pregnant & non-pregnant women Oct 2020; Phase II Trials Remdesivir + Lenzilumab Oct 2020; ; ACTV-1 IM adaptive remdesivir trial begins Oct 2020","remdesivir, nucleotide analog ","NCT04257656, NCT04252664, NCT04292730, NCT04292899, NCT04280705, EudraCT 2020-000936-23, NCT04315948, NCT04302766, NCT04323761, NCT04349410, NCT04401579, EudraCT 2020-001052-18, ISRCTN83971151 (Solidarity), EudraCT 2020-001366-11 (Solidarity Spain), EudraCT 2020-000982-18 (Norway Solidarity), EudraCT 2020-001784-88 (Finland Solidarity), EudraCT 2020-001549-38 (Solidarity Germany), NCT04330690, NCT04431453, NCT04409262, NCT04321616, EudraCT 2020-001448-24, NCT04365764, NCT04410354, NCT04365725, NCT04480333 (inhaled remdesevir + neurosivir), NCT04488081, EudraCT 2020-000841-15, EudraCT 2020-001453-49, EudraCT 2020-000842-32, EudraCT 2020-001803-17, EudraCT 2020-002060-31, NCT04501978, NCT04582266, NCT04583969, NCT04583956",Unknown,"NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2007016), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2001191), Stat News (https://www.statnews.com/2020/04/16/early-peek-at-data-on-gilead-coronavirus-drug-suggests-patients-are-responding-to-treatment/), Reuters (https://www.reuters.com/article/us-health-coronavirus-gilead-sciences/gilead-disputes-report-that-coronavirus-drug-trial-flopped-idUSKCN225326), Stat (https://www.statnews.com/2020/04/23/data-on-gileads-remdesivir-released-by-accident-show-no-benefit-for-coronavirus-patients/), medRxiv (https://doi.org/10.1101/2020.04.21.20066761), Gilead (https://www.businesswire.com/news/home/20200429005424/en/Gilead-Announces-Results-Phase-3-Trial-Investigational), NIAID (https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19?utm_campaign=+42538088&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term=), Lancet (https://doi.org/10.1016/S0140-6736(20)31022-9), medRxiv (https://doi.org/10.1101/2020.05.02.20088559), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2007764?query=featured_home), Gilead (https://www.gilead.com/news-and-press/press-room/press-releases/2020/6/gilead-announces-results-from-phase-3-trial-of-remdesivir-in-patients-with-moderate-covid-19), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2007016), medRxiv (https://doi.org/10.1101/2020.05.17.20104711), medRxiv (https://doi.org/10.1101/2020.06.03.20121558), medRxiv (https://doi.org/10.1101/2020.05.26.20109595), medRxiv (https://doi.org/10.1101/2020.05.23.20110932), medRxiv (https://doi.org/10.1101/2020.06.15.20131227), medRxiv (https://doi.org/10.1101/2020.06.15.20132407), medRxiv (https://doi.org/10.1101/2020.06.22.20136531), Gilead (https://www.gilead.com/news-and-press/press-room/press-releases/2020/7/gilead-presents-additional-data-on-investigational-antiviral-remdesivir-for-the-treatment-of-covid-19), medRxiv (https://doi.org/10.1101/2020.07.22.20160002), JAMA (https://jamanetwork.com/journals/jama/fullarticle/2769871?resultClick=24), medRxiv (https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1.full.pdf), medRxiv (doi: https://doi.org/10.1101/2020.10.30.20215301), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2031994), Reuters (https://www.reuters.com/article/health-coronavirus-remdesivir/single-patient-study-adds-to-debate-over-gileads-remdesivir-for-covid-19-idINL8N2IU1ZG), AJN (https://journals.lww.com/ajnonline/Abstract/2021/01000/Remdesivir_in_The_Treatment_of_COVID_19.17.aspx), NCBI (https://www.ncbi.nlm.nih.gov/research/coronavirus/publication/33350698), Medical News Today (https://www.medicalnewstoday.com/articles/remdesivir-and-baricitinib-shortened-recovery-time-from-covid-19), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2031994), MedRxiv (https://www.medrxiv.org/content/10.1101/2021.03.04.21252903v1), CIDRAP (https://www.cidrap.umn.edu/news-perspective/2021/03/study-remdesivir-speeds-recovery-hospitalized-covid-patients), JAMA (https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777863), PubMed (https://pubmed.ncbi.nlm.nih.gov/33765239/), Eureka Alert (https://www.eurekalert.org/pub_releases/2021-06/e-crr062421.php), Heart Rhythm Case Reports (https://www.heartrhythmcasereports.com/article/S2214-0271(21)00100-7/fulltext), Eureka Alert (https://www.eurekalert.org/pub_releases/2021-07/ifqa-ric070521.php), PubMed (https://pubmed.ncbi.nlm.nih.gov/34192469/), JAMA (https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2781959), University of Iowa Healthcare (https://medicine.uiowa.edu/content/research-shows-remdesivir-treatment-covid-19-has-little-impact-survival-increases-hospital), PLOS (https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0255093), UCSD (https://health.ucsd.edu/news/releases/Pages/2021-08-02-rethinking-remdesivir.aspx), PubMed (https://pubmed.ncbi.nlm.nih.gov/34479903/), Environmental Science and Pollution Research (https://link.springer.com/article/10.1007/s11356-021-16096-3), Lancet (https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00485-0/fulltext), Lancet (https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00384-2/fulltext), Nature (https://www.nature.com/articles/s41467-021-26760-4), PubMed (https://pubmed.ncbi.nlm.nih.gov/34843589/),  PubMed (https://pubmed.ncbi.nlm.nih.gov/34839450/), Lancet (https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00695-2/fulltext), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2116846), Nature (https://www.nature.com/articles/s44160-021-00013-0), CMAJ (https://www.cmaj.ca/content/194/7/E242), Wiley (https://onlinelibrary.wiley.com/doi/10.1002/ccr3.5467)",Treatment of Ebola,FDA Approved Oct 2020 to treat COVID-19 (Vekruly),https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/27/2022
"Multiple global research sponsors
",Treatment,Antivirals,Clinical,Phase IV trials recruiting May 2020,"Arbidol (umifenovir), licensed in Russia and China for treatment of respiratory viral infections","NCT04252885, NCT04350684, NCT04286503, NCT04260594, NCT04273763",Unknown,"medRxiv (https://doi.org/10.1101/2020.03.19.20038984), Chinese Journal of Infectious Diseases (http://rs.yiigle.com/yufabiao/1182592.htm), medRxiv (https://doi.org/10.1101/2020.03.17.20037432), medRxiv (https://doi.org/10.1101/2020.03.28.20045955), medRxiv (https://doi.org/10.1101/2020.04.08.20057539), medRxiv (https://doi.org/10.1101/2020.04.06.20042580), medRxiv (https://doi.org/10.1101/2020.04.11.20056523), medRxiv (https://doi.org/10.1101/2020.04.25.20079079), medRxiv (https://doi.org/10.1101/2020.06.09.20076646), medRxiv (https://doi.org/10.1101/2020.05.30.20117598), Frontiers in Public Health (https://www.frontiersin.org/articles/10.3389/fpubh.2020.00249/full), BMC (https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05698-w), Science (https://www.sciencedirect.com/science/article/pii/S2666634020300015), PubMed (https://pubmed.ncbi.nlm.nih.gov/33387467/), medRxiv (https://www.medrxiv.org/content/10.1101/2020.04.11.20056523v2), PubMed (https://pubmed.ncbi.nlm.nih.gov/33811756/), Virology Journal (https://virologyj.biomedcentral.com/articles/10.1186/s12985-021-01617-w), PubMed (https://pubmed.ncbi.nlm.nih.gov/34269012/), JOGH (http://www.jogh.org/documents/2021/jogh-11-05017.htm), PubMed (https://pubmed.ncbi.nlm.nih.gov/34326998/), Environmental Science and Pollution Research (https://link.springer.com/article/10.1007/s11356-021-16096-3), NCBI (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451976/), PubMed (https://pubmed.ncbi.nlm.nih.gov/34616801/), Wiley (https://onlinelibrary.wiley.com/doi/10.1002/jmv.27481), ACS Publications (https://pubs.acs.org/doi/full/10.1021/acs.jcim.1c01061), Science Direct (https://www.sciencedirect.com/science/article/pii/S0048969721054577)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/25/2022
"Multiple global research sponsors
",Treatment,Antivirals,Clinical,Phase III trials recruiting May 2020,"Prezcobix (darunavir, HIV-1 protease inhibitor/cobicistat, CYP3A inhibitor)","ChiCTR2000029541, NCT04252274, NCT04303299, NCT04304053, EudraCT 2020-001528-32, NCT04435587, NCT04425382",Unknown,"MedRxiv (https://www.medrxiv.org/content/10.1101/2020.03.22.20034041v1.full.pdf), PubMed (https://pubmed.ncbi.nlm.nih.gov/34854327/)",,FDA-approved since 2015; approved to treat HIV-1 infection,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/7/2021
"Global hospital testing (AbbVie); World Health Organization SOLIDARITY trial (studying lopinavir/ ritonavir with and without interferon beta); University of Oxford RECOVERY trial; REMAP-CAP global trial; Univ. of College, London",Treatment,Antivirals,Clinical,WHO discontinues lopinavir-ritonavir arm in the SOLIDARITY trial July 2020; RECOVERY trial results released June 2020 and stopped that trial arm,"Kaletra/Aluvia (lopinavir/ritonavir), HIV-1 protease inhibitor","NCT04303299, NCT04255017, ChiCTR2000029548, ChiCTR2000029539, EudraCT 2020-000936-23, NCT04307693, NCT04315948, NCT04252885, NCT04276688, NCT02735707, NCT04321993, 2020-001113-21, NCT04286503, NCT04328012, NCT04346147, NCT04350671, NCT04466241, EudraCT 2020-001825-29, EudraCT 2015-002340-14 (REMAP-CAP), EudraCT number: 2020-001321-31, ISRCTN83971151 (Solidarity), EudraCT 2020-001366-11 (Solidarity Spain), EudraCT 2020-001528-32, EudraCT  2020-001723-13, EudraCT 2020-000982-18 (Norway Solidarity), EudraCT 2020-001549-38 (Solidarity Germany), NCT04381936 (RECOVERY), NCT04386070, NCT04372628, NCT04330690, EudraCT 2020-001448-24, NCT04435587, NCT04425382, NCT04376814, EudraCT 2020-001605-23, NCT04251871, NCT04275388, NCT04521400, NCT04499677",UK Government (University of Oxford RECOVERY trial); Life Arc (FLARE trial),"NEJM (https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true), medRxiv, (https://doi.org/10.1101/2020.03.19.20038984), Chinese Journal of Infectious Diseases (http://rs.yiigle.com/yufabiao/1182592.htm), medRxiv (https://doi.org/10.1101/2020.03.28.20045955), medRxiv (https://doi.org/10.1101/2020.04.08.20057539), medRxiv (https://doi.org/10.1101/2020.04.21.20066761), medRxiv (https://doi.org/10.1101/2020.04.25.20079079), medRxiv (https://doi.org/10.1101/2020.04.24.20077735), The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31042-4/fulltext), medRxiv (https://doi.org/10.1101/2020.05.13.20094193), medRxiv (https://doi.org/10.1101/2020.05.18.20105650), medRxiv (https://doi.org/10.1101/2020.06.05.20123299), medRxiv (https://doi.org/10.1101/2020.05.27.20114470), medRxiv (https://doi.org/10.1101/2020.06.16.20133298), Recovery Trial press release (https://www.recoverytrial.net/news/no-clinical-benefit-from-use-of-lopinavir-ritonavir-in-hospitalised-covid-19-patients-studied-in-recovery), WHO (https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19), Circulation: Arrhy and Electro (https://doi.org/10.1161/CIRCEP.120.008798), PubMed (https://pubmed.ncbi.nlm.nih.gov/34269012/), Future Medicine (https://www.futuremedicine.com/doi/10.2217/fvl-2021-0066)",,"FDA-approved since 2000, approved to treat HIV-1 infection",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/1/2022
"Stanford
  University/ US Department of Energy's Lawrence Berkeley National Laboratory",Treatment,Antivirals,Pre-clinical,Unknown,Prophylactic antiviral CRISPR in human cells (PAC-MAN),,Unknown,"PubMed (https://pubmed.ncbi.nlm.nih.gov/33778788/), PubMed (https://pubmed.ncbi.nlm.nih.gov/33899542/)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/27/2021
"Anivive
  Lifesciences",Treatment,Antivirals,Pre-clinical,,"GC376, protease inhibitor",,,"BioRxiv (https://www.biorxiv.org/content/10.1101/2021.01.27.428428v1), PubMed (https://pubmed.ncbi.nlm.nih.gov/34029993/), PubMed (https://pubmed.ncbi.nlm.nih.gov/34118724/)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/6/2021
Selva Therapeutics ,Treatment,Antivirals,Pre-clinical,FDA IND approved for Phase I trial; First patient dosed Nov 2020 ,"SLV213, cysteine protease inhibitor","NCT04431414, NCT04403880, NCT04843787",Unknown,"medRxiv (doi: https://doi.org/10.1101/2020.10.23.347534), American Chemical Society (https://pubs.acs.org/doi/full/10.1021/acschembio.0c00875), Selva Therapeutics (https://selvarx.com/selva/selva-to-present-preclinical-data-at-asv-2021/)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/20/2022
Various  global research sponsors/University of Liverpool/Obafemi Awolowo University,Treatment,Antivirals,Clinical,Phase II trial (Nitazoxanide + atazanavir/ritonavir) began Oct 2020,"Atazanavir, protease inhibitor","NCT04459286, NCT04468087, NCT04452565, EudraCT 2020-005919-51",Unknown,"PubMed (https://pubmed.ncbi.nlm.nih.gov/34255369/), PNAS (https://www.pnas.org/content/118/36/e2106095118)",,"FDA approved since 2003, approved to treat HIV infection",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/29/2021
NeuroActiva,Treatment,Antivirals,Clinical,Phase II/III trial recruiting July 2020 (neurosivir); Phase I trial recruiting July 2020 (inhaled remdesevir + neurosivir),Neurosivir (NA-831),"NCT04452565, NCT04480333 (inhaled remdesevir + neurosivir), NCT04540185",Unknown,,Alzheimer's disease,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/16/2020
Various global research sponsors,Treatment,Antivirals,Clinical,Unknown,"Daklinza (daclatasvir), hepatitis C virus (HCV) NS5A inhibitor","NCT04443725, NCT04468087, NCT04535869, NCT04561063, NCT04729153",Unknown,"Journal of Antimicrobial Chemotherapy (https://pubmed.ncbi.nlm.nih.gov/33880524/), PubMed (https://pubmed.ncbi.nlm.nih.gov/34225541/)",,"FDA approved since 2015, approved to treat HCV genotype 1 or 3 infection",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/7/2021
Hospital do Coracao,Treatment,Antivirals,Clinical,Phase II/III trial not yet recruiting July 2020,Sofusbuvir,"NCT04468087, NCT04561063, NCT04729153, NCT04773756",Unknown,"Journal of Antimicrobial Chemotherapy, Oxford Academic (https://pubmed.ncbi.nlm.nih.gov/33880524/), Antimicrobial Agents and Chemotherapy (https://pubmed.ncbi.nlm.nih.gov/33903110/), PubMed (https://pubmed.ncbi.nlm.nih.gov/34037760/), PubMed (https://pubmed.ncbi.nlm.nih.gov/34225541/), PubMed (https://pubmed.ncbi.nlm.nih.gov/34469609/), Journal of Pharmaceutical Analysis (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416689/), (https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkab433/6445131) ",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/30/2021
"Hospital
  Universitario Infanta Leonor/ Viiv Healthcare; Hospital General de México Dr.
  Eduardo Liceaga; Rhode Island Hospital",Treatment,Antivirals,Clinical,Phase II trial recruiting July 2020,"Selzentry (maraviroc), a CCR5 co-receptor antagonist","NCT04475991, NCT04441385, NCT04435522, NCT04710199",Unknown,,,"FDA approved since 2007, approved to treat HIV infection",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/4/2021
National Institute of Allergy and Infectious Disease (NIAID)/University of Minnesota,Treatment,Antivirals,Clinical,Phase III adaptive trial (ITAC) began Oct 2020; Phase III recruitment began Oct 2020,Hyperimmune immunoglobulin (hIVIG) + Remdesivir,"NCT04546581, EudraCT 2020-002542-16, NCT04910269","National Institute of Allergy and Infectious Diseases (NIAID); 
The International Network for Strategic Initiatives in Global HIV Trials",,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/2/2021
 Pfizer,Treatment,Antivirals,Clinical,Phase I trial in healthy patients. Phase II and III trials complete. FDA emergency use authorization December 2021. Phase 2/3 trials initiated for pediatric patients. ,Paxlovid (PF-07321332),"NCT04756531, NCT04909853, NCT04960202, NCT04962022, NCT05011513, NCT05047601",Unknown,"PubMed (https://pubmed.ncbi.nlm.nih.gov/34029993/), PubMed (https://pubmed.ncbi.nlm.nih.gov/34289752/), International Journal of Molecular Sciences (https://www.mdpi.com/1422-0067/22/17/9124/htm), Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02657-X/fulltext)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/19/2022
Pfizer,Treatment,Antivirals,Clinical,Phase Ib trial in hospitalized COVID patients,PF-07304814,"NCT04535167, NCT05050682",Unknown,"PubMed (https://pubmed.ncbi.nlm.nih.gov/32935104/), PubMed (https://pubmed.ncbi.nlm.nih.gov/34029993/), PubMed (https://pubmed.ncbi.nlm.nih.gov/34289752/)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/15/2022
"Iaterion, Inc.",Treatment,Antivirals,Pre-clinical, In vitro models found no cytotoxicity; expected to enter clinical trials early 2021,"AVIM1 (MyD88 inhibitor, S1/S2 site inhibitor, and entry inhibitor composed of three molecules: IATAV049, IATAV051, IATAV052)",,Unknown,"https://static1.squarespace.com/static/5f2ae367e6fdff23584810a5/t/5f4e9b2b5439c714bc68bdbc/1598987051702/Iaterion%2C+Inc.+COVID+Screen+Results.pdf, PubMed (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425433/)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/9/2021
Lattice Biologics,Treatment,Cell-based therapies,Clinical,Phase I enrolling April 2020,"AmnioBoost, concentrated allogeneic MSCs and cytokines derived from amniotic fluid",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/28/2020
Naturecell Co. LTD,Treatment,Cell-based therapies,Clinical,Phase I/IIa trial approved by South Korea Ministry of Food and Drug Safety in March 2020; Phase I/II efficacy trial to start Dec 2020,"Astrostem-V, Allogenic, adipose-derived mesenchymal stem cells (HB-adMSCs)","NCT04486001, NCT04527224",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/10/2020
ImmunityBio / NantKwest / Be The Match BioTherapies,Treatment,Cell-based therapies,Clinical,Phase Ib trial to start June 2020,Bone marrow-derived allogenic mesenchymal stem cells (BM-Allo-MSC),NCT04397796,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/10/2020
Numerous trials with global research sponsors/ MD Anderson Cancer Center,Treatment,Cell-based therapies,Clinical,Phase I trials ongoing May 2020; Phase I/II trials recruiting May 2020; Phase II/III trial recruiting May 2020; Phase 2 trial enrollment Sept 2020-EXIT COVID-19,Mesenchymal stem cells,"30 trials listed in clinicaltrials.gov, including: ChiCTR2000029990, NCT04315987, NCT04302519, NCT04288102, NCT04313322, NCT04273646, NCT04371601, NCT04315987, NCT04252118, NCT04336254, NCT04339660, NCT04371601, NCT04366063, NCT04467047, NCT04461925, NCT04444271, NCT04493242, NCT04565665",Unknown,"Aging and Disease (http://www.aginganddisease.org/article/0000/2152-5250/ad-0-0-216.shtml), ChinaXiv (http://chinaxiv.org/abs/202002.00084), Lancet (https://doi.org/10.1016/j.eclinm.2020.100454), Stem Cell Research and Therapy (https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-01678-8), UCSF (https://www.ucsf.edu/news/2020/08/418351/stem-cell-trial-tests-treatment-often-fatal-covid-19-lung-damage), Thorax (https://thorax.bmj.com/content/early/2020/12/14/thoraxjnl-2020-215717), PubMed (https://pubmed.ncbi.nlm.nih.gov/33400390/), PubMed (https://pubmed.ncbi.nlm.nih.gov/33765239/), PubMed (https://pubmed.ncbi.nlm.nih.gov/33815870/), PubMed (https://pubmed.ncbi.nlm.nih.gov/33865879/), Sorrento Therapeutics (https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-positive-results-phase-1b-study-covi-msctm), Biomed Central (https://stemcellres.biomedcentral.com/articles/10.1186/s13287-021-02376-9), PubMed (https://pubmed.ncbi.nlm.nih.gov/34124322/)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/13/2021
Hope Biosciences/Daewoong Pharmaceutical Co. LTD/ Other global research sponsors,Treatment,Cell-based therapies,Clinical,"Phase II started in April 2020, Phase I efficacy trial began Aug 2020 ","Allogenic, adipose-derived mesenchymal stem cells (HB-adMSCs)","NCT04348435, NCT04349631, NCT04362189, NCT04535856",Hope Biosciences Stem Cell Research Foundation,,Rheumatoid arthritis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/10/2020
ImmunityBio / NantKwest,Treatment,Cell-based therapies,Pre-clinical,Pre-IND submitted to FDA in May 2020,"haNK, natural killer cells",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/28/2020
Mesoblast/ Cardiothoracic Surgical Trials Network,Treatment,Cell-based therapies,Clinical,Expanded access protocol started for children July 2020; Phase II/III trial started May 2020  ,"Ryoncil (remestemcel-L), allogenic mesenchymal stem cells","NCT04366830, NCT04371393, NCT04456439",Unknown,"Mesoblast (http://investorsmedia.mesoblast.com/static-files/337e723a-340d-493e-a4a1-0971d2c71460), Mesoblast (http://investorsmedia.mesoblast.com/static-files/49b5c98d-f6ec-4ba1-9047-36208c1c0f0e)","Graft versus host disease and other rare diseases, chronic obstructive pulmonary disease",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/7/2021
Athersys / The University of Texas Health Science Center at Houston,Treatment,Cell-based therapies,Clinical,Phase II/III trial recruiting May 2020,"MultiStem, bone marrow stem cells",NCT04367077,Medical Technology Enterprise Consortium (MTEC),,Acute Respiratory Distress Syndrome; Stroke,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/19/2020
AlloVir / Baylor College of Medicine,Treatment,Cell-based therapies,Clinical,Phase I not yet recruiting July 2020; ; FDA IND approved Sept 2020; Dosing began Nov 2020,Allogeneic T-cell therapies,NCT04401410,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/10/2020
Celltex,Treatment,Cell-based therapies,Clinical,FDA approves Phase II trial June 2020,Autologous Adipose-Tissue Derived Mesenchymal Stem Cells (ADMSCs) and allogeneic MSCs,"NCT04428801, NCT04352803",Unknown,"Celltex (https://celltexbank.com/transplantation-of-ace2-mesenchymal-stem-cells-improves-the-outcome-of-patients-with-covid-19-pneumonia/) Celltex (https://celltexbank.com/chinaxiv-reports-clinical-remission-of-a-critically-ill-covid-19-patient-treated-by-human-umbilical-cord-mesenchymal-stem-cells/),  Stem Cells Translational Medicine (https://doi.org/10.1002/sctm.12818)","Injuries, Pain, and Autoimmune, Vascular and Other Disease, including Inflammatory lung conditions, pneumonia, and chronic obstructive pulmonary disease (COPD)",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/11/2020
Celularity/ Lung Biotechnology PBC/ California Institute for Regnerative Medicine (CIRM),Treatment,Cell-based therapies,Clinical,Phase I/II study recruiting August 2020; Dosing began for Phase I/II Phase; I/II evaluation complete Dec 2020. ,"CYNK-001, allogeneic, natural killer cell therapy",NCT04365101,Unknown,"Environmental Sustainability (https://link.springer.com/article/10.1007/s42398-021-00204-7), MDPI (https://www.mdpi.com/2076-393X/9/9/1018/htm)",Various hematologic cancers and solid tumors,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/28/2021
Capricor Inc.,Treatment,Cell-based therapies,Clinical,Expanded access protocol trial ongoing May 2020; FDA approved IND in August 2020 for Phase II trial,"CAP-1002, allogenic cardiosphere-derived cells",NCT04338347,Unknown,BioSpace (https://www.biospace.com/article/releases/capricor-therapeutics-reports-topline-results-from-phase-2-exploratory-inspire-trial-in-severe-hospitalized-covid-19-patients/),Duchenne muscular dystrophy,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/31/2022
Pluristem Therapeutics/ BIH Center for Regenerative Therapy/ Berlin Center for Advanced Therapies,Treatment,Cell-based therapies,Clinical,Phase II trial recruiting July 2020; Results from individual patient expanded access released in April/May 2020; Phase II trials began Nov 2020. PLI study terminated Dec 2020.,"PLX cell product, placenta-based cell therapy","NCT04389450, NCT04614025 ",Unknown,"Pluristem Therapeutics (https://www.pluristem.com/wp-content/uploads/2020/04/PSTI-PR-Follow-up-on-Covid-19-treatments-FINAL-FOR-RELEASE.pdf), Pluristem Therapeutics (https://www.pluristem.com/wp-content/uploads/2020/05/PSTI-28-day-follow-up-FOR-RELEASE.pdf)","Various conditions
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/28/2021
Duke-NUS Medical School; various hospitals (Singapore),Treatment,Cell-based therapies,Clinical,Phase I/II open label trials began in July 2020,Chimeric antigen receptors (CAR)/T cell receptors (TCR)-T cell therapy ,NCT04457726,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/10/2020
GC LabCell / KLEO Pharmaceuticals,Treatment,Cell-based therapies,Pre-clinical,Begin Phase I by end of 2020,Natural killer cell-based therapy,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/20/2020
SMSbiotech,Treatment,Cell-based therapies,Pre-clinical,Unknown,Small mobile stem (SMS) cells,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/9/2020
"AgeX
  Therapeutics/ ImStem Biotechnology",Treatment,Cell-based therapies,Pre-clinical,,"IMS001, human embryonic stem cell-derived mesenchymal stem cells (hES-MSC)",,,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
"Baylx, Inc. ",Treatment,Cell-based therapies,Pre-clinical,FDA cleared Investigational New Drug (IND) application for BX-U001,"BX-U001, allogeneic umbilical cord derived mesenchymal stem cell (hUC-MSC)",,Unknown,,Rheumatoid arthritis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/6/2020
Sentien Biotechnologies,Treatment,Cell-based therapies,Clinical,Phase I/II trial to start August 2020 Phase I/II now recruiting Nov 2020.,"SBI-101, biologic/device combo product with allogeneic mesenchymal stem cells and a phasmapheresis device",NCT04445220,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/9/2021
Daewoong,Treatment,Cell-based therapies,Clinical,Phase I trial started July 2020,"DWP710, DW-MSC, a mesenchymal stem cell therapy",NCT04535856,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/1/2021
Vitro Biopharma/ Global Institute of Stem Cell Therapy and Research,Treatment,Cell-based therapies,Clinical,Individual expanded access results released July 2020; IND submitted to FDA April 2020,"AlloRx stem cells, umbilical cord mesenchyma stem cell therapy",,Unknown,Vitro Biopharma (https://vitrobiopharma.com/critically-ill-covid-19-patient-successfully-treated-with-vitro-biopharmas-allorx-stem-cells/),Inflammatory conditions,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/27/2021
AgenTus Therapeutics (Agenus) ,Treatment,Cell-based therapies,Clinical,FDA cleared Phase I trial June 2020; First patient dosed Nov 2020 ,"AgenT-797, allogeneic invariant natural killer T cells",,Unknown,GenEdge (https://www.genengnews.com/covid-19-candidates/agenus-agent-797/),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/10/2021
Cellenkos,Treatment,Cell-based therapies,Clinical,Two case reports released July 2020; FDA cleared Phase I trial July 2020,"CK0802, allogeneic cell therapy containing T-regulatory cells from umbilical cord blood processed to express lung homing markers on the cell surface ",NCT04468971,Unknown,Annuals Intern Med (https://doi.org/10.7326/L20-0681),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/23/2021
Red de Terapia Celular (TerCel),Treatment,Cell-based therapies,Clinical,"Phase
  I/II trial recruiting July 2020","MSV_allo, allogenic mesenchymal stem cells","NCT04361942, EudraCT 2020-001682-36",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/11/2021
Aspire Health Science,Treatment,Cell-based therapies,Clinical,Phase I/II trial FDA cleared June 2020,"ACT-20, allogeneic cell preparation of mesenchymal stem cells from umbilical cord tissue",NCT04398303,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/23/2020
Trustem Cell Therapy,Treatment,Cell-based therapies,Clinical,Phase II trial to start in Columbia in July 2020,Umbilical cord-derived mesenchymal stem cells,NCT04429763,Unknown,"Journal of Translational Medicine (https://pubmed.ncbi.nlm.nih.gov/33853637/), Stem Cells Journals (https://stemcellsjournals.onlinelibrary.wiley.com/doi/10.1002/sctm.21-0046)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/9/2021
Caladrius Biosciences,Treatment,Cell-based therapies,Clinical,Phase II trial expected to start Q3 2020; Phase I open label trial began Oct 2020,"CLBS119, autologous peripheral blood-derived CD34+ cell therapy ",NCT04522817,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/11/2021
Enlivex Therapeutics,Treatment,Cell-based therapies,Clinical,Phase II trial started May 2020; First patient dosed in phase II trials in Israel,"Allocetra, early apopototic cells","NCT04659304, NCT04922957",Unknown,"Globes (https://en.globes.co.il/en/article-enlivex-reports-further-success-with-covid-19-patients-1001351817), Globe Newswire (https://www.globenewswire.com/news-release/2021/02/03/2168999/0/en/Enlivex-Reports-Positive-Top-Line-Results-from-Phase-II-Clinical-Trial-Evaluating-Allocetra-in-Severe-and-Critical-COVID-19-Patients-and-Provides-a-Program-Update.html)",Sepsis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/13/2021
Cynata Therapeutics,Treatment,Cell-based therapies,Clinical,Phase II to start in July 2020 in Australia,"CYP-001 (Cymerus MSC), Mesenchymal stem cells",NCT04537351,Unknown,Nature (https://www.nature.com/articles/s41536-021-00161-z?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+npjregenmed%2Frss%2Fcurrent+%28npj+Regenerative+Medicine%29),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/9/2021
BioCardia,Treatment,Cell-based therapies,Pre-clinical,Unknown,"BCDA-4, bone marrow-derived allogenic neurokinin-1 receptor positive mesenchymal stem cells",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/6/2020
Kangstem Biotech,Treatment,Cell-based therapies,Pre-clinical,Unknown,"Furestem RA, allogenic umbilical cord blood-derived stem cell therapy",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/23/2020
Therapeutic Solutions International,Treatment,Cell-based therapies,Clinical,Unknown,"StemVacs, universal donor natural killer cell-based therapy ",,Unknown,,Cancer,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/27/2020
Citius/Novellus,Treatment,Cell-based therapies,Pre-clinical,Phase I trial to start by end of 2020,"NoveCite cells (NC-MSCs), mesenchymal stem cells derived from a single donor's fibroblasts",,Unknown,CitiusPharma (https://ir.citiuspharma.com/press-releases/detail/128/citius-pharmaceuticals-subsidiary-novecite-announces-data),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/8/2020
CAR-T (Shanghai) Biotechnology,Treatment,Cell-based therapies,Pre-clinical,Phase I/II trials began April 2020 ,Dental pulp-derived mesenchymal stem cells,"NCT04336254, NCT04302519",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/24/2020
Regeneris Medical,Treatment,Cell-based therapies,Pre-clinical,Unknown,Autologous Adipose-Tissue Derived Mesenchymal Stem Cells (ADMSCs) ,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/23/2020
Sirnaomics,Treatment,RNA-based treatments,Pre-clinical,Unknown,RNAi - testing 150 RNAis,,Unknown,Frontiers in Microbiology (https://doi.org/10.3389/fmicb.2020.571553),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/4/2020
Vir Biotech / Alnylam Pharmaceuticals,Treatment,RNA-based treatments,Pre-clinical,Phase I to start by the end of 2020,VIR-2703 (ALN-COV) siRNA candidate,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/5/2020
Mateon Therapeutics,Treatment,RNA-based treatments,Clinical,"Phase II study IND submitted to FDA on April 27, 2020; Phase II trials approved in Peru Nov 2020","OT-101, a TGF-Beta antisense drug candidate",,Unknown,Globe Newswire (https://www.globenewswire.com/en/news-release/2021/04/20/2213564/0/en/ONCOTELIC-THERAPEUTICS-INC-ANNOUNCES-POSITIVE-TOP-LINE-DATA-FOR-ARTI-19-CLINICAL-TRIAL-EVALUATING-PULMOHEAL-VERSUS-COVID-19.html),Various cancers,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/27/2021
Neurimmune/ Ethris,Treatment,RNA-based treatments,Pre-clinical,Phase I to start Q4 2020,Inhaled mRNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/16/2021
Sarepta Therapeutics / US Army Medical Research Institute of Infectious Diseases (USAMRIID),Treatment,RNA-based treatments,Pre-clinical,Unknown,"Antisense oligonucleotides, peptide conjugated",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/28/2020
AIM ImmunoTech/ National Institute of Infectious Diseases in Japan/ Roswell Park Comprehensive Cancer Center,Treatment,RNA-based treatments,Clinical,"Phase I/II trial of Ampligen (rintatolimod), in combination with interferon alfa-2b, in cancer patients with COVID-19 not yet recruiting July 2020",Ampligen; (rintatolimod),NCT04379518,National Cancer Institute,"Biospace (https://www.biospace.com/article/releases/aim-immunotech-announces-positive-safety-data-in-first-cohort-of-phase-1-clinical-study-investigating-intranasal-administration-of-ampligen-as-a-potential-prophylaxis-or-treatment-for-covid-19-and-other-respiratory-viral-diseases/), Biospace (https://www.biospace.com/article/releases/aim-immunotech-announces-positive-safety-data-in-second-cohort-of-phase-1-clinical-study-investigating-intranasal-administration-of-ampligen-as-a-potential-prophylaxis-or-treatment-for-covid-19-and-other-respiratory-viral-diseases/), Wiley Online (https://onlinelibrary.wiley.com/doi/10.1002/rmv.2315)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/18/2022
COVID-19 Therapeutics Accelerator,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Scanning compound libraries. Specifically small molecule drugs: monoclonal and polyclonal antibodies,,Gates Foundation / Wellcome / Mastercard Impact Fund,,N/A,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/14/2020
Vir Biotechnology / GSK,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Identify anti-coronavirus compounds that target cellular host genes,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/29/2020
Southwest Research Institute,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Screening drug compounds,,Henry M. Jackson Foundation for the Advancement of Military Medicine,,N/A,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/13/2020
Janssen Pharmaceutical Companies,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Scanning library of antiviral compounds,,Biomedical Advanced Research and Development Authority (BARDA),,N/A,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Anixa Biosciences / OntoChem,Treatment,Scanning compounds to repurpose,Pre-clinical,"Initial in silico screening completed July 2020, testing identified compounds in pre-clincial studies July 2020",Screening for antiviral drug candidates.  Specified antiviral drug candidates: remdesivir,,Unknown,,,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/14/2020
Vanda Pharmaceuticals / University of Illinois at Chicago,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Screening of drug compounds,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/29/2020
Queens University Belfast,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Scanning compounds to repurpose,,UK Government,,N/A,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/7/2020
Healx,Treatment,Scanning compounds to repurpose,Pre-clinical,Combinations will be ready for pre-clinical testing in May 2020,Artifical intellegence based screening to identify repurposed drug combinations. AI has specifically noted Baricitinib,,Unknown,,N/A,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/14/2020
Materia Medica/Cyclica/Manin,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Repurposing antiviral drug candidates,,Unknown,,N/A,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/7/2020
Takeda,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Scanning compounds to repurpose,,Unknown,,N/A,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Enanta Pharmaceuticals,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Screening new drugs + library of antiviral compounds,,Unknown,,N/A,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Shionogi / Hokkaido University Research Center for Zoonosis Control,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Identify novel drugs,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/14/2022
Nuritas,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,AI-based screening to identify a peptide cocktail,,Partnership for Advanced Computing in Europe (PACE),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/24/2020
Pfizer,Treatment,Scanning compounds to repurpose,Pre-clinical,Lead candidate (protease inhibitor) to start Phase I trial in Q3 2020,Scanning antiviral compounds previously in development,,Unknown,,N/A,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/28/2020
Novartis,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Scanning compounds to repurpose,,Unknown,,N/A,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"Sanford Burnham Prebys Medical Discovery Institute, the University of Hong Kong, Scripps Research, UC San Diego School of Medicine, the Icahn School of Medicine at Mount Sinai and UCLA",Treatment,Scanning compounds to repurpose,Pre-clinical,"Identifying drugs to repurpose. Specified drugs: astemizole, clofazamine, remdesivir, chloroquine derivative hanfangchin A (tetrandrine), apilimod, and ONO 5334",Identifying drugs to repurpose,,US Department of Defense; California Institute for Regenerative Medicine,"bioRxiv (https://doi.org/10.1101/2020.04.16.044016), Nature (https://www.nature.com/articles/s41586-020-2577-1)",,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/24/2021
The Castleman Disease Collaborative Network and the Center for Study & Treatment of Inflammatory Lymphadenopathies,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Identifying drugs to repurpose,,Unknown,,,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Merck,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,CD24Fc (MK-7110) Scanning compounds to repurpose,,Unknown,,N/A,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/27/2021
Wyss Institute,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Identify FDA-approved drugs to repurpose to prevent or treat COVID-19,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12150,US Defense Advanced Research Projects Agency (DARPA),Nature (https://www.nature.com/articles/s41551-021-00718-9),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/27/2021
"Exscalate4Cov,
  public-private consortium",Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Screening a chemical library of 500 billion molecules,,European Commision's Horizon 2020,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/25/2020
Quantitative Biosciences Institute Coronavirus Research Group,Treatment,Scanning compounds to repurpose,Pre-clinical,Unknown,Reviewing existing drugs and compounds through mapping viral-human protein interactions,,Unknown,"Nature (https://www.nature.com/articles/s41586-020-2286-9), BioRxiv (https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1), Globe Newswire (https://www.globenewswire.com/news-release/2021/01/25/2163793/0/en/UCSF-QBI-and-Icahn-School-of-Medicine-at-Mount-Sinai-Scientists-Report-New-Preclinical-Data-Published-in-Science-on-Potential-Best-in-Class-COVID-19-Anti-Viral-Treatment-Plitidepsi.html)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/1/2021
Bioxytran,Treatment,Other,Pre-clinical,Unknown,BXT-25; glycoprotein,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/27/2020
Evelo Biosciences/ Rutgers University/ Robert Wood Johnson University Hospital/ TACTIC-E trial (Cambridge University Hospitals NHS Foundation Trust),Treatment,Other,Clinical,Part of Phase II/III Phase TACTIC-E trial and interim data expected 4Q 2020; Phase II US trial to start August 2020,"EDP1815, oral single strain of microbe ",NCT04393246,Unknown,,Psoriasis and Atopic Dermatitis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/29/2021
MedinCell/ University of Utah/ Surgisphere Corp; University of Baghdad; Tanta University; other global research sponsors,Treatment,Other,Clinical,Phase II to start in August 2020; Phase II began Oct 2020,ivermectin,"NCT04343092, NCT04345419, NCT04351347, NCT04407507, NCT04392713, NCT04425707, NCT04438850, NCT04405843, NCT04429711, NCT04374279, NCT04360356, NCT04381884, NCT04447235, NCT04435587, NCT04434144, NCT04445311, EudraCT 2020-001474-29, EudraCT 2020-002091-12, EudraCT 2020-001994-66, NCT04460547, NCT04431466, NCT04446104, NCT04446429, NCT04472585, ISRCTN40302986, EudraCT 2020-001971-33, NCT04482686, NCT04551755, NCT04602507, NCT04668469, NCT04673214, NCT04681053, NCT04701710",Unknown,"medRxiv (https://doi.org/10.1101/2020.06.06.20124461), medRxiv (https://doi.org/10.1101/2020.07.07.20145979), Antiviral Research (https://www.sciencedirect.com/science/article/pii/S0166354220302011), medRxiv (doi: https://doi.org/10.1101/2020.10.29.20222661), Research Square (doi:10.21203/rs.3.rs-100956/v1), Healio (https://www.healio.com/news/primary-care/20201208/this-was-a-gift-to-us-ivermectin-effective-for-covid19-prophylaxis-treatment), MedRxiv (https://www.medrxiv.org/content/10.1101/2021.01.26.21250420v1), American Journal of Therapeutics(https://journals.lww.com/americantherapeutics/fulltext/2021/00000/review_of_the_emerging_evidence_demonstrating_the.4.aspx), Nature (https://www.nature.com/articles/s41429-021-00430-5), The Lancet (https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00239-X/fulltext), BioSpace (https://www.biospace.com/article/data-supports-use-of-anti-parasitic-drug-ivermectin-in-covid-19-patients-study-shows/), Clinical Infectious Diseases (https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab591/6310839), BMC Infectious Disease (https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06348-5), Oxford Academic (https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofab358/6316214), PubMed (https://pubmed.ncbi.nlm.nih.gov/34215210/), Nature (https://www.nature.com/articles/d41586-021-02081-w), AJT (https://journals.lww.com/americantherapeutics/fulltext/2021/08000/ivermectin_for_prevention_and_treatment_of.7.aspx), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMc2114907), Lancet (https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00421-7/fulltext), Nature (https://www.nature.com/articles/s41467-022-28113-1), PubMed (https://pubmed.ncbi.nlm.nih.gov/35135310/)",,FDA-approved since 1996; approved to treat intestinal parasites and head lice infestations,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/21/2022
Vanda Pharmaceuticals / Feinstein Institutes for Medical Research at Northwell Health,Treatment,Other,Clinical,Phase III trial started in April 2020,"tradipitant, a neurokinin-1 receptor antagonist",NCT04326426,Unknown,Vanda Pharmaceuticals (https://vandapharmaceuticalsinc.gcs-web.com/node/14256/pdf),"Gastroparesis, motion sickness, and atopic dermatitis",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/1/2020
Can-Fite BioPharma,Treatment,Other,Clinical,IND (investigational new drug application) expected to be filed with FDA by end of July 2020; IND approved Sept 2020,"piclidenoson, A3 adenosine receptor agonist",NCT04333472,Unknown,,Rheumatoid arthritis; psoriasis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/26/2021
Eagle Pharmaceuticals / Amneal Pharmaceuticals / Alcami Corporation / Hackensack University Medical Center,Treatment,Other,Clinical,Unknown,"Ryanodex (dantrolene sodium), skeletal muscle relaxant",,Unknown,,,"FDA-approved since 2014, approved to prevent and treat malignant hyperthermia",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/21/2020
"Novartis / Incyte, numerous researchers globally",Treatment,Other,Clinical,Novartis/Incyte Phase III trial started April 2020; Expanded access protocols,Jakafi/jakavi (ruxolitinib),"ChiCTR2000029580, NCT04334044, NCT04331665, NCT04337359, NCT04348071, NCT04338958, NCT04348695, NCT04355793, NCT04354714, NCT04377620, NCT04362137, NCT04366232, NCT04361903, NCT04374149, NCT04338958, NCT04359290, NCT04414098, NCT04403243, EudraCT 2020-001754-21, EudraCT 2020-001963-10",LIfeArc (RAVEN trial),"J. Allergy & Clinical Immuno. (https://www.jacionline.org/article/S0091-6749(20)30738-7/abstract), BioSpace (https://www.biospace.com/article/incyte-s-and-novartis-jakafi-fails-to-hit-endpoints-in-phase-iii-covid-19-study/), PubMed (https://pubmed.ncbi.nlm.nih.gov/33992887/)",,"FDA-approved since 2011, approved to treat myelofibrosis, polycythemia vera, and acute graft-versus-host disease",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/24/2021
Romark Laboratories; various researchers globally,Treatment,Other,Clinical,Phase II/III and Phase III trials recruiting July 2020; Phase II trial completed (Brazil); Phase II trials began for the TriACT Trial Nov 2020,"nitazoxanide, antiprotozoal","NCT04351347, NCT04348409, NCT04343248, NCT04341493, NCT04345419, NCT04435314, NCT04441398, NCT04463264, NCT04459286, NCT04486313, NCT04423861, NCT04392427, NCT04406246, NCT04382846, NCT04552483, NCT04561219, NCT04605588",Unknown,"PubMed (https://pubmed.ncbi.nlm.nih.gov/33480414/), PubMed (https://pubmed.ncbi.nlm.nih.gov/33590901/), medRxiv (https://www.medrxiv.org/content/10.1101/2021.03.03.21252509v1), PR Newswire (https://www.prnewswire.com/news-releases/romark-announces-initial-results-of-phase-3-clinical-trial-of-nt-300-tablets-for-the-treatment-of-covid-19-301268321.html), medRxiv (https://www.medrxiv.org/content/10.1101/2021.04.19.21255441v1), PubMed (https://pubmed.ncbi.nlm.nih.gov/33590901/), PubMed (https://pubmed.ncbi.nlm.nih.gov/34131543/), The Lancet (https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00261-3/fulltext), PubMed (https://pubmed.ncbi.nlm.nih.gov/34249367/), medRxiv (https://www.medrxiv.org/content/10.1101/2021.04.19.21255441v2.full), MedRxiv (https://www.medrxiv.org/content/10.1101/2021.09.10.21263376v1), PubMed (https://pubmed.ncbi.nlm.nih.gov/34699618/), Lancet (https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00040-2/fulltext#:~:text=This%20randomized%2C%20double%2Dblind%20placebo,severe%20illness%20in%20participants%20at)",,"FDA-approved since 2002, approved to treat diarrhea caused by Giardia lamblia or Cryptosporidum parvum",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/3/2022
CEL-SCI / University of Georgia Center for Vaccines and Immunology,Treatment,Other,Pre-clinical,Animal study results released July 2020,LEAPS COVID 19 conjugate; Peptides targeting the NP protein,,Unknown,https://www.drugtargetreview.com/news/77830/novel-peptide-therapy-improves-covid-19-survival-by-leaps-and-bounds-in-mice/,,Unknown,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/8/2020
"Zydus Cadila Group; The Camelot Foundation
",Treatment,Other,Clinical,Phase II/III enrolling May 2020. Phase III began Dec 2020.,"interferon/peginterferon alpha-2b, PegIntron, Sylatron, IntronA, PegiHep 
","NCT04273763, NCT04349410, NCT04379518, NCT04647695",Unknown,"medRxiv (https://doi.org/10.1101/2020.05.29.20109199), Practice Update (https://www.practiceupdate.com/content/peginterferon-lambda-accelerates-sars-cov-2-decline-in-outpatients/113597), Allergy and Clinical Immunology (https://www.jacionline.org/article/S0091-6749(21)00556-X/fulltext), Nature (https://www.nature.com/articles/s12276-021-00592-0), PubMed (https://pubmed.ncbi.nlm.nih.gov/34101851/), PubMed (https://pubmed.ncbi.nlm.nih.gov/34468995/), Journal of Medical Virology (https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.27317), medRxiv (https://www.biorxiv.org/content/10.1101/2021.06.16.448653v1), Nature (https://www.nature.com/articles/s41467-021-25509-3), Nature (https://www.nature.com/articles/s41590-021-01037-6), medRxiv (https://www.medrxiv.org/content/10.1101/2021.11.01.21265766v1), Nature (https://www.nature.com/articles/s41598-021-02522-6), Nature (https://www.nature.com/articles/s41598-021-02489-4)",,"PegIntron - FDA-approved since 2001, approved to treat hepatitis C; Sylatron - FDA-approved since 2001, approved for the adjuvant treatment of melanoma; Intron A - FDA-approved since 1986, approved to treat hepatitis C and certain cancers",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/2/2021
Cyclacel Pharmaceuticals / University of Edinburgh,Treatment,Other,Clinical,Unknown,"roscovitine seliciclib, cyclin-dependent kinase (CDK)2/9 inhibitor",,LifeArc,,Rheumatoid arthritis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/23/2020
aTyr,Treatment,Other,Clinical,Phase II study started in June 2020; Phase 2 enrollment completed Oct 2020,"ATYR1923, fusion protein (immuno-modulatory domain of histidyl tRNA synthetase fused to the Fc region of a human antibody) modulator of neuropilin-2",NCT04412668,Unknown,Atyr Pharma (https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-positive-topline-results-phase-2-clinical),Pulmonary sarcoidosis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2021
"Partner Therapeutics/ Singapore General Hospital/ University Hospital, Ghent",Treatment,Other,Clinical,"Phase II and Phase IV trials recruiting July 2020, enrollment for Phase II began August 2020","Leukine (sargramostim, rhu-Granulocyte macrophage colony stimulating factor )","NCT04326920, NCT04400929, NCT04411680, EudraCT 2020-001254-22, NCT04411680, https://clinicaltrials.gov/ct2/show/NCT04642950?term=Leukine&cond=COVID&draw=2&rank=4",Other Transaction Agreement (OTA) with Department of Defense (DoD),"https://clinicaltrials.gov/ct2/show/NCT04642950?term=Leukine&cond=COVID&draw=2&rank=4, Biospace (https://www.biospace.com/article/releases/second-randomized-trial-of-leukine-sargramostim-in-covid-19-demonstrates-improvement-in-lung-function/ )",Pulmonary conditions that affect alveolar macrophases (nebulized leukine); ARDS (IV leukine),"FDA-approved since 1991, approved to shorten the time to neutrophil recovery and reduce the incidence of infections following chemotherapy, mobilize hematopoietic progenitor cells, accelerate myeloid reconstitution following bone marrow or cell transplantation, treat delayed neutrophil recovery or graft failure after bone marrow transplantation, and increase survival of radiation",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2021
Aldeyra Therapeutics,Treatment,Other,Clinical,IND submission to FDA in June 2020; FDA approval to begin Phase II trials in Sept 2020,"ADX-1612, HSP 90 inhibitor",,Unknown,Business Wire (https://www.businesswire.com/news/home/20201222005310/en/Aldeyra-Therapeutics-Announces-Confirmation-of-Antiviral-Activity-of-ADX-1612),Various cancers,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/12/2021
"Chimerix
",Treatment,Other,Clinical,Phase II/III trial recruiting July 2020,"DSTAT (dociparstat sodium), glycosaminoglycan derivative of heparin
",NCT04389840,Unknown,,"Acute myeloid leukemia
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/25/2021
Biomarck Pharmaceuticals,Treatment,Other,Clinical,Unknown,"BIO-11006, inhaled peptide",,Unknown,,Acute Respiratory Distress Syndrome; Non-Small Cell Lung Cancer; Chronic Obstructive Pulmonary Disease (COPD),N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/24/2020
Numerous global sponsors,Treatment,Other,Clinical,Phase III trial recruiting May 2020,Recombinant human interferon alpha-1b,"NCT04320238, NCT04251871, NCT04275388",Unknown,medRxiv (https://doi.org/10.1101/2020.04.11.20061473),,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/27/2020
"SciTech Development, LLC",Treatment,Other,Clinical,Unknown,"ST-001 nanoFenretinide (fenretinide)
",,Unknown,,non-Hodgkin's lymphoma,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
"Beth Israel Deaconess, the University of Colorado Anschultz Medical Campus, and Denver Health (Genentech); University College London; Boehringer Ingelheim",Treatment,Other,Clinical,Phase II trial recruiting; Individual patient expanded access,"Activase (alteplase), tissue plasminogen activator (tPA)","NCT04357730, NCT04356833, EudraCT 2020-001640-26, NCT04453371, https://clinicaltrials.gov/ct2/show/NCT04640194?term=Activase&cond=COVID&draw=2&rank=4",Unknown,J Thromb Haemost (https://onlinelibrary.wiley.com/doi/epdf/10.1111/jth.14828),,"FDA-approved since 1987, approved to treat stroke, myocardial infarction, and pulmonary embolism",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/10/2021
"Multiple global research sponsors, including UK SPIKE-1 trial",Treatment,Other,Clinical,"Phase I/II, Phase II, and Phase III trials recruiting in May 2020; Phase II (CAMELOT Trial) enrollment began Nov 2020","camostat mesylate, transmembrane protease serine 2 (TMPRSS2) inhibitor, approved in Japan to treat multiple conditions including pancreatitis","NCT04321096, NCT04353284, NCT04338906, NCT04374019, NCT04355052, EudraCT 2020-002233-15, NCT04455815, NCT04583592, NCT04652765, NCT04657497, NCT04662073, NCT04662086, NCT04782505",LIfeArc (SPIKE-1 trial),"The Lancet (https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00048-7/fulltext), Springer Link (https://link.springer.com/article/10.1007/s00134-021-06395-1), The Lancet (https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00129-2/fulltext), bioRxiv (https://www.biorxiv.org/content/10.1101/2021.04.23.440619v2), PubMed (https://pubmed.ncbi.nlm.nih.gov/33982445/), bioRxiv (https://www.biorxiv.org/content/10.1101/2021.07.08.451654v1.full.pdf), Nature (https://www.nature.com/articles/s41598-021-94095-7), PubMed (https://pubmed.ncbi.nlm.nih.gov/34406858/), Royal Society of Chemistry (https://pubs.rsc.org/en/content/articlehtml/2021/sc/d1sc01494c), Royal Society of Chemistry (https://pubs.rsc.org/es-co/content/articlepdf/2021/sc/d0sc05064d), Journal of Virology (https://journals.asm.org/doi/full/10.1128/JVI.00975-21), PNAS (https://www.pnas.org/content/118/43/e2108728118), Journal of Clinical Medicine (https://www.researchgate.net/publication/357344819_Association_between_Nafamostat_Mesylate_and_In-Hospital_Mortality_in_Patients_with_Coronavirus_Disease_2019_A_Multicenter_Observational_Study), medRxiv (https://www.medrxiv.org/content/10.1101/2022.01.28.22270035v1?rss=1), Research Gate (https://www.researchgate.net/publication/362176931_Camostat_Mesylate_Versus_LopinavirRitonavir_in_Hospitalized_Patients_With_COVID-19-Results_From_a_Randomized_Controlled_Open_Label_Platform_Trial_ACOVACT)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/25/2022
Massachusetts General Hospital; University of British Columbia; Sanotize Research and Development,Treatment,Other,Clinical,Massachusetts General Hospital Phase II trial ongoing July 2020; other Phase II trials recruiting July 2020,Nitric oxide,"NCT04305457, NCT04312243, NCT04306393, NCT03331445, NCT04443868, NCT04337918, NCT04456088, NCT04421508, NCT04383002, NCT04388683, NCT04338828, EudraCT 2020-001490-68, EudraCT 2020-001329-30, NCT04460183, NCT04443868, NCT04306393, NCT04476992",Unknown,"The Physiological Society (https://physoc.onlinelibrary.wiley.com/doi/10.14814/phy2.14748), Science Direct (https://www.sciencedirect.com/science/article/pii/S2666354621000582), Pub Med (https://pubmed.ncbi.nlm.nih.gov/33992687/), MedRxiv (https://www.medrxiv.org/content/10.1101/2021.08.19.21262314v1)",,FDA-approved since 1999; approved to improve oxygenation in neonates,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/1/2021
"Multiple global research sponsors
",Treatment,Other,Clinical,Gates Foundation trial results expected by end of summer 2020; Phase III trials began Oct 2020 in Canada,"Cozaar (losartan), angiotensin II receptor blocker (ARB)
","NCT04312009, NCT04311177, NCT04349410, NCT04335123, NCT04343001, NCT04328012, NCT04340557, NCT04447235, NCT04428268, EudraCT 2020-001766-11, NCT04394117, NCT04467931, ISRCTN48734830, EudraCT 2020-002040-22, NCT04606563, https://clinicaltrials.gov/ct2/show/NCT04643691?term=Cozaar&cond=COVID&draw=2&rank=3","COVID-19 Treatment Accelerator 
",,,FDA-approved since 1995; approved to treat hypertension and diabetic nephropathy,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/11/2021
Amgen; I-SPY COVID trial/Takeda/AbbieVie   ,Treatment,Other,Clinical, I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (I-SPY_COVID) starts July 2020. Enrolling patients August 2020. First patients enrolled Dec 2020.,"Otezla (apremilast), inhibitor of phosphodiesterase 4 (PDE4)",NCT04488081,Unknown,,,"FDA-approved since 2014, approved to treat psoriatic arthritis, severe plaque psoriasis, and oral ulcers associated with Behcet's Disease",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/14/2021
"Immunic, Inc./University Hospitals Coventry and Warwickshire NHS Trust",Treatment,Other,Clinical,"Phase II trial started June 2020, top line results expected in 2020, Recruiting Aug 2020 (IMU 838 +Oseltamivir); ; Phase II enrollment began Oct 2020","IMU-838, selective oral dihydroorotate dehydrogenase (DHODH) inhibitor","NCT04516915, EudraCT 2020-001805-21, NCT04379271, EudraCT 2020-001264-28",University Hospitals Coventry and Warwickshire NHS Trust,Immunic Therapeutics (https://www.immunic-therapeutics.com/2021/02/17/immunic-inc-announces-that-oral-treatment-imu-838-shows-evidence-of-clinical-activity-in-moderate-covid-19-in-phase-2-calvid-1-trial/),Ulcerative colitis; remitting multiple sclerosis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/26/2021
Numerous research sponsors globally,Treatment,Other,Clinical,Open-label Greek study results published June 2020,colchicine,"NCT04326790, NCT04328480, NCT04322565, NCT04322682, NCT04392141, NCT04375202, NCT04355143, NCT04360980, NCT04350320, NCT04416334, NCT04403243, NCT04363437, NCT04324463, NCT04367168, EudraCT 2020-001511-25, EudraCT 2020-001258-23, EudraCT 2020-001603-16, EudraCT 2020-001475-33, EudraCT 2020-001689-12, EudraCT  2020-001841-38, EudraCT 2020-001455-40, NCT04472611, NCT04516941, NCT04510038, NCT04527562, NCT04539873, NCT04654416, NCT04667780, NCT04867226",Unknown,"JAMA Network Open (https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2767593), medRxiv (https://doi.org/10.1101/2020.08.06.20169573), Montreal Heart Institute (https://app.cyberimpact.com/newsletter-view-online?ct=guhsMu_jogsWK5zuKuZWMiFdWXxrNhn6Nkcjb1fm-HUAuS81ZbwD0N6bKX9bJ23ALFDAfrG83CWBnSzT41zxRA~~), MedRxiv (https://www.medrxiv.org/content/10.1101/2021.01.26.21250494v1), News Medical (https://www.news-medical.net/news/20210201/Colchicine-may-have-therapeutic-potential-against-COVID-19.aspx), Reuters (https://www.reuters.com/article/us-health-coronavirus-britain-treatment/second-uk-trial-to-study-gout-drug-colchicine-as-covid-19-treatment-idUSKBN2AV1G8), PubMed (https://pubmed.ncbi.nlm.nih.gov/33719081/), medRxiv (https://www.medrxiv.org/content/10.1101/2021.05.18.21257267v1), Wiley (https://onlinelibrary.wiley.com/doi/10.1111/eci.13645), PMC (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290220/), PubMed (https://pubmed.ncbi.nlm.nih.gov/34285885/), Lancet (https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00435-5/fulltext), PubMed (https://pubmed.ncbi.nlm.nih.gov/35107804/), Journal LWW (https://journals.lww.com/americantherapeutics/_layouts/15/oaks.journals/downloadpdf.aspx?an=00045391-202202000-00012&pdfToken=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), Nature (https://www.nature.com/articles/s41598-022-13424-6#:~:text=The%20COLCORONA%20trial%2C%20a%20randomized,of%20death%20or%20hospitalizations10.)",,"N/A (but has been used in the US since the early 1800s, and FDA-approved in combination with probenecid; approved to treat gout)",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/3/2022
Innovation Pharmaceuticals,Treatment,Other,Clinical,Phase II trial anticipated to start Q4 2020,"Brilacidin, a defensin mimetic",,Unknown,MDPI (https://www.mdpi.com/1999-4915/13/2/271/notes),Oral Mucositis; Ulcerative Proctitis/Ulcerative Proctosigmoiditis; Acute Bacterial Skin and Skin Structure Infection,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/9/2022
Arch Biopartners,Treatment,Other,Clinical,FDA and Health Canada approved Phase II trial start in July 2020; Phase II trials approved to begin patient enrollment in Turkey Oct 2020; first patient dosed for Phase II trials in Turkey and US (Louisiana),"Metablok (LSALT peptide), selective dipeptidase-1 antagonist",NCT04402957,Unknown,,Lung and Kidney Inflammation,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/17/2022
"Multiple global research sponsors, including University of Tokyo/ National Center for Global Health and Medicine/ Ensysce Biosciences/ Institut Pasteur Korea/ Daiichi Sankyo (inhalation formulation)/ University of Edinburgh ",Treatment,Other,Clinical,University of Tokyo trial (IV formulation) starts April 2020; Ensysce trial will be with oral formulation,"nafamostat, approved in Japan to treat pancreatitis and other diseases ","NCT04352400, NCT04418128, EudraCT 2020-002230-32, NCT04473053, ISRCTN14212905, https://clinicaltrials.gov/ct2/show/NCT04628143?term=nafamostat&cond=COVID&draw=2&rank=4, https://clinicaltrials.gov/ct2/show/NCT04623021?term=nafamostat&cond=COVID&draw=2&rank=5",Life Arc (University of Edinburgh),"Critical Care (https://doi.org/10.1186/s13054-020-03078-z), The Lancet (https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00129-2/fulltext), Wiley (https://onlinelibrary.wiley.com/doi/10.1002/nano.202100123), PubMed (https://pubmed.ncbi.nlm.nih.gov/34276987/), PubMed (https://pubmed.ncbi.nlm.nih.gov/34340553/), PubMed (https://pubmed.ncbi.nlm.nih.gov/34406858/), Royal Society of Chemistry (https://pubs.rsc.org/en/content/articlehtml/2021/sc/d1sc01494c), Annals of Medicine and Surgery (https://www.sciencedirect.com/science/article/pii/S2049080121005100), BioRxiv (https://www.biorxiv.org/content/10.1101/2021.06.16.448653v1), Royal Society of Chemistry (https://pubs.rsc.org/es-co/content/articlepdf/2021/sc/d0sc05064d), MedRxiv (https://www.medrxiv.org/content/10.1101/2021.10.06.21264648v1), Journal of Clinical Medicine (https://www.mdpi.com/2077-0383/11/1/116/pdf)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/29/2021
OncoImmune,Treatment,Other,Clinical,Phase III trial progress report released in June 2020,"CD24Fc, biological immunomodulator (nonpolymorphic regions of CD24 attached to the Fc region of human IgG1)",NCT04317040,Merck,"(https://www.businesswire.com/news/home/20200614005028/en/OncoImmune-Reports-Progress-Phase-III-Clinical-Trial), MedRiv (https://www.medrxiv.org/content/10.1101/2021.08.18.21262258v1)",Graft versus Host Disease,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/16/2021
PharmaMar/ Boryung Pharmaceutical/ Hospitals in Spain,Treatment,Other,Clinical,Phase I trial recruiting July 2020; Trials in Korea to start 3Q 2020,"Aplidin (plitidepsin), approved in Australia to treat multiple myeloma","NCT04382066, NCT04784559",Unknown,"Science (https://science.sciencemag.org/content/early/2021/01/22/science.abf4058), Global Newswire (https://www.globenewswire.com/news-release/2021/01/25/2163793/0/en/UCSF-QBI-and-Icahn-School-of-Medicine-at-Mount-Sinai-Scientists-Report-New-Preclinical-Data-Published-in-Science-on-Potential-Best-in-Class-COVID-19-Anti-Viral-Treatment-Plitidepsi.html), Science (https://science.sciencemag.org/content/371/6532/926), PubMed (https://pubmed.ncbi.nlm.nih.gov/33558296/)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/28/2021
Cyclacel Pharmaceuticals / University of Edinburgh,Treatment,Other,Clinical,Unknown,"fadraciclib (CYC065), cyclin-dependent kinase (CDK)2/9 inhibitor",,LifeArc,,Various cancers,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/19/2021
NeuroRx/ Relief Therapeutics/ Thomas Jefferson University Hospital/ NYU Langone Health/ Houston Methodist Hospital,Treatment,Other,Clinical,Phase II/III trial ongoing July 2020; FDA grants Fast Track Designation June 2020; Expanded access protocols ,"Aviptadil, synthetic form of Vasoactive Intestinal Polypeptide (RLF-100)","NCT04311697, NCT04453839, NCT04360096, NCT04536350, NCT04844580",Unknown,"European Biotechnology (https://european-biotechnology.com/up-to-date/latest-news/news/drug-set-to-rescue-covid-19-patients-at-icus.html, PR Newswire (https://www.prnewswire.com/news-releases/neurorx-reports-initial-phase-2b3-study-results-demonstrating-significant-benefit-of-zyesami-aviptadil-in-reducing-hospital-stay-among-patients-with-respiratory-failure-due-to-critical-covid-19-301224915.html), PR Newswire (https://www.prnewswire.com/news-releases/neurorx-announces-that-zyesami-aviptadil-has-successfully-demonstrated-10-day-accelerated-recovery-from-respiratory-failure-in-critically-ill-patients-with-covid-19-treated-with-high-flow-nasal-oxygen-at-28-day-interim-endpoint-301233805.html), Contagion Live (https://www.contagionlive.com/view/showing-promising-recovery-results-from-respiratory-failure-in-covid-19-patients), PR Newswire (https://www.prnewswire.com/news-releases/neurorx-announces-zyesami-aviptadil-rlf-100-met-the-primary-endpoint-of-its-phase-2b3-clinical-trial-and-also-demonstrated-a-meaningful-benefit-in-survival-from-critical-covid-19-301257291.html), PR Newswire (https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-announces-positive-results-for-zyesami-aviptadil-acetate-and-submits-emergency-use-authorization-application-to-us-food-and-drug-administration-to-treat-critical-covid-19-in-patients-suffering-from-respirato-301302408.html), PR Newswire (https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-announces-positive-data-results-from-zyesami-aviptadil-expanded-access-protocol-301312412.html), CCE Journal (https://journals.lww.com/ccejournal/_layouts/15/oaks.journals/downloadpdf.aspx?an=02107256-202201000-00001&pdfToken=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)","Sarcoid, Pulmonary Fibrosis, Bronchospasm, Erectile Dysfunction, and Acute Respiratory Distress Syndrome (ARDS)",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/5/2022
Apeptico/ Medical University Vienna,Treatment,Other,Clinical,Phase II trials ongoing July 2020; Individual expanded access in Austria April 2020,solnatide (synthetic molecule with a structure based on the lectin-like domain of human Tumour Necrosis Factor alpha),EudraCT 2020-001244-26,EU Commission (Horizon 2020 Program),"Science Direct (https://www.sciencedirect.com/science/article/pii/S1569904821000306), Trials Journal (https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05588-9)","Pneumonia, sepsis, ARDS, Primary Graft Dysfunction, and pulmonary dysfunctions",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/23/2021
Eyegate Pharma,Treatment,Other,Clinical,Unknown,PP-001,,Unknown,,Severe eye diseases,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
4D Pharma,Treatment,Other,Clinical,Phase II enrolling July 2020,"MRx-4DP0004, strain of Bifidobacterium breve isolated from the gut microbiome of a healthy human","NCT04363372, EudraCT 2020-001597-30",Unknown,,Asthma,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/10/2021
ARMS Pharmaceutical / UH Cleveland Medical Center / Case Western Reserve University,Treatment,Other,Clinical,Trial starts April 2020,ARMS-1,https://clinicaltrials.gov/ct2/show/NCT04644276?term=ARMS-1&cond=COVID&draw=2&rank=3,Cleveland Foundation,,Influenza prophylaxis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/30/2020
Blade Therapeutics,Treatment,Other,Clinical,Enrollment completed for Phase II trials ,"BLD-2660, synthetic small molecule inhibitor of calpain (CAPN) 1, 2, and 9",NCT04334460,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/17/2020
Laurent Pharmaceuticals,Treatment,Other,Clinical,"Phase II trial recruiting July 2020, FDA approval to start enrollment August 2020",LAU-7b (fenretinide),NCT04417257,Unknown,,Treat exaggerated inflammatory response in adult cystic fibrosis patients,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/7/2021
ImmunityBio/ NantKwest,Treatment,Other,Clinical,Phase Ib trial to start June 2020,"N-803, IL-15 ""superagonist"" (Nogapendekin alfa inbakicept)",NCT04385849,Unknown,"https://nantkwest.com/immunitybio-announces-publication-of-preclinical-data-demonstrating-il-15-superagonist-n-803-improves-natural-killer-mediated-tumor-cell-killing/, ImmunityBio (https://immunitybio.com/immunitybios-had5-t-cell-covid-19-vaccine-shows-complete-protection-of-airways-in-non-human-primates/)",Bladder Carcinoma In Situ,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/16/2020
Institut National de la Sante et de la Recherche Medicale (Merck KGaA); IRCCS San Raffaele; WHO global SOLIDARITY Trial,Treatment,Other,Clinical,Phase III trial recruiting May 2020,Rebif (interferon beta-1a),"EudraCT 2020-000936-23, NCT04315948, 2020-001366-11 (Solidarity Spain), NCT04350671, NCT04449380, 2020-002060-31 (Solidarity Chech Republic), EudraCT 2015-002340-14 (REMAP-CAP), NCT04460547, EudraCT 2020-001549-38 (Solidarity Germany), NCT04647669",Unknown,,,FDA-approved since 2002; approved to treat multiple sclerosis,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/7/2020
Chelation Partners,Treatment,Other,Pre-clinical,Unknown,"DIBI, iron-binding polymer",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/15/2020
KD Pharma / SLA Pharma,Treatment,Other,Clinical,Unknown,"EPAspire, oral formulation of highly purified eicosapentaenoic acid free fatty acid (EPA-FFA) in gastro-resistant capsules",,Unknown,,Familial adenomatous polyposis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"MediciNova/ Yale
",Treatment,Other,Clinical,Phase II trial FDA approved and not yet recruiting July 2020  ,"MN-166 (ibudilast), orally bioavailable, small molecule macrophase migration inhibitory factor (MIF) inhibitor and phosphodiesterase (PDE) -4 and -10 inhibitor",NCT04429555,Unknown,"BioSpace (https://www.biospace.com/article/releases/medicinova-announces-positive-top-line-results-from-phase-2-clinical-trial-of-mn-166-ibudilast-in-hospitalized-covid-19-patients-at-risk-for-acute-respiratory-distress-syndrome/#:~:text=We%20believe%20MN%2D166%20has,approximately%2040%25%20for%20ARDS%20patients.)","Treatment of numerous neurodegenerative diseases and substance dependence
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/17/2022
Aldeyra Therapeutics,Treatment,Other,Clinical,IND submission to FDA in June 2020; FDA approval to begin Phase II trials in Sept 2020; Phase II trials to begin 4th qtr 2020; Phase II began Dec 2020.,"ADX-629, orally available reactive aldehyde species (RASP) inhibitor",https://www.clinicaltrialsarena.com/news/aldeyra-therapeutics-initiates-trials/,Unknown,,Systemic immune-mediated diseases,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/12/2021
AstraZeneca; ACCORD study/Rigel Pharmaceuticals,Treatment,Other,Clinical,Case series results released June 2020; ACCORD Phase II trial to start May 2020; Phase 2 trial (fostamatinib) starts Sept 2020,"Calquence (acalabrutinib), Bruton's tyrosine kinase (BTK) inhibitor","NCT04346199, NCT04380688, EudraCT 2020-001736-95 (ACCORD Trial), EudraCT 2020-001644-25, NCT04497948","UK Government (ACCORD study)
",Science Immunology (https://immunology.sciencemag.org/content/5/48/eabd0110),,"FDA-approved since 2017, approved to treat mantle cell lymphoma and chronic lymphocytic leukemia",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/22/2020
CalciMedica,Treatment,Other,Clinical,Open label phase II trial top line data released July 2020; Phase II trial recruiting July 2020,"Auxora (CM4620-IE), calcium release-activated calcium (CRAC) channel inhibitor",NCT04345614,Unknown,"CalciMedica (https://www.calcimedica.com/news/calcimedica-announces-positive-topline-data-from-interim-analysis-of-trial-evaluating-auxora-in-patients-with-severe-covid-19-pneumonia), CalciMedica (https://calcimedica.com/2020/07/16/calcimedica-announces-data-showing-auxora-substantially-improved-outcomes-in-patients-with-severe-covid-19-pneumonia/), Research Square (https://www.researchsquare.com/article/rs-42600/v1), Critical Care (https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03220-x), Globe Newswire (https://www.globenewswire.com/news-release/2021/02/02/2168099/0/en/CalciMedica-Presents-New-Clinical-Data-Demonstrating-Improved-D-Dimer-Biomarker-Levels-with-Auxora-in-Severe-COVID-19-Pneumonia-at-the-50th-Critical-Care-Congress.html), Journal of Immunology (https://www.jimmunol.org/content/early/2021/08/13/jimmunol.2100127), Critical Care (https://link.springer.com/epdf/10.1186/s13054-022-03964-8?sharing_token=3Y8kSc8AgIpRHpdksMq6Im_BpE1tBhCbnbw3BuzI2RNgljyjp_MC0UeLOpYbVoy4Catf2o1CPvZ9wGTDZgUwpYZuWDT8bfuJG9TbOiKMNKveLI72hbHo2LeXuzTz9fRlS7nYiCG03iBRpWSw5DkjlyQVC7Vq2QJGkYrC6D_b6es%3D)",Pancreatitis,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/14/2022
Pneumagen Ltd.,Treatment,Other,Pre-clinical,Unknown,"Neumifil, multivalent carbohydrate binding molecules",,Unknown,Pneumagen Ltd. (https://www.pneumagen.com/news/24/70/Pneumagen-Announces-Neumifil-is-Efficacious-In-an-Established-Model-of-COVID-19-Infection.html),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/11/2021
"Multiple global research sponsors
",Treatment,Other,Clinical,Veterans observational study ongoing July 2020; Phase IV trials recruiting July 2020,"Diovan (valsartan), angiotensin II receptor blocker (ARB)","NCT04335786, NCT04330300, NCT04394117, NCT04467931, EudraCT 2020-001544-26, EudraCT 2020-001431-27",Unknown,PubMed (https://pubmed.ncbi.nlm.nih.gov/35235999/),,"FDA-approved since 1996; approved to treat hypertension, treat heart failure, and reduce cardiovascular mortality in patients after myocardial infarction",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/9/2022
"RedHill Biopharma
",Treatment,Other,Clinical,"Phase II/III trials in Russia and UK to start in July 2020; Phase IIa in US ongoing in July 2020; Preliminary data from individual patient expanded access released in April 2020; Phase II/III approved for trials in Mexico, UK, Italy, and Russia; Global Phase II/III trial has passed 4 DSMB reviews","Yeliva (opaganib, ABC294640), oral sphingosine kinase-2 (SK2) selective inhibitor, orally administered","NCT04435106, NCT04414618, NCT04467840, EudraCT 2020-002677-95",Unknown,"RedHill Biopharma (https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15258), RedHill Biopharma (https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15257), RedHill Biopharma (https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15261), medRxiv (https://doi.org/10.1101/2020.06.20.20099010), RedHill Biopharma (https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=16269), RedHill Biopharma (https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=19317), RedHill Biopharma (https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=19319), RedHill Biopharma (https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=4457&PID=0&IID=19326), RedHill BioPharma (https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=4457&PID=0&IID=19350), RedHill Biopharma (https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=4457&PID=0&IID=19351)","Various oncology indications
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/16/2022
Moleculin Biotech/ University of Texas Medical Branch/ Sterling Pharma USA,Treatment,Other,Pre-clinical,Unknown,"WP1122, glucose decoy prodrug (and related drug candidates)",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/11/2022
Swedish Orphan Biovitrum/ REMAP-CAP global trial/ Numerous global trial sponsors ,Treatment,Other,Clinical,Some trial results released June 2020,"Kineret (anakinra), interleukin-1 receptor antagonist","NCT04324021, NCT02735707, NCT04339712, NCT04330638, NCT04366232, NCT04443881, NCT04462757, EudraCT 2020-001636-95, EudraCT 2020-001825-29, EudraCT 2020-001734-36, EudraCT 2020-001466-11, EudraCT 2020-001754-21, EudraCT 2020-001963-10, EudraCT 2020-001739-28, EudraCT 2020-001500-41, EudraCT 2020-001246-18, EudraCT 2020-001039-29, EudraCT 2015-002340-14 (REMAP-CAP)",Unknown,"medRxiv (https://doi.org/10.1101/2020.04.23.20076612), Lancet (https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30164-8/fulltext), medRxiv (https://doi.org/10.1101/2020.06.15.20132407), Lancet Rheum (https://doi.org/10.1016/S2665-9913(20)30127-2), Lancet Rheum (10.1016/S2665-9913(20)30177-6), Int'l J Infect Dis (10.1016/j.ijid.2020.05.026), Science Direct (https://www.sciencedirect.com/science/article/pii/S1201971221002496), PubMed (https://pubmed.ncbi.nlm.nih.gov/35237791/)",,"FDA-approved since 2001, approved to treat rheumatoid arthritis and cryopyrin-associated periodic syndromes",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/9/2022
Persephone Biosciences,Treatment,Other,Pre-clinical,Clinical trials to start in 2020,Microbiome therapeutic,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/30/2020
Silkim Pharma,Treatment,Other,Pre-clinical,Unknown,"Coronzot, a novel family of drugs, sequestration of the labile iron",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/1/2020
BerGenBio; ACCORD study,Treatment,Other,Clinical,"ACCORD trial started June 2020, top line data expected summer 2020 ","bemcentinib, selective AXL kinase inhibitor","EudraCT 2020-001736-95 (ACCORD Trial), NCT04890509",UK Government (ACCORD study),"Doc Wire News (https://www.docwirenews.com/abstracts/virtual-high-throughput-screening-potential-inhibitors-for-sars-cov-2-plpro-and-3clpro-proteases/), PR Newswire (https://www.prnewswire.com/news-releases/bergenbio-announces-update-from-investigational-phase-ii-trials-assessing-bemcentinib-in-hospitalised-covid-19-patients-301271176.html), PR Newswire (https://www.prnewswire.com/news-releases/bergenbio-announces-top-line-data-from-phase-ii-trial-assessing-bemcentinib-in-hospitalised-covid-19-patients-301293183.html), PR Newswire (https://www.prnewswire.com/news-releases/bergenbio-presents-encouraging-combined-data-for-bemcentinib-from-two-phase-ii-covid-19-studies-at-eccmid-301331468.html)",Various cancers ,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/2/2022
NanoViricides/ TheraCour Pharma Inc.,Treatment,Other,Pre-clinical,Unknown,A number of synthesized nanoviricide drug candidates,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/10/2021
"Numerous trials with global research sponsors including World Health Organization SOLIDARITY trial; ORCHID trial with National Heart, Lung, and Blood Institute (NHLBI); REMAP-CAP global trial; Novartis; PRINCIPLE trial",Treatment,Other,Clinical,"Brazilian study results released July 2020; Univ. of Minnesota early, mild outpatient trial results released July 2020; Prevention studies continue in Asia; NIH study stopped in June 2020; Novartis discontinues trial due to feasibility of recruitment in June 2020; WHO discontinues hydroxychloquine arm in the SOLIDARITY trial July 2020; FDA revoked the March 28, 2020 Emergency Use Authorization on June 15, 2020; RECOVERY trial prelim results released June 2020, trial arm stopped","Chloroquine/ Hydroxychloroquine, antimalarial","Over 50 trials registered at Clinicaltrials.gov, including: NCT04261517, NCT04303507, NCT04303299, NCT04304053, NCT04307693, NCT04316377, NCT04315948, NCT04321993, ECT2020-001113-21, NCT04323527, NCT04333732, NCT04332991, NCT04345419, NCT04341870, NCT04345289, NCT02735707, NCT04351347, NCT04341493, NCT04332094, NCT04349410, NCT04286503, NCT04328012, NCT04346147, NCT04428268, NCT04350671, EudraCT 2020-001303-16, EudraCT 2020-001825-29, EudraCT 2020-00124618, EudraCT 2015-002340-14 (REMAP-CAP), EudraCT 2020-001367-88, EudraCT number: 2020-00132131, EudraCT 2020-001357-52, NCT04434144, EudraCT 2020-001449-38, NCT04460547, NCT04446104, ISRCTN83971151 (Solidarity), EudraCT 2020-001366-11 (Solidarity Spain), EudraCT 2020-000982-18 (Norway Solidarity), NCT04381936 (RECOVERY), NCT04386070, NCT04330690, NCT04321616, EudraCT 2020-001448-24, EudraCT 2020-001723-13, EudraCT 2020-001528-32, NCT04435587, NCT04308668, NCT04376814, NCT04411433, NCT04392973, NCT04359615, NCT04387760, NCT04322123, EudraCT 2020-001605-23, NCT04365764, EudraCT 2020-001971-33",COVID-19 Treatment Accelerator (University of Washington/ NYU trial and Mahidol Oxford Tropical Medicine Research Unit trial); UK Government (University of Oxford RECOVERY trial and PRINCIPLE trial); Life Arc (PIONEER trial),"NCT04261517 (https://clinicaltrials.gov/ct2/show/NCT04261517?draw=5+%28prelim+outcomes%3F%29), IHU-Méditerranée Infection (https://www.mediterranee-infection.com/wp-content/uploads/2020/03/Hydroxychloroquine_final_DOI_IJAA.pdf), Journal of ZheJiang University (Medical Sciences) (http://www.zjujournals.com/med/CN/10.3785/j.issn.1008-9292.2020.03.03), medRxiv (https://doi.org/10.1101/2020.03.22.20040758), Int'l Journal of Antimicrobial Agents (https://doi.org/10.1016/j.ijantimicag.2020.105949), medRxiv (ChiCTR2000029559) (https://doi.org/10.1101/2020.04.10.20060558), medRxiv (https://doi.org/10.1101/2020.03.22.20040949), medRxiv (https://doi.org/10.1101/2020.04.02.20047050), medRxiv (https://doi.org/10.1101/2020.03.31.20048777), medRxiv (https://doi.org/10.1101/2020.03.24.20042366), medRxiv (NCT04323527) (https://doi.org/10.1101/2020.04.07.20056424), medRxiv (https://doi.org/10.1101/2020.04.08.20057539), medRxiv (https://doi.org/10.1101/2020.04.08.20054551), ScienceDirect (https://www.sciencedirect.com/science/article/pii/S0399077X20300858?via%3Dihub), ISAC (https://www.isac.world/news-and-publications/official-isac-statement), ScienceDirect (https://www.sciencedirect.com/science/article/pii/S0924857920300996), medRxiv (https://doi.org/10.1101/2020.04.10.20060699), medRxiv (ChiCTR2000029868) (https://doi.org/10.1101/2020.04.10.20060558), medRxiv (https://doi.org/10.1101/2020.04.14.20065276), medRxiv (https://doi.org/10.1101/2020.04.16.20065920), medRxiv (https://doi.org/10.1101/2020.04.16.20068205), medRxiv (https://doi.org/10.1101/2020.04.22.20075671), medRxiv (https://doi.org/10.1101/2020.04.21.20066761), medRxiv (https://doi.org/10.1101/2020.04.26.20081059), medRxiv (https://doi.org/10.1101/2020.04.27.20082180), medRxiv (https://doi.org/10.1101/2020.04.27.20073379), medRxiv (https://doi.org/10.1101/2020.04.27.20074583), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2012410), medRxiv (https://doi.org/10.1101/2020.05.02.20080036), medRxiv (https://doi.org/10.1101/2020.05.02.20088872), JAMA (https://jamanetwork.com/journals/jama/fullarticle/2766117), medRxiv (https://doi.org/10.1101/2020.05.07.20093831), medRxiv (https://doi.org/10.1101/2020.05.07.20094326), medRxiv (https://doi.org/10.1101/2020.05.05.20088757), BMJ (https://www.bmj.com/content/369/bmj.m1849), BMJ (https://www.bmj.com/content/369/bmj.m1844), medRxiv (https://doi.org/10.1101/2020.05.14.20101774), medRxiv (https://doi.org/10.1101/2020.05.12.20099028), medRxiv (https://doi.org/10.1101/2020.05.13.20094193), The Lancet (retracted) (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext), Lancet correction (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31249-6/fulltext), Lancet concern (https://www.thelancet.com/journals/lanpub/article/PIIS0140-6736(20)31290-3/fulltext), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2016638), Lancet retraction (https://www.thelancet.com/lancet/article/s0140673620313246), medRxiv (https://doi.org/10.1101/2020.05.18.20066902), medRxiv (https://doi.org/10.1101/2020.05.21.20109207), medRxiv (https://doi.org/10.1101/2020.06.11.20126359), medRxiv (https://doi.org/10.1101/2020.06.05.20123299), medRxiv (https://doi.org/10.1101/2020.06.05.20122705), medRxiv (https://doi.org/10.1101/2020.06.09.20116806), medRxiv (https://doi.org/10.1101/2020.06.10.20101105), medRxiv (https://doi.org/10.1101/2020.06.03.20121558), medRxiv (https://doi.org/10.1101/2020.05.27.20114066), medRxiv (https://doi.org/10.1101/2020.05.28.20114835), medRxiv (https://doi.org/10.1101/2020.06.01.20118901), medRxiv (https://doi.org/10.1101/2020.05.28.20115741), medRxiv (https://doi.org/10.1101/2020.05.19.20106906), medRxiv (https://doi.org/10.1101/2020.06.15.20132407), medRxiv (https://doi.org/10.1101/2020.06.16.20132597), medRxiv (https://doi.org/10.1101/2020.06.17.20133884), medRxiv (https://doi.org/10.1101/2020.06.16.20133066), medRxiv (https://doi.org/10.1101/2020.06.16.20132878), J of Critical Care (https://doi.org/10.1016/j.jcrc.2020.03.005), medRxiv (https://doi.org/10.1101/2020.06.19.20136093), medRxiv (https://doi.org/10.1101/2020.06.19.20135475), medRxiv (https://doi.org/10.1101/2020.06.23.20137992), medRxiv (https://doi.org/10.1101/2020.06.26.20056507), medRxiv (https://doi.org/10.1101/2020.06.24.20139386), WHO (https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19), It'l J Infectious Disease (ttps://doi.org/10.1016/j.ijid.2020.06.099), The Lancet (https://doi.org/10.1016/S0140-6736(20)31528-2), Annals Internal Med (https://doi.org/10.7326/M20-4207), Clinical Infect Dis (https://doi.org/10.1093/cid/ciaa1009), NEJM (10.1056/NEJMoa2019014), medRxiv (https://doi.org/10.1101/2020.07.20.20157651), medRxiv (https://doi.org/10.1101/2020.07.16.20155531), medRxiv (https://doi.org/10.1101/2020.07.17.20155960), medRxiv (https://doi.org/10.1101/2020.07.15.20151852), medRxiv (https://doi.org/10.1101/2020.07.12.20150110), medRxiv (https://doi.org/10.1101/2020.07.08.20148841), medRxiv (https://doi.org/10.1101/2020.07.06.20147470), medRxiv (https://doi.org/10.1101/2020.07.04.20146548), medRxiv (https://doi.org/10.1101/2020.07.04.20146381), NCT04627467 (https://clinicaltrials.gov/ct2/show/NCT04627467?term=Chloroquine&cond=COVID&draw=2&rank=3), BMC Infectious Disease (https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-05773-w), Cochrane Library (https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013587.pub2/full), The Lancet (https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00053-5/fulltext), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMc2035374), PubMed (https://pubmed.ncbi.nlm.nih.gov/33674391/), PubMed (https://pubmed.ncbi.nlm.nih.gov/33663646/), Nature (https://www.nature.com/articles/s41467-021-22446-z), JAMA (https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779044), Nature (https://www.nature.com/articles/s41467-021-23559-1), Lancet (https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(21)00058-2/fulltext), DovePress (https://www.dovepress.com/effectiveness-and-safety-of-favipiravir-compared-to-hydroxychloroquine-peer-reviewed-fulltext-article-IJGM), PubMed (https://pubmed.ncbi.nlm.nih.gov/34865592/), PubMed (https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06897-9)",,"FDA-approved since 1949; approved to treat malaria (chloroquine), FDA-approved since at least 1955, approved to treat malaria, rheumatoid arthritis, and lupus (hydroxychloroquine)",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/19/2022
Aarhus University,Treatment,Other,Clinical,Phase II trial ongoing July 2020; Phase II trials recruitment begin Oct 2020,senicapoc,"EudraCT 2020-001420-34, NCT04594668",The Danish Government,,Sickle cell anemia; Alzheimer's disease,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/22/2020
Biohaven/ Thomas Jefferson University,Treatment,Other,Clinical,Phase II/III recruiting July 2020,"vazegepant, CGRP receptor antagonist",NCT04346615,Unknown,,Acute migraine,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/26/2021
University of British Columbia/Apeiron Biologics,Treatment,Other,Clinical,Phase II trial recruiting July 2020. Patient enrollment complete Dec 2020.,APN01; recombinant soluble human Angiotensin Converting Enzyme 2,"NCT04335136, EudraCT 2020-001172-15",Austrian Government,"BioPharma (https://www.technologynetworks.com/biopharma/product-news/apn01-shows-clinical-benefit-for-severely-ill-covid-19-patients-in-phase-ii-trial-346670), ResearchGate (https://www.researchgate.net/publication/354606167_Development_of_a_novel_pan-variant_aerosol_intervention_for_COVID-19)","Acute lung injury, Acute respiratory distress syndrome, Pulmonary arterial hypertension",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/28/2021
Quotient Sciences/ CytoAgents,Treatment,Other,Pre-clinical,Phase I/II to start in 2020,"GP1681, small molecule inhibitor of cytokine release",,Richard King Mellon Foundation,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/10/2020
Noveome Biotherapeutics/ Singota Solutions,Treatment,Other,Clinical,Phase I/II to start in Q4 2020; Phase I IV trials expected 1st QTR 2021,"ST266, cell-free biologic made from anti-inflammatory proteins secreted by placental cells",NCT04720378,Commonwealth of Pennsylvania,,Multiple ophthalmic indications,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/24/2021
BioAegis Therapeutics Inc.,Treatment,Other,Clinical,Phase II trial has recruited one third of enrollees/Trial expanded to EU Dec 2020. ,recombinant human plasma gelsolin (rhu-pGSN),NCT04358406,Unknown,,Community-acquired pneumonia,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/7/2020
CTI Biopharma,Treatment,Other,Clinical,"Phase III trial recruiting July 2020, results expected by the end of 2020","pacritinib, oral kinase inhibitor with specificity for JAK2, IRAK1 and CSFIR",NCT04404361,Unknown,,Myelofibrosis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/7/2021
Pharming,Treatment,Other,Clinical,Phase II trial not yet recruiting July 2020; compassionate use; 2nd Phase II open label trial to start Sept 2020. First patient enrolled Dec 2020.,Ruconest (recombinant human C1 esterase inhibitor),"NCT04414631, NCT04530136",Unknown,"Pharming (https://www.pharming.com/sites/default/files/imce/Press%20releases/Ruconest%20Covid%20compassionate%20use%2021%20April%202020.pdf), Front. Immunol. (https://www.frontiersin.org/articles/10.3389/fimmu.2020.02072/full)",,"FDA-approved since 2014, approved to treat hereditary angioedema",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/14/2021
Algernon Pharmaceuticals,Treatment,Other,Clinical,Phase IIb/III trial to start July 2020. Patients enrolled Nov 2020. Patient enrollment complete Dec 2020.,"Cerocal (ifenprodil), NP-120, an NDMA receptor glutamate receptor antagonist targeting Glu2NB",NCT04382924,Unknown,BioSpace (https://www.biospace.com/article/releases/algernon-pharmaceuticals-announces-topline-data-from-its-phase-2b-3-covid-19-trial-of-ifenprodil/),Idiopathic Pulmonary Fibrosis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/14/2021
"Eiger BioPharmaceuticals, Inc./ Johns Hopkins University",Treatment,Other,Clinical,Phase II began in April 2020,Peginterferon lambda,"NCT04331899, NCT04344600",Unknown,"medRxiv (doi: https://doi.org/10.1101/2020.11.09.20228098), The Lancet (https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3719080), The Lancet (https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30566-X/fulltext), Nature (https://www.nature.com/articles/s41467-021-22177-1), PR Newswire (https://www.prnewswire.com/news-releases/eigers-single-dose-peginterferon-lambda-for-covid-19-reduced-risk-of-hospitalization-or-er-visits-by-50-in-a-predominantly-vaccinated-population-in-phase-3-together-study-301504827.html )",Hepatitis Delta,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/21/2022
Feinstein Institutes for Medical Research at Northwell Health/ Alchem,Treatment,Other,Clinical,Phase II study underway in April 2020; Phase II trials recruiting Nov 2020 ,"Pepcid (famotidine), histamine-2 (H2) receptor antagonist","NCT04389567, NCT04370262, NCT04565392, NCT04621149",Unknown,"medRxiv (https://doi.org/10.1101/2020.05.01.20086694), Gastroenterology (10.1053/j.gastro.2020.05.053), medRxiv (https://doi.org/10.1101/2020.06.30.20137752), PubMed (https://pubmed.ncbi.nlm.nih.gov/33625613/), PubMed (https://pubmed.ncbi.nlm.nih.gov/33625612/), medRxiv (https://www.medrxiv.org/content/10.1101/2021.03.14.21253537v1.full), American Journal of Gastroenterology (https://journals.lww.com/ajg/Abstract/2021/04000/Comparative_Effectiveness_of_Famotidine_in.21.aspx), PubMed (https://pubmed.ncbi.nlm.nih.gov/34735523/)",,"FDA-approved since 1986, approved to treat ulcers, gastroesophageal reflux disease, erosive esophagitis, pathological hypersecretory conditions, and to reduce the risk of duodenal ulcer recurrence",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/11/2021
Multiple global research sponsors; ACCORD Trial,Treatment,Other,Clinical,Phase II/III/IV trials began June 2020; Sept 2020,"heparin; low molecular weight heparin (enoxaparin), anticoagulant
","NCT04366960, NCT04360824, NCT04359277, NCT04354155, NCT04367831, NCT04345848, NCT04373707, NCT04372589, NCT04362085, NCT04344756, NCT04408235, NCT04406389, NCT04400799, NCT04377997, NCT04393805, NCT04427098, EudraCT 2020-001739-28, EudraCT 2020-001308-40, EudraCT  2020-001709-21, EudraCT 2020-001891-14, EudraCT 2020-001972-13, NCT04444700, NCT04466670, EudraCT 2020-001736-95 (ACCORD Trial), EudraCT 2020-001708-41, EudraCT 2020-001823-15, NCT04485429, NCT04461925, NCT04486508, NCT04511923, NCT04512079, NCT04530578, NCT04508439, NCT04528888, NCT04542408, NCT04545541, NCT04584580, NCT04635241, NCT04655586",Unknown,"medRxiv (https://doi.org/10.1101/2020.03.28.20046144), medRxiv (https://doi.org/10.1101/2020.04.15.20067017), medRxiv (https://doi.org/10.1101/2020.04.23.20076851), JACC (http://www.onlinejacc.org/content/early/2020/05/05/j.jacc.2020.05.001?_ga=2.52741547.2046438614.1588863110-2104341714.1587686709), medRxiv (https://doi.org/10.1101/2020.05.27.20114694), J. Thrombosis and Thrombolysis (doi: 10.1007/s11239-020-02162-z), medRxiv (https://doi.org/10.1101/2020.06.22.20134957), medRxiv (https://doi.org/10.1101/2020.07.20.20147769), NIH (https://www.nih.gov/news-events/news-releases/full-dose-blood-thinners-decreased-need-life-support-improved-outcome-hospitalized-covid-19-patients), The Lancet (https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00054-7/fulltext), PubMed (https://pubmed.ncbi.nlm.nih.gov/33666246/), PubMed (https://pubmed.ncbi.nlm.nih.gov/33758036/), medRxiv (https://www.medrxiv.org/content/10.1101/2021.03.21.21253754v1.full), The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01291-5/fulltext), Hematology Advisor (https://www.hematologyadvisor.com/home/topics/general-hematology/heparin-covid19-case-studies-hematoma-treatment-risk/), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2103417), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2105911), PubMed (https://pubmed.ncbi.nlm.nih.gov/34862791/), Journal LWW (https://journals.lww.com/pec-online/_layouts/15/oaks.journals/downloadpdf.aspx?an=00006565-202202000-00026&pdfToken=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), PubMed (https://pubmed.ncbi.nlm.nih.gov/35099994/), Antiviral Research Journal (https://www.sciencedirect.com/science/article/pii/S0166354220302874)",,FDA-approved since at least 1993; approved to prevent blood clots and prevent/treat venous thromboembolism and myocardial infarction,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/17/2022
Pfizer; other global research sponsors,Treatment,Other,Clinical,Pfizer and other Phase II trial not yet recruiting July 2020,"Xeljanz (tofacitinib), Janus kinase (JAK) inhibitor","NCT04332042, NCT04415151, NCT04390061, NCT04412252, NCT04469114, EudraCT 2020-001357-52, EudraCT 2020-002035-30",Unknown,,,"FDA-approved since 2012, approved to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2021
Karyopharm Therapeutics,Treatment,Other,Clinical,Phase II trial ongoing July 2020,"Xpovio (selinexor), oral, selective inhibitor of nuclear export (SINE) compound","NCT04355676, NCT04349098, EudraCT 2020-001411-25, NCT04534725",Unknown,,Treat various cancers,"FDA-approved since 2019, approved to treat multiple myeloma",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/7/2020
pHbarrier,Treatment,Other,Pre-clinical,Unknown,"pH barrier, transepithelial nebulized alkaline treatment",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/30/2020
Washington University School of Medicine in St. Louis/ Covid-19 Early Treatment Fund (CETF),Treatment,Other,Clinical,Phase II trial recruiting May 2020; Phase II trial completed Oct 2020,"Luvox (fluvoxamine), a selective serotonin reuptake inhibitor","NCT04342663, NCT04668950, NCT04711863, NCT04718480, NCT04727424, NCT04885530",Unknown,"PR Newswire (https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fantidepressant-plays-key-role-in-battling-covid-19-at-california-horseracing-track-301209454.html&data=04%7C01%7C%7Cff2378d89cea417f6a1308d8bcb30f95%7C4f96fd4653b94a44b39518a615885a42%7C0%7C0%7C637466824567197051%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=SyYCi75yKFRQF0BymA4S11HD6YHozibWluzgkzP0oHw%3D&reserved=0), Open Forum Infectious Diseases (https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofab050/6124100?searchresult=1), Lancet (https://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(21)00448-4.pdf)",,"FDA-approved since 1994, approved to treat obsessive compulsive disorder",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/21/2022
University of Hawaii (Boehringer Ingelheim); other global research sponsors,Treatment,Other,Clinical,Phase II Univ. of Hawaii trial started June 2020,Micardis (telmisartan),"NCT04360551, NCT04355936, NCT04359953, EudraCT 2020-001303-16, EudraCT 2020-001435-27, NCT04394117, NCT04466241, NCT04356495, NCT04467931, NCT04510662",Unknown,medRxiv (https://www.medrxiv.org/content/10.1101/2020.08.04.20167205v2),,"FDA-approved since 1998, approved to treat hypertension and reduce cardiovascular risk in patients unable to take ACE inhibitors",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/9/2020
Insmed Inc.,Treatment,Other,Clinical,Phase III trial recruiting July 2020,"brensocatib, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1)","EudraCT 2020-001643-13, ISRCTN30564012",Unknown,,Bronchiectasis and other inflammatory diseases,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/18/2022
"RedHill Biopharma/ NIAID
",Treatment,Other,Clinical,Phase II/III trials begin 4th qtr 2020; Unique home-based phase II/III trial started March 2021.,"RHB-107 (upamostat, WX-671), serine protease inhibitor, orally administered",NCT04723537,Unknown,,"Various oncology indications
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/14/2022
Union Therapeutics/ Institute Pasteur Korea/ Daewoong Therapeutics; First Wave Bio/ANA Therapeutics,Treatment,Other,Clinical,"Danish Medicines Agency approved a Phase I trial July 2020 (UN9011, Union Therapeutics); Daewoong to apply for Phase I trial in Korea in July 2020; FDA cleared to begin clinical trials in Aug 2020; Dosing completed in Aug 2020","UNI9011 (Union Therapeutics), FW-1022 (First Wave Bio), DWRX2003 (Daewoong) niclosamide","NCT04345419, NCT04399356, NCT04436458, EudraCT 2020-002233-15",Unknown,,Atopic Dermatitis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/15/2020
University of Alabama at Birmingham; Leading Biosciences,Treatment,Other,Clinical,Phase II recruiting July 2020,"Lysteda/Cyklokapron/LB1148 (tranexamic acid), an antifibrinolytic","NCT04338074, NCT04338126, NCT04390217, NCT04550338",Unknown,,,"FDA-approved since 1986, approved to treat cyclic heavy menstrual bleeding",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/13/2021
Pulmotect,Treatment,Other,Phase II,Phase II trials recruiting July 2020; Phase 2 results released February 2022.,PUL-042 inhalation solution,"NCT04312997, NCT04313023",Unknown,"Global Biodefense (https://globalbiodefense.com/2021/02/07/macaques-develop-promising-immune-response-to-sars-cov-2/), Science Direct (https://www.sciencedirect.com/science/article/pii/S0198885921001166)",Prevent and treat respiratory complications in immunosuppressed cancer patients,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/17/2022
Abivax,Treatment,Other,Clinical,"Phase IIb/III trial started July 2020, top line results expected in 2020",ABX464 ,"NCT04393038, EudraCT 2020-001673-75",Bpifrance,,"Ulcerative colitis; rheumatoid arthritis; hepatocellular carcinoma
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/1/2021
Exvastat Ltd / Global sponsors,Treatment,Other,Clinical,Phase II and Phase III trials recruiting July 2020,"Gleevec (imatinib), kinase inhibitor","NCT04346147, NCT04357613, NCT04356495, NCT04422678, NCT04394416, EudraCT 2020-001435-27, EudraCT 2020-001321-31, NCT04794088, EudraCT 2020-005447-23, NCT04953052",Innovative Medicines Initiative,"PubMed (https://pubmed.ncbi.nlm.nih.gov/33956935/), The Lancet (https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00237-X/fulltext), Exvastat (https://exvastat.com/News/countercovid-study-shows-imatinib-significantly-reduces-mortality-by-49-in-patients-with-covid-19)",,"FDA-approved since 2001, approved to treat various cancers",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/2/2021
Faron Pharmaceuticals / REMAP-CAP global trial/ WHO SOLIDARITY trial/ various global researchers,Treatment,Other,Clinical,Results from various trials released June 2020; REMAP-CAP trial recruiting May 2020 ,Traumakine (interferon beta 1-a),"NCT02735707, IRCT20100228003449N28, NCT04350671, NCT04343768, NCT04315948, NCT04492475",Unknown,"medRxiv (https://doi.org/10.1101/2020.05.28.20116467), Antimicrob Agents and Chemo (10.1128/AAC.01061-20)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/10/2021
Noxopharm,Treatment,Other,Clinical,Phase I started July 2020; Phase I approved in Austrilia for NOXCOVID-1 trial to begin at clinical sites in Ukraine and Moldova,Veyonda (idronoxil),NCT04488575,Unknown,(https://www.proactiveinvestors.com.au/companies/news/947324/noxopharms-interim-trial-data-indicates-veyonda-potentially-prevents-cytokine-storm-in-patients-with-moderately-severe-covid-19-947324.html),Prostate cancer,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/26/2021
AstraZeneca/ Saint Luke's Mid America Heart Institute; Cambridge University Hospitals NHS Foundation Trust; TACTIC-E trial studying dapagliflozin + ambrisentan,Treatment,Other,Clinical,Phase III study started in April 2020 (AstraZeneca),"Farxiga (dapagliflozin), sodium-glucose cotransporter 2 (SGLTs) inhibitor","NCT04350593, NCT04393246",Unknown,,Heart failure; Chronic kidney disease,"FDA-approved since 2014, approved to improve glycemic controls in adults with type 2 diabetes and reduce the risk of hospitalization for heart failure in adults with type 2 diabetes",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/15/2021
BioIncept,Treatment,Other,Pre-clinical,Preparing for a Phase I/IIa trial in May 2020,"sPIF (synthetic pre implantation factor)
",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/20/2020
Synairgen/ University of Southampton,Treatment,Other,Clinical,Phase II trial initial results released July 2020,"SNG001, inhaled formulation of interferon beta-1a","NCT04385095, NCT04732949",Unknown,"Synairgen (https://www.globenewswire.com/news-release/2020/07/20/2064154/0/en/Synairgen-announces-positive-results-from-trial-of-SNG001-in-hospitalised-COVID-19-patients.html), The Lancet (DOI:https://doi.org/10.1016/S2213-2600(20)30511-7), Healio (https://www.healio.com/news/pulmonology/20201123/inhaled-interferon-beta-improves-odds-of-recovery-from-covid19), Clinical Trials Arena (https://www.clinicaltrialsarena.com/news/synairgen-inhaled-treatment-hospitalisation/), Globe Newswire (https://www.globenewswire.com/news-release/2021/05/12/2227975/0/en/Preliminary-results-for-the-year-ended-31-December-2020.html), Globe Newswire (https://www.globenewswire.com/news-release/2021/05/24/2234443/0/en/Synairgen-announces-results-of-in-vitro-studies-showing-antiviral-activity-of-interferon-beta-against-key-SARS-CoV-2-variants.html)",Asthma patients with cold or flu infection; COPD patients with viral infections,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/18/2022
Numerous trials with research sponsors globally; University of Oxford RECOVERY trial; REMAP-CAP global trial; Covis Pharma B.V.,Treatment,Other,Clinical,Japan approves dexmethasone as COVID treatment July 2020; RECOVERY trial results released (dexamethasone) June/July 2020; Phase III trial to begin July 2020,Methylprednisolone/ ciclesonide (Alvesco)/ hydrocortisone/ corticosteroids,"NCT04244591, NCT04263402, NCT04273321, ChiCTR2000029656, ChiCTR2000029386, NCT02735707, NCT04330586, 2020-001113-21, NCT04345445, NCT04349410, NCT04329650, EudraCT 2015-002340-14 (REMAP-CAP), EudraCT 2020-001854-23, EudraCT 2020-001413-20, NCT04381936 (RECOVERY), NCT04485429, NCT04461925, NCT04452565, NCT04484493",UK Government (University of Oxford RECOVERY trial),"medRxiv (https://doi.org/10.1101/2020.03.06.20032342), medRxiv (https://doi.org/10.1101/2020.03.28.20045955), medRxiv (https://doi.org/10.1101/2020.04.07.20056390), medRxiv (https://doi.org/10.1101/2020.04.17.20064469), medRxiv (https://doi.org/10.1101/2020.04.17.20069773), medRxiv (https://doi.org/10.1101/2020.04.21.20066258), medRxiv (https://doi.org/10.1101/2020.05.04.20074609), medRxiv (https://doi.org/10.1101/2020.05.08.20094755), medRxiv (https://doi.org/10.1101/2020.05.11.20097709), medRxiv (https://doi.org/10.1101/2020.05.22.20110544), (http://www.ox.ac.uk/news/2020-06-16-low-cost-dexamethasone-reduces-death-one-third-hospitalised-patients-severe), medRxiv (https://doi.org/10.1101/2020.06.15.20132407), medRxiv (https://doi.org/10.1101/2020.06.17.20133579), medRxiv (https://doi.org/10.1101/2020.06.17.20134031), medRxiv (https://doi.org/10.1101/2020.06.19.20135491), medRxiv (https://doi.org/10.1101/2020.06.22.201372730), medRxiv (https://doi.org/10.1101/2020.06.23.20137471), medRxiv (https://doi.org/10.1101/2020.06.19.20109173), medRxiv (https://doi.org/10.1101/2020.06.22.20137273), medRxiv (https://doi.org/10.1101/2020.06.22.20134957), medRxiv (https://doi.org/10.1101/2020.06.22.20133413), NEJM (DOI: 10.1056/NEJMoa2021436), medRxiv (https://doi.org/10.1101/2020.07.16.20152868), medRxiv (https://doi.org/10.1101/2020.07.17.20155960), medRxiv (https://doi.org/10.1101/2020.07.18.20157008), medRxiv (https://doi.org/10.1101/2020.07.17.20155994), medRxiv (https://doi.org/10.1101/2020.07.17.20156315), medRxiv (https://doi.org/10.1101/2020.07.02.20145565), JAMA (doi:10.1001/jama.2020.17023), Lancet (DOI:https://doi.org/10.1016/S2213-2600(20)30503-8), https://clinicaltrials.gov/ct2/show/NCT04636671?term=Methylprednisolone&cond=COVID&draw=2&rank=5), MedRxiv (https://www.medrxiv.org/content/10.1101/2021.02.03.21251088v1), PubMed (https://pubmed.ncbi.nlm.nih.gov/33632000/), Oxford Academic (https://academic.oup.com/bioinformatics/advance-article/doi/10.1093/bioinformatics/btab163/6164952?login=true), medRxiv (https://www.medrxiv.org/content/10.1101/2021.03.05.21251351v1), Academic (https://academic.oup.com/cid/article/72/9/e373/5891816), PLOS One (https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0252057), NEJM (https://www.jwatch.org/na53560/2021/06/01/methylprednisolone-better-dexamethasone-severe-covid-19), Science Direct (https://www.sciencedirect.com/science/article/pii/S1876034121001581), PubMed (https://pubmed.ncbi.nlm.nih.gov/34153729/), DocWire News (https://www.docwirenews.com/abstracts/intravenous-methylprednisolone-with-or-without-tocilizumab-in-patients-with-severe-covid-19-pneumonia-requiring-oxygen-support-a-prospective-comparison/), PubMed ( https://pubmed.ncbi.nlm.nih.gov/34122618/ ), PubMed (https://pubmed.ncbi.nlm.nih.gov/33945381/), PubMed (https://pubmed.ncbi.nlm.nih.gov/34389970/), Journal of Emergency Medicine (https://scirp.org/journal/paperinformation.aspx?paperid=111400), CTA (https://onlinelibrary.wiley.com/doi/full/10.1002/clt2.12056), PubMed (https://pubmed.ncbi.nlm.nih.gov/34291223/), Reactions Weekly (https://link.springer.com/article/10.1007/s40278-021-02098-7), Cureus (https://www.cureus.com/articles/60588-encephalopathy-due-to-covid-19-with-great-response-to-glucocorticoids), Critical Care Explorations (https://journals.lww.com/ccejournal/Fulltext/2021/07000/Methylprednisolone_and_60_Days_in_Hospital.33.aspx), JAMA (https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2784632), PubMed (https://pubmed.ncbi.nlm.nih.gov/34650867/), PubMed (https://pubmed.ncbi.nlm.nih.gov/34677701/), Frontiers (https://www.frontiersin.org/articles/10.3389/fmed.2021.758405/full), Oxford (https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofab619/6456439), PubMed (https://pubmed.ncbi.nlm.nih.gov/34856779/), MDPI (https://www.mdpi.com/2077-0383/10/24/5812/pdf), DARU Journal of Medical Sciences (https://link.springer.com/article/10.1007/s40199-021-00430-8), PLOS One (https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0266901#:~:text=Physicians%20should%20avoid%20routine%20methylprednisolone,shock%20or%20acute%20respiratory%20failure.)",,"FDA-approved since at least the 1950s; approved to treat many diseases, including anti-inflammatory conditions and some cancers; asthma (ciclesconide)",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/29/2022
National Institute of Allergy and Infectious Disease (NIAID)'s Adaptive COVID-19 Treatment Trial; Nova Scotia Health Authority; Hospital of Prato; University of Colorado (Eli Lilly); TACTIC-R trial,Treatment,Other,Clinical,"Eli Lilly Phase III trial started June 2020; NIAID trial remdesivir + baricitinib recruiting May 2020, Received Emergency Use Authorization from the FDA in Nov 2020","Olumiant (baricitinib), Janus kinase (JAK) inhibitor","NCT04321993, NCT04320277, NCT04340232, NCT04280705, NCT04345289, NCT04346147, NCT04358614, NCT04373044, NCT04438629, NCT04421027, NCT04362943, NCT04393051, NCT04401579, NCT04390464, NCT04399798, NCT04365764, EudraCT 2020-001246-18, EudraCT 2020-001367-88, EudraCT 2020-001517-21, EudraCT 2020-001854-23, EudraCT 2020-001354-22 (TACTIC-R), EudraCT 2020-001321-31, EudraCT 2020-001052-18, ISRCTN11188345, NCT04640168, NCT04693026",Unknown,"medRxiv (https://doi.org/10.1101/2020.06.26.20135319), J Infect (10.1016/j.jinf.2020.04.017), Medical News Today (https://www.medicalnewstoday.com/articles/remdesivir-and-baricitinib-shortened-recovery-time-from-covid-19), Eli Lilly (https://investor.lilly.com/news-releases/news-release-details/lilly-and-incyte-announce-results-phase-3-cov-barrier-study), The Pharma Letter (https://www.thepharmaletter.com/article/baricitinib-misses-goal-in-phase-iii-hospitalized-covid-19-patient-study)",,"FDA-approved since 2018, approved to treat rheumatoid arthritis",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/17/2022
Numerous research sponsors globally,Treatment,Other,Clinical,Phase II recruiting July 2020; Individual patient expanded access ,"dipyridamole (Persantine), anticoagulant","NCT04424901, NCT04391179, NCT04410328",Unknown,"medRxiv (https://doi.org/10.1101/2020.02.27.20027557), Acta Pharm Sin B (https://doi.org/10.1016/j.apsb.2020.04.008), Nature (https://www.nature.com/articles/s41577-021-00536-9), Nature (https://www.nature.com/articles/s41392-021-00508-4), Nature (https://www.nature.com/articles/s41418-021-00805-z), Medical Hypotheses (https://www.sciencedirect.com/science/article/pii/S0306987721002036?dgcid=rss_sd_all)",,"FDA-approved since 1961, approved to prevent postoperative thromboembolic complications of cardiac valve replacement",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/23/2021
Applied Therapeutics/ numerous New York City hospitals,Treatment,Other,Clinical,Phase II recruiting July 2020; Individual patient expanded access,"AT-001, aldose reductase inhibitor",NCT04365699,Unknown,"JACC (https://casereports.onlinejacc.org/content/2/9/1331), ScienceDirect (https://www.sciencedirect.com/science/article/pii/S1871402121003489)",Diabetic cardiomyopathy,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/10/2020
Amarin Corp,Treatment,Other,Clinical,Unknown,"Vascepa (icosapent ethyl), a form of eicosapentaenoic acid","NCT04412018, NCT04460651",Estudios Clínicos Latino América,"https://investor.amarincorp.com/news-releases/news-release-details/vascepar-icosapent-ethyl-related-scientific-findings-be, https://investor.amarincorp.com/news-releases/news-release-details/amarin-highlights-multiple-vascepar-icosapent-ethyl-related, PRNewswire (https://www.prnewswire.com/news-releases/canadian-pilot-study-suggests-prescription-icosapent-ethyl-vascepa-might-improve-symptoms-of-covid-19-and-reduce-inflammation-301191627.html), AJMC (https://www.ajmc.com/view/study-finds-vascepa-reduces-patient-reported-covid-19-symptoms)",,"FDA approved since 2012, approved to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina, and reduce triglyceride levels in patients with severe hypertriglyceridemia",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/7/2021
"Orpheris
  (Ashvattha Therapeutics)",Treatment,Other,Clinical,FDA agreed to Phase II June 2020; patient enrollment began Sept 2020,"OP-101, dendrimer-based therapy",NCT04458298,Unknown,"Ashvattha Therapeutics (https://avttx.com/ashvattha-therapeutics-announces-positive-interim-data-from-ongoing-phase-2-prana-clinical-study-of-op-101-in-severe-covid-19-patients/), Science Translational Medicine (https://www.science.org/doi/10.1126/scitranslmed.abo2652)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/27/2022
Resverlogix,Treatment,Other,Clinical,Unknown,"apabetalone (RVX-208), selective BET (bromodomain and extra-terminal) inhibitor",NCT04894266,Unknown,"Resverlogix Corp. (https://www.resverlogix.com/investors/news?article=686), PNAS (https://www.pnas.org/content/118/1/e2021450118), BioRxiv (https://www.biorxiv.org/content/10.1101/2020.08.23.258574v3.full.pdf), Resverlogix Corp. (https://www.resverlogix.com/investors/news?article=691), Resverlogix Corp. (https://www.resverlogix.com/investors/news?article=693), bioRxiv (https://www.biorxiv.org/content/10.1101/2021.03.10.432949v1), Resverlogix Corp. (https://www.resverlogix.com/investors/news?article=694), Cell (https://www.cell.com/cell/fulltext/S0092-8674(21)00354-8), Resverlogix Corp. (https://www.resverlogix.com/investors/news?article=696), mdpi (https://www.mdpi.com/2227-9059/9/4/437)",Treat various conditions ,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/18/2022
King's College London,Treatment,Other,Clinical,Phase IV trial recruiting in July 2020,Flarin (lipid ibuprofen),"NCT04334629, EudraCT 2020-001203-16",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/16/2021
"Various researchers globally, including University of Oxford",Treatment,Other,Clinical,"Observational trial completed April in France;, Phase III trial recruiting Sept 2020 in France",almitrine,"NCT04357457, NCT04380727, EudraCT 2020-002567-57",LifeArc (University of Oxford trial),American Journal of Physiology (https://journals.physiology.org/doi/full/10.1152/ajplung.00280.2021),Various lung diseases including Acute Respiratory Distress Syndrome (ARDS),N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/14/2021
Vicore Pharma,Treatment,Other,Clinical,Phase II dosing began of ATTRACT study in India,"VP01, C21, Angiotensin II Type 2 receptor activator ","NCT04452435, NCT04878913, NCT04880642",Life Arc ,"Vicore Pharma (https://vicorepharma.com/investors/press-releases/press/?releaseID=82FD41BA3EBA3689), Vicore Pharma (https://vicorepharma.com/investors/press-releases/press/?releaseID=ED4DA8E16B826D8A, MedRxiv (https://www.medrxiv.org/content/10.1101/2021.01.26.21250511v1), https://clinicaltrials.gov/ct2/show/results/NCT04452435?term=vicore&cond=COVID-19&draw=2&rank=1&view=results",Pulmonary fibrosis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/2/2021
"Various researchers worldwide, including Ashford and St Peters Hospital NHS Trust/  Guangdong Uni-Innovation Pharmaceuticals Co., Ltd./ Clear Creek Bio, LLC/BMS",Treatment,Other,Clinical,FDA IND application accepted for Phase Ia/II open label safety trials began in summer 2020; First patient dosed for Phase I trial Sept 2020 (Brequinar); Phase II recruitment began Nov 2020 (CRISIS 2),"leflunomide, pyrimidine synthesis inhibitor; Dihydroorotate dehydrogenase inhibitor (DHODH- Brequinar)","NCT04361214, NCT04575038, NCT04532372","Life Arc (Ashford and St Peters Hospital NHS Trust/ Guangdong Uni-Innovation Pharmaceuticals Co., Ltd. trial)",medRxiv (https://doi.org/10.1101/2020.05.29.20114223) ,,"FDA-approved since 1998, approved to treat rheumatoid arthritis",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/8/2020
"Various researchers worldwide, including University College London/ The Francis Crick  Institute (COVASE study)/ I-SPY COVID trial",Treatment,Other,Clinical,Phase III trials recruiting June 2020,"Pulmozyme (nebulised dornase alfa), a recombinant DNase enzyme","NCT04409925, NCT04359654, NCT04387786, NCT04355364, NCT04402944, NCT04402970",Life Arc (COVASE study),"https://clinicaltrials.gov/ct2/show/results/NCT04402970?term=Pulmozyme&cond=COVID-19&draw=2&rank=8&view=results, PubMed (https://pubmed.ncbi.nlm.nih.gov/34139362/)",,"FDA-approved since 1993, approved to treat cystic fibrosis",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/18/2021
"Sun
  Pharmaceutical Industries Ltd",Treatment,Other,Clinical,"Phase II trial started June 2020, results expected by October","AQCH, plant-derived (phytopharmaeutical) drug",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/7/2020
Genentech,Treatment,Other,Clinical,Unknown,"MSTT1041A (anti-ST2, the receptor for IL-33)",NCT04386616,Biomedical Advanced Research and Development Authority (BARDA),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/17/2021
Genentech,Treatment,Other,Clinical,Unknown,UTTR1147A (IL-22-Fc),NCT04386616,Biomedical Advanced Research and Development Authority (BARDA),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/17/2021
"Genetic Engineering and Biotechnology Center (CIGB), Cuba",Treatment,Other,Clinical,Unknown,"CIGB-258, immunoregulatory peptide, Jusvinza","https://rpcec.sld.cu/ensayos/RPCEC00000313-Sp, ",Ministry of Public Health of Cuba,"medRxiv (https://doi.org/10.1101/2020.05.27.20110601), PubMed (https://pubmed.ncbi.nlm.nih.gov/33629254/)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/26/2021
FSD Pharma,Treatment,Other,Clinical,Phase I topline results released June 2020; IND submitted to FDA Aug 2020,FSD-201 (ultramicronized palmitoylethanolamide),,,(https://www.businesswire.com/news/home/20200621005031/en/FSD-Pharma-Reports-Favorable-Topline-Results-Phase),Respiratory infections,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/30/2020
PhaseBio,Treatment,Other,Clinical,Phase II trial started July 2020 and results in Q4 2020. Clinical trial terminated Dec 2020.,"PB1046, long-acting, sustained release human vasoactive intestinal peptide (VIP) analogue",NCT04433546,,,Pulmonary arterial hypertension,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12//2020
PTC Therapeutics,Treatment,Other,Clinical,Phase II/III trial initiated in Australia November 2020,"PTC299, oral small molecule inhibitor of dihydroorotate dehydrogenase (DHODH)","NCT04439071, EudraCT 2020-001872-13",,"bioRxiv (https://www.biorxiv.org/content/10.1101/2020.08.05.238394v1), Science Direct (https://www.sciencedirect.com/science/article/pii/S0168170220311539)",Various oncology indications,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/17/2021
Dompe farmaceutici (as part of Exscalate4CoV),Treatment,Other,Clinical,Safety/efficacy trials began in Italy Oct 2020 ,"raloxifene (Evista), an estrogen agonist/antagonist",,,"Mdpi (https://www.mdpi.com/1422-0067/22/1/257), FEBS Press (https://febs.onlinelibrary.wiley.com/doi/10.1002/2211-5463.13153)",Eudra CT 2020-003936-25,"FDA approved since 1997, approved to treat osteoporosis and reduce risk of breat cancer in postmenopausal women with osteoporosis",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/28/2021
"Fulcrum
  Therapeutics",Treatment,Other,Clinical,"Phase III trial to begin June 2020; Enrollment began for Phase III trials, Phase III trial discontinued March 2020","losmapimod, oral selective p38 mitogen activated protein kinase inhibitor",,,,"Multiple indications, including facioscapulohumeral muscular dystrophy ",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/15/2021
"Applied
  Biology/ Brown University/ Corpometria Institute",Treatment,Other,Clinical,Unknown,"dutasteride, anti-androgen","NCT04446429, NCT04729491",,Doc Wire News (https://www.docwirenews.com/abstracts/early-antiandrogen-therapy-with-dutasteride-reduces-viral-shedding-inflammatory-responses-and-time-to-remission-in-males-with-covid-19-a-randomized-double-blind-placebo-controlled-interventional/),,"FDA approved since 2001, approved to treat benign prostatic hyperplasia",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/3/2021
Merck KGaA,Treatment,Other,Clinical,FDA cleared Phase 2 trial to begin in June 2020; Phase 2 recruitment began Aug 2020,"M5049, small molecule that block the activation of Toll-like receptor (TLR)7 and TLR8",NCT04448756,Unknown,,Various immuology indications,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/13/2020
Eisai ,Treatment,Other,Clinical,Added to REMAP-COVID trial in June 2020; First patient enrolled in Aug 2020,"Eritoran, TLR-4 antagonist",,,,Sepsis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/13/2020
Zydus Cadila/ Avant Sante Research Center,Treatment,Other,Clinical,Phase IIb trials approved to start in Mexico July 2020,"desidustat, a hypoxia inducible factor prolyl hydroxylase inhibitor",NCT04463602,Unknown,Zydus Cadila (https://zyduscadila.com/public/pdf/pressrelease/Zydus_%20Desidustat_shows_efficacy_and_safety_in_treating_Hypoxia_in_hospitalized_Covid_19_patients_in_Mexico.pdf),Chronic Kidney Disease,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/10/2022
ViralClear Pharmaceuticals,Treatment,Other,Clinical,Phase II trial recruiting July 2020,"merimepodib, IMPDH inhibitor",NCT04410354 (terminated),Unknown,,Chronic Hepatitis C; Psoriasis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/9/2020
RECOVERY trial and multiple global research sponsors,Treatment,Other,Clinical,Unknown,"azithromycin, antibiotic","Over 100 clinical trials registered at clinicaltrials.gov; EudraCT 2020-001303-16, EudraCT 2020-001246-18, EudraCT 2015-002340-14 (REMAP-CAP), EudraCT 2020-001449-38, NCT04446429, EudraCT 2020-001723-13, EudraCT 2020-001113-21 (RECOVERY Trial), NCT04381936 (RECOVERY), NCT04411433, EudraCT 2020-001605-23, EudraCT 2020-001971-33, NCT04461925, NCT04321278, NCT04370782",Unknown,"Lancet (https://doi.org/10.1016/S0140-6736(20)31862-6), NEJM (https://www.nejm.org/doi/full/10.1056/nejmoa2019014), Wiley (https://onlinelibrary.wiley.com/doi/10.1111/ijcp.13856), https://clinicaltrials.gov/ct2/show/study/NCT04673214?term=azithromycin&cond=COVID-19&draw=2&rank=29, MedRxiv (https://www.medrxiv.org/content/10.1101/2020.12.10.20245944v1.full.pdf), PubMed (https://pubmed.ncbi.nlm.nih.gov/33465426/), Clinical Trials Arena (https://www.clinicaltrialsarena.com/news/uk-study-azithromycin-doxycycline/), The Lancet (https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00053-5/fulltext), The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00461-X/fulltext), PubMed (https://pubmed.ncbi.nlm.nih.gov/33934125/), Wiley (https://onlinelibrary.wiley.com/doi/10.1002/jbt.22795), Wiley (https://onlinelibrary.wiley.com/doi/full/10.1002/rmv.2258), medRxiv (https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1), European Respiratory Journal (https://erj.ersjournals.com/content/early/2021/05/28/13993003.00752-2021?rss=1), PubMed (https://pubmed.ncbi.nlm.nih.gov/34106964/), Wiley (https://onlinelibrary.wiley.com/doi/abs/10.1111/ijcp.14461), JAMA (https://jamanetwork.com/journals/jama/fullarticle/2782166?resultClick=24), PubMed (https://pubmed.ncbi.nlm.nih.gov/34315385/), Journal of Medical Virology (https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.27259), Lancet (https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00379-9/fulltext)",,FDA approved since at least 2005; approved to treat or prevent bacterial infections,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/16/2021
I-SPY COVID Trial (Allergan); National Center for Advancing Translational Science (NCATS) Biomedical Advanced Research and Development Authority (BARDA),Treatment,Other,Clinical,Clinical trials to start in Aug 2020; ACTIV-1 1M Phase III trials began Oct 2020,"Cenicriviroc, chemokine receptor 2 and 5 dual antagonist","NCT04593940, EudraCT 2020-001493-29",Unknown,PR Newswire (https://www.prnewswire.com/news-releases/quantum-leap-healthcare-collaborative-concludes-cenicriviroc-not-likely-to-reduce-time-to-recovery-or-mortality-in-critically-ill-patients-in-i-spy-covid-trial-301279438.html),Non-Alcoholic SteatoHepatitis (NASH),N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/29/2021
 I-SPY COVID Trial (Takeda),Treatment,Other,Clinical,Unknown,"Firazyr (icatibant), bradykinin B2 antagonist","EudraCT 2020-002225-29, NCT04978051",Unknown,,,"FDA approved since 2011, approved to treat hereditary angioedema ",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/30/2021
"I-SPY COVID Trial (Aerpio Pharmaceuticals), - RESCUE Trial various academic researchers/Medical Technology Enterprise Consortium (MTEC)",Treatment,Other,Clinical,Second trial to start in August 2020; Dosing began Phase II platform/I-SPY trial Sept 2020; Phase II/RESCUE Trial Sept 2020; Phase II Discontinued March 2021; Trials terminated June 2021,"Razuprotafib, Tie 2 activating compound (AKB-9778)",NCT04511650,Unknown,medRxiv (https://www.medrxiv.org/content/10.1101/2021.05.13.21257070v1),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/18/2021
"Lupa Bio, Inc.",Treatment,Other,Pre-clinical,Plans to sumit an IND in 2020,New drug based on a sugar found in human milk,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/14/2020
Heron Therapeutics,Treatment,Other,Clinical,Phase II trial recruiting July 2020,"Cinvanti (aprepitant), a substance P/neurokinin-1 receptor antagonist",NCT04470622,,,,"FDA approved since 2017, approved to prevent chemotherapy-induced nausea and vomiting in cancer patients",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/16/2020
Nocion Therapeutics,Treatment,Other,Pre-clinical,Phase I trial to start July 2020; First patient dosed Sept 2020,"Nocions, molecules that either selectively block Nav 1.7 or antagonize large-pore channels",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/13/2020
Hebrew University of Jerusalem/ University of Pennsylvania/ University Arizona ,Treatment,Other,Clinical,Invite only intervention trial Sept 2020 ,"Tricor (fenofibrate), peroxisome proliferator-activated receptor (PPAR) alpha agonist ","NCT04517396, NCT04661930",Unknown,"EurekaAlert (https://www.eurekalert.org/pub_releases/2020-12/thuo-pcd122220.php), BioRxiv (https://www.biorxiv.org/content/10.1101/2021.01.10.426114v1)",,"FDA approved since 2004, approved to treat primary hypercholesterolemia or mixed dyslipidemia, and to treat severe hypertriglyceridemia",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/28/2021
Merck/ IRBM/ RaPharma,Treatment,Other,Pre-clinical,Unknown,"PCSK9, Peptides",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/23/2020
Organicell Regenerative Medicine,Treatment,Other,Clinical,Phase I/II trial cleared by FDA in May 2020; Individual expanded access results released May 2020,"Organicell Flow, acellular product derived from amniotic fluid ","NCT04384445, NCT04657406",Unknown,"Organicell (https://organicell.com/organicell-reports-positive-results-from-compassionate-use-of-organicell-flow-in-severely-ill-covid-19-patients/), Organicell (https://organicell.com/2021/04/28/organicell-announces-positive-results-of-initial-covid-19-zofin-patient-trial-in-india-and-trial-expansion/), Frontiers in Medicine (https://www.frontiersin.org/articles/10.3389/fmed.2021.583842/full), Organicell (https://organicell.com/2021/06/15/organicell-announces-positive-results-of-their-expanded-access-trial-for-the-treatment-of-mild-to-moderate-covid-19-using-zofin/)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/22/2021
Global research sponsors,Treatment,Other,Clinical,Unknown,"TD139, specific inhibitor of galectin-3, inhalation powder","EudraCT 2020-001736-95 (ACCORD Trial), NCT04473053, ISRCTN14212905, EudraCT 2020-002230-32","Life
  Arc (University of Edinburgh)",The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01826-2/fulltext),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/9/2021
Various global research sponsors,Treatment,Other,Clinical,Unknown,"Aldactone (spironolactone), aldosterone antagonist","EudraCT 2020-001766-11, NCT04424134, NCT04345887, NCT04643691, NCT04826822",Unknown,"MDPI (https://www.mdpi.com/1424-8247/14/1/71/htm), PubMed (https://pubmed.ncbi.nlm.nih.gov/34477316/)",,"FDA approved since 1960, approved to treat heart failure, hypertension, edema, and hyperaldosternism",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/10/2021
REMAP-CAP trial,Treatment,Other,Clinical,Unknown,"Levaquin (levofloxacin), a fluoroquinolone antibacterial","EudraCT 2015-002340-14 (REMAP-CAP), NCT02735707 (REMAP-CAP)",Unknown,,,"FDA approved since 1996, approved to treat bacterial infections",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/27/2020
REMAP-CAP trial,Treatment,Other,Clinical,Unknown,"ceftriaxone, broad-spectrum cephalosporin antibiotic","EudraCT 2015-002340-14 (REMAP-CAP), NCT02735707 (REMAP-CAP), NCT04869579",Unknown,"PubMed (https://pubmed.ncbi.nlm.nih.gov/34464372/), Lancet (https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00463-1/fulltext), British Journal of Hematology (https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.17806)",,"FDA approved since 1984, approved to treat or prevent bacterial infections",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/7/2021
"ACCORD trial; University Hospital, Ghent/UCB Pharma ",Treatment,Other,Clinical,Phase II trial began recruitment July 2020 Patient enrollment began Dec 2020.,"Zilucoplan, a synthetic macrocyclic peptide inhibitor of the terminal complement protein C5","EudraCT 2020-001736-95 (ACCORD Trial), NCT04382755",Unknown,,"Myasthenia gravis; immune-mediated necrotizing myopathy, ALS",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/2/2020
"Center for Clinical Metabolic Research, Gentofte Hospital",Treatment,Other,Clinical,Unknown,"Entresto (sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker)","EudraCT 2020-001544-26, NCT04883528",Unknown,,,"FDA approved since 2015, approved to reduce the risk of cardiovascular death and hospitalization for heart failure and treat heart failure ",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/2/2021
Inotrem,Treatment,Other,Clinical,"Phase II trial cleared by FDA, French and Belgian authorities July 2020; First patient dosed Oct 2020 (COVITREM- 1)",Nangibotide,"NCT04429334, EudraCT 2020-001504-42",Unknown,,Septic shock,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/13/2021
NeoImmune Tech/ NIAID / University of Nebraska Medical Center,Treatment,Other,Clinical,Phase I trial cleared by FDA July 2020; Second study for NT-I7 approved by FDA. Patient dosing began 2020.,"NT-I7 (efineptakin alfa), long-acting human IL-7","NCT04498325, NCT04501796, NCT04730427, NCT04810637",Unknown,,Treat solid tumors,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/23/2021
Kintor/ Applied Biology,Treatment,Other,Clinical," 1st patient enrolled in Brazil Aug 2020; Expanding patient enrollment Oct 2020, Female patient trial enrollment Dec 2020; Approval of investigational new drug application of phase III trial.","proxalutamide (GT0918), anti-androgen","NCT04446429, NCT04728802, NCT04853134, NCT04870606, NCT04869228",Unknown,"Kintor (https://en.kintor.com.cn/news/152.html), Kintor (https://en.kintor.com.cn/news/156.html), NCT04446429 (https://clinicaltrials.gov/ct2/show/results/NCT04446429?term=proxalutamide&cond=COVID-19&draw=1&rank=2), Doc Wire News (https://www.docwirenews.com/abstracts/proxalutamide-significantly-accelerates-viral-clearance-and-reduces-time-to-clinical-remission-in-patients-with-mild-to-moderate-covid-19-results-from-a-randomized-double-blinded-placebo-controlled/), Kintor (https://en.kintor.com.cn/news/166.html), Kintor (https://en.kintor.com.cn/news/173.html), https://clinicaltrials.gov/ct2/show/results/NCT04728802?term=proxalutamide&cond=COVID-19&draw=2&rank=2, PubMed (https://pubmed.ncbi.nlm.nih.gov/34531332/)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/15/2022
AI Therapeutics/ Yale University  ,Treatment,Other,Clinical,Phase II trial started July 2020  ,"LAM-002A (apilimod dimesylate), PIKfyve kinase inhibitor",NCT04446377,Unknown,,Lymphangioleiomyomatosis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/29/2020
National Institute of Allergy and Infectious Disease (NIAID),Treatment,Other,Clinical,Phase III trial started August 2020,"Adaptive COVID-19 Treatment Trial 3 (ACTT-3), Remdesivir + interferon beta-1a","NCT04492475, NCT04315948, NCT04647669",National Institute of Allergy and Infectious Diseases (NIAID),"medRxiv (https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1), https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/9/2021
NIH ACTIV-4 Antithrombotics/ nonprofit organizations/numerous biopharmaceutical companies,Treatment,Other,Clinical,Phase III trials for ACTIV-4 Antithrombotics launched Sept 2020; Recruitment began for Phase III trial Nov 2020,"Apixaban (Eliquis) blood thinner, direct oral anticoagulant","NCT04498273, NCT04650087, NCT04736901, NCT04746339, NCT04788355","National Institute of Heart, Lung, and Blood Institute (NHLBI)/U.S. Operation Warp Speed","PubMed (https://pubmed.ncbi.nlm.nih.gov/33683064/), PubMed (https://pubmed.ncbi.nlm.nih.gov/34633405/)",,FDA approved since 2019 to treat nonvalvular atrial fibrillation; deep vein thrombosis (DVT) and pulmonary embolism (PE),https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/20/2021
"Senhwa Biosciences, Inc",Treatment,Other,Clinical,"FDA IIT approved was granted Aug 2020 for use in COVID patients, First patient dosed in Dec 2020.","Silmitasertib, small molecule drug, targets CK2 & CK2-inhibitor","NCT04663737, NCT04668209",Unknown,,,Granted Rare Pediatric Disease Designation (RPD) in Medulloblastoma by FDA. ,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/25/2021
ACTIV-5/BET-B  for COVID-19/National Institute of Allergy and Infectious Disease (NIAID)/Boehringer Ingelheim/AbbVie,Treatment,Other,Clinical,Phase 2 ACTIV-5 Big Effect Trial (BET-B) began Oct 2020 ,risankizumab monoclonal antibody & remdesivir + lenzilumab ,"NCT04583969, NCT04583956",National Institute of Allergy and Infectious Disease (NIAID)/NIH,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/20/2021
"Revive Therapeutics, Ltd.",Treatment,Other,Clinical,Phase III Trial began Nov 2020. Currently in Phase 3 trials.,"Bucillamine, a cysteine derivative thiol-based drug",NCT04504734,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/19/2022
Ohio State University,Treatment,Other,Clinical,Phase II trial currently recruiting patients,"VentaProst, inhaled epoprostenol delivered via a dedicated delivery system",NCT04452669,Aerogen Pharma Limited,,,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/23/2021
Trevena; REMAP-CAP COVID-19 ACE2 RAS Modulation Domain; ACTIV-4d RAAS; Vanderbilt University Medical Center; Imperial College London,Treatment,Other,Clinical,Provisional patent application filed with US Patent and Trademark Office for ARDS and prevention/treatment of abnormal clotting in COVID-19 April 2020; Added to REMAP-CAP April 2021; Added to ACTIV-4d RAAS trial May 2021,TRV027 (Novel AT1 receptor-selective agonist),"NCT04419610, NCT04924660","NHLBI, FNIH, BARDA, Imperial College London",,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/6/2021
Constant Therapeutics LLC; Columbia University Irving Medical Center; ACTIV-4d RAAS; Vanderbilt University Medical Center; Multiple global research sponsors,Treatment,Other,Clinical,Phase II trial initiated July 2020; Added to ACTIV-4d RAAS trial May 2021,TXA127 (human peptide angiotensin-(1-7)),"NCT04401423, NCT04605887, NCT04924660","NHLBI, FNIH, BARDA",https://pubmed.ncbi.nlm.nih.gov/32894568/,,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/15/2021
Inhalon Biopharma Inc; Phase I study is being conducted in collab with Celltrion Inc,Treatment,Other,Pre-clinical,First patient dosed in Phase I safety and tolerability study in healthy volunteers,IN-006 (inhaled muco-trapping antibody platform),,Study is partly funded by U.S. Army Medical Research & Development Command,,,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/11/2021
Baxter,Treatment,Device,Clinical,"FDA issued an Emergency Use Authorization on April 23, 2020",Oxiris Blood Purification Filter,NCT04478539,Unknown,"BMC/Springer (doi.org/10.1186/s13054-020-03322-6), Doc Wire News (https://www.docwirenews.com/abstracts/endotoxin-adsorbent-therapy-in-severe-covid-19-pneumonia/), PubMed (https://pubmed.ncbi.nlm.nih.gov/34486793/)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/23/2022
Bellerophon; Ohio State University Wexner Medical Center ,Treatment,Device,Clinical,Phase III trial began July 2020; Expanded access trial ended July 2020; Phase III (COViNOX Study) Trials began Summer/Fall 2020,INOpulse,"NCT04398290, NCT04358588 (Expanded access), NCT04421508, EudraCT 2020-002394-94",Unknown,,,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2021
ExThera Medical,Treatment,Device,Clinical,"DOD to fund a multi-center trial June 2020; FDA issued an Emergency Use Authorization on April 17, 2020","Seraph100MicrobindAffinity Blood Filter (Seraphy 100), approved in the EU for pathogen reduction","NCT04606498, NCT04470999, NCT04413955, NCT04361500, NCT04547257",US Department of Defense (DOD),"medRxiv (https://www.medrxiv.org/content/10.1101/2021.04.20.21255810v1), PubMed (https://pubmed.ncbi.nlm.nih.gov/34261058/)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/27/2021
CytoSorbents Corporation,Treatment,Device,Clinical,Intervention trial started May 2020; Recruitment began Oct 2020,"CytoSorb (blood purification device, extracorporeal cytokine adsorber))","NCT04324528, ChiCTR2000030475, NCT04344080, DRKS00021447, NCT04385771, NCT04344080, NCT04324528",Unknown,"medRxiv (https://doi.org/10.1101/2020.06.28.20133561), (https://onlinelibrary.wiley.com/doi/10.1111/aor.13864, Cytosorbents (https://cytosorbents.com/cytosorbents-highlights-largest-published-case-series-to-date-using-cytosorb-in-critically-ill-covid-19-patients/), Pneumologie (https://pubmed.ncbi.nlm.nih.gov/33882609/), The Lancet (https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00177-6/fulltext), PubMed (https://pubmed.ncbi.nlm.nih.gov/33998306/), PubMed (https://pubmed.ncbi.nlm.nih.gov/34152629/), PubMed (https://pubmed.ncbi.nlm.nih.gov/34256643/), Biospace (https://www.biospace.com/article/releases/topline-results-from-cytosorbents-u-s-ctc-multicenter-registry-demonstrate-high-survival-using-cytosorb-in-critically-ill-covid-19-patients-on-extracorporeal-membrane-oxygenation-ecmo-/), SAGE Journals (https://journals.sagepub.com/doi/abs/10.1177/03913988211052572?journalCode=jaoa)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/1/2022
ALung Technologies,Treatment,Device,Clinical,Phase III (COViNOX Study) Trials began Summer/Fall 2020,Hemolung Respiratory Assist System,NCT03255057,Unknown,Hindawi (https://www.hindawi.com/journals/cricc/2021/9958343/),Acute Exacerbation of Chronic Obstructive Pulmonary Disease; Acute Respiratory Distress Syndrome (ARDS),N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/19/2021
Terumo BCT Inc / Marker Therapeutics AG,Treatment,Device,Clinical,"FDA issued an Emergency Use Authorization on April 9, 2020","Extracorporeal blood purification (EBP) devices, Spectra Optia® Apheresis System combined with D2000 Adsorption Cartridge",NCT04358003,Unknown,Wiley (https://onlinelibrary.wiley.com/doi/10.1111/hdi.12951),,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/20/2021
Fresenius Medical,Treatment,Device,Clinical,"FDA issued an Emergency Use Authorization on April 30, 2020","MultiFiltrate PRO System and multiBic/multiPlus Solutions, continuous renal replacement therapy (CRRT)",NCT04871893,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2021
Abiomed,Treatment,Device,Clinical,"FDA issued an Emergency Use Authorization for Impella heart pumps in COVID-19 therapy on May 29, 2020",Impella RP heart pump,NCT04527575,Unknown,PubMed (https://pubmed.ncbi.nlm.nih.gov/33437917/),,"FDA-approved since 2017, approved to treat advanced heart failure",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/7/2021
electroCore,Treatment,Device,Clinical,"FDA granted Emergency Use Authorization July 10, 2020","gammaCore Sapphire CV, vagus nerve stimulation device ",NCT04368156,Unknown,"electroCore (https://investor.electrocore.com/news-releases/news-release-details/electrocore-inc-announces-inclusion-gammacore-sapphiretm-new-nhs), electrocore (https://investor.electrocore.com/news-releases/news-release-details/electrocore-announces-top-line-results-savior-1-study-non)",Asthma,"FDA cleared since 2018, cleared to treat migraines and cluster headaches",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/7/2022
Beyond Air Ltd,Treatment,Device,Clinical,Phase II trial enrolling July 2020,LungFit (with ultra-high concentrations of nitric oxide),"NCT04397692, NCT04456088, NCT04606407",Unknown,BeyondAir (https://www.beyondair.net/news-and-events/press-releases/detail/135/beyond-air-presents-data-in-hospitalized-patients-with),Bronchiolitis and nontuberculous mycobacteria,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/29/2022
Scancell/ University of Nottingham/ Nottingham Trent University,Vaccine,DNA-based,Phase I,Phase I COVIDITY clinical trial dosed October 2021,DNA; plasmid vaccine RBD&N,NCT05047445,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/30/2022
Entos Pharmaceuticals/ Cytiva,Vaccine,DNA-based,Phase I/II,Phase I/II began April 2021,DNA; (Covigenix),NCT04591184,Canadian Institutes of Health Research (CIHR)/ Research Nova Scotia (RNS)/ Institute for Ageing (IA)/ National Research Council of Canada Industrial Research Assistance Program (NRC IRAP),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/31/2021
BioNet Asia/ Technovalia/ Vax4COVID/ The University of Sydney/ The University of Western Australia/ Telethon Kids Institute/ PharmaJet,Vaccine,DNA-based,Phase I,Phase I dosed end of June 2021,DNA; (COVIGEN) needle-free delivery,NCT04742842,Australian Government Medical Research Future Fund (MRFF),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/18/2022
Inovio Pharmaceuticals/ Beijing Advaccine Biotechnology/ VGXI Inc./ Richter-Helm BioLogics/ Ology Bioservices/ International Vaccine Institute/ Seoul National University Hospital/ Thermo Fisher Scientific/ Kaneka Eurogentec,Vaccine,DNA-based,Phase II/III,"Phase III segment of INNOVATE trial has received regulatory authorizations to proceed in Brazil, Colombia, India, Mexico, Philippines, Thailand, and the U.S. as of 11/09/21; Announced (10/26/2021) as one of two candidate vaccines to be included in the Solidarity Trial Vaccines with WHO and the Ministries of Health of Colombia, Mali, and the Philippines; Phase III efficacy trial receives authorization to proceed from Brazil's ANVISA on 8/26/2021; Phase II preliminary results released on 5/7/2021; ex-US Global Phase III trial planning announced 4/23/2021; Study results on the human immune responses against variants of concern announced 4/15/2021; Phase I data published December 2020; Phase II dosed December 2020, as part of its Phase II/III clinical trial (INNOVATE); FDA partial clinical hold for planned Phase II/III trial reported on 9/28/2020; Phase I/IIa trial began July 2020; Animal study results released July 2020; Joined US Operation Warp Speed in June 2020; Phase I began April 2020, interim data of ongoing study released June 2020",DNA; (INO-4800) plasmid vaccine with electroporation ,"ChiCTR2000038152, ChiCTR2000040146, NCT04336410, NCT04447781, NCT04642638",Coalition for Epidemic Preparedness (CEPI) / Gates Foundation / US Department of Defense,"Inovio (http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Announces-Positive-Interim-Phase-1-Data-For-INO-4800-Vaccine-for-COVID-19/default.aspx), EClinicalMedicine (https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30433-8/fulltext), bioRxiv (https://www.biorxiv.org/content/10.1101/2021.04.14.439719v1), medRxiv (https://www.medrxiv.org/content/10.1101/2021.05.07.21256652v1), PubMed (https://pubmed.ncbi.nlm.nih.gov/35079784/)",Same platform as multiple vaccine candidates,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/2/2022
University of Cambridge/ DIOSynVax/ PharmaJet,Vaccine,DNA-based,Pre-clinical,Phase I expected to begin late fall 2020 or early 2021,DNA; (DIOS-CoVax2) synthetic gene inserts compatible with multiple delivery systems ,,Innovate UK,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/28/2020
Mediphage Bioceuticals/ University of Waterloo/ Lambton College,Vaccine,DNA-based,Pre-clinical,Unknown,DNA; msDNA-VLP,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/23/2020
Symvivo,Vaccine,DNA-based,Phase I,Phase I dosed November 2020,DNA; bacTRL-Spike,NCT04334980,National Research Council of Canada Industrial Research Assistance Program (NRC IRAP),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/29/2021
Takis/ Applied DNA Sciences/ Evvivax/ Rottapharm Biotech,Vaccine,DNA-based,Phase I/II,"Phase I/II began March 2021, announced the authorization of the clinical trial by the Italian Medicines Agency (AIFA) on 2/3/2021; Pre-clinical results released in May and July 2020",DNA (COVID-eVax),"EudraCT 2020-003734-20, NCT04788459",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/28/2021
Immunomic Therapeutics/ EpiVax/ PharmaJet,Vaccine,DNA-based,Pre-clinical,Unknown,"DNA; plasmid vaccine, needle-free delivery",,Unknown,,Same platform as vaccine candidates for SARS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Zydus Cadila Healthcare Limited ,Vaccine,DNA-based,Phase III,"India granted ""emergency use approval"" for use in adults and children aged 12 years and above on 8/20/2021; Applied to the office of Drug Controller General of India (DCGI) for EUA on 7/1/2021; Phase III data expected to be announced May 2021; Phase III dosed January 2021; Pre-clinical results released January 2021; DCGI approved start of Phase III trial in January 2021; Phase I/II study: Phase I began July 2020 and Phase II began August 2020, initial results expected September 2020",DNA; (ZyCoV-D) plasmid vaccine ,"CTRI/2020/07/026352, CTRI/2021/01/030416",Unknown,The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00151-9/fulltext),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/41/2022
OPENCORONA Project: Karolinska Institute/ Justus Liebig University Giessen/ Public Health Agency of Sweden (FoHM)/ IGEA/ Cobra Biologics/ Adlego Biomedical/ Region Stockholm,Vaccine,DNA-based,Pre-clinical,Phase I expected to begin in 2020,DNA with electroporation,,European Commission (Horizon 2020 Program),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/23/2020
Osaka University/ AnGes/ Takara Bio/ Cytiva/ Brickell Biotech,Vaccine,DNA-based,Phase II/III,"Phase II/III trial began December 2020; Pre-clinical study results released October 2020; Phase I/II trials began end of June (AG0301) and August (AG0302) 2020, results expected during Q1 2021",DNA; (AG0301 & AG0302) plasmid vaccine + adjuvant ,"jRCT2051200085,  jRCT2051200088, NCT04463472, NCT04527081, NCT04655625",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/31/2021
"Genexine Consortium (GenNBio, International Vaccine Institute, Korea Advanced Institute of Science and Technology (KAIST), Pohang University of Science and Technology (POSTECH)/ Binex/ PT Kalbe Pharma",Vaccine,DNA-based,Phase I/II,Phase II/III study expected to begin in Indonesia as of July 2021; Phase IIa began February 2021; Updated development plan to GX-19N formula and will reconduct Phase I/IIa study as of December 2020. Phase I of Phase I/IIa study began end of June 2020; Animal study results announced August 2020,DNA; (formerly GX-19) (GX-19N) ,"NCT04445389, NCT04715997",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/19/2021
Chula Vaccine Research Center,Vaccine,DNA-based,Pre-clinical,Unknown,DNA with electroporation,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/23/2020
"National
  Research Centre, Egypt",Vaccine,DNA-based,Pre-clinical,Unknown,"DNA; plasmid vaccine S, S1, S2, RBD & N",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
Ege University Drug Development and Pharmacokinetic Research Application Center (ARGEFAR)/ Scientific and Technological Research Council of Turkey (TUBITAK),Vaccine,DNA-based,Pre-clinical,Unknown,DNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/23/2020
"Statens Serum Institute, Denmark",Vaccine,DNA-based,Pre-clinical,Phase I is expected to start in late 2020 or early 2021,DNA; (CoVAXIX) plasmid vaccine,,Folketing's Finance Committee,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/16/2020
"Globe Biotech Limited, Bangladesh",Vaccine,DNA-based,Pre-clinical,Unknown,DNA plasmid vaccine,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/9/2020
"National Institute of Chemistry, Slovenia",Vaccine,DNA-based,Pre-clinical,Unknown,"Plasmid DNA, nanostructured RBD",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/9/2020
OncoSec Medical Incorporated / Providence Cancer Institute ,Vaccine,DNA-based,Phase I,Phase I dosed January 2021,"(CORVax12), IL-12 expression platform + “S” glycoprotein ",NCT04627675,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/2/2021
"GeneOne
  Life Science",Vaccine,DNA-based,Phase I/II,Phase IIa expected to be dosed July 2021; Phase I/IIa began December 2020,DNA; (GLS-5310),NCT04673149,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/19/2021
"Vaccibody
  AS",Vaccine,DNA-based,Phase I/II,Phase I/II began October 2021,"Second-generation DNA plasmid vaccine, RBD; VB10.2129 (C1)",NCT05069623,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/29/2021
Vaccibody AS,Vaccine,DNA-based,Phase I/II,Phase I/II began October 2021,"Second generation DNA plasmid vaccine, T-cell; VB10.2210 (C2)",NCT05069623,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/29/2021
The University of Hong Kong/ Immuno Cure 3 Limited,Vaccine,DNA-based,Pre-clinical,Phase I expected to begin November 2021,SARS-CoV-2 DNA Vaccine Delivered Intramuscularly Followed by Electroporation,NCT05102643,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/29/2021
"Valneva/ Dynavax/ National Institute for Health Research, United Kingdom",Vaccine,Inactivated virus,Phase III,Phase III positive topline results announced 10/18/2021; Commenced recruitment of adolescents (12-17 years) into Phase III trial “Cov-Compare” and enrolled participants in the Phase I/II booster trial in September 2021; Initiated a further Phase III trial with participants aged 56 years and older in August 2021; Phase III began April 2021; Phase I/II data announced April 2021; Phase I/II began December 2020,"Inactivated (Inactivated + CpG 1018), VLA2001","NCT04671017, NCT04864561",Unknown,"Valneva (https://www.globenewswire.com/en/news-release/2021/04/06/2204606/0/en/Valneva-Reports-Positive-Phase-1-2-Data-for-Its-Inactivated-Adjuvanted-COVID-19-Vaccine-Candidate-VLA2001.html), Valneva (https://valneva.com/press-release/valneva-reports-positive-phase-3-results-for-inactivated-adjuvanted-covid-19-vaccine-candidate-vla2001/#_ftn1), Valneva (https://valneva.com/press-release/valneva-announces-positive-homologous-booster-data-for-inactivated-adjuvanted-covid-19-vaccine-candidate-vla2001/)",Same platform as vaccine candidates for Japanese Encephalitis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/4/2022
Beijing Institute of Biological Products/ Sinopharm ,Vaccine,Inactivated virus,Phase III,"Vietnam granted approval on 6/4/2021; World Health Organization (WHO) granted Emergency Use Listing (EUL) on 5/7/2021; Indonesia granted ""emergency use"" approval on 4/30/2021; Hungary granted ""emergency use"" approval on 1/29/2021; Pakistan granted ""emergency use authorization"" on 1/18/2021; China ""granted conditional market approval"" on 12/31/2020; Midterm clinical results released on 12/30/2020; Bahrain National Health Regulatory Authority (NHRA) ""approved"" on 12/13/2020; UAE Ministry of Health and Prevention (MOHAP) announced ""official registration"" on 12/9/2020, following review of Phase III interim analysis; Phase I/II results published October 2020; Phase III trial began July 2020; Received early approval for ""emergency use"" in China (Aug 2020) and the UAE (Sep 2020)","Inactivated, (BBIBP-CorV)","ChiCTR2000032459, ChiCTR2000034780, NCT04510207, NCT04560881",Unknown,"The Lancet (https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30831-8/fulltext), National Medical Products Administration (http://english.nmpa.gov.cn/2020-12/30/c_578717.htm), BioRxiv (https://www.biorxiv.org/content/10.1101/2021.12.12.472269v1) The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00011-3/fulltext)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/17/2022
Wuhan Institute of Biological Products/ Sinopharm,Vaccine,Inactivated virus,Phase III,"China granted ""conditional approval"" on 2/25/2021; Applied for regulatory approval in China as of February 2021; Phase III trial began July 2020; Phase I/II early trial results released June 2020, Phase I/II interim analysis published August 2020; Received early approval for ""emergency use"" in China (Aug 2020) and the UAE (Sep 2020)",Inactivated," ChiCTR2000031809, ChiCTR2000034780, ChiCTR2000039000, NCT04510207, NCT04612972",Unknown,"CNBG (https://www.cnbg.com.cn/content/details_12_5545.html), JAMA (https://jamanetwork.com/journals/jama/fullarticle/2769612)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/27/2021
"Research Institute for Biological Safety Problems, Republic of Kazakhstan",Vaccine,Inactivated virus,Phase III,"Kazakhstan lauched nationwide vaccine roll out as of 4/27/2021; Kazakhstan granted ""temporary registration for nine months"" as of 1/13/2021; Phase III began December 2020; Phase I/II began September 2020","Inactivated, (QazCovid-in®)","NCT04530357, NCT04691908",Unknown,"The Lancet (https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00256-5/fulltext#:~:text=QazCovid%2Din%C2%AE%20is%20a,14%20after%20the%20first%20immunisation.)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/22/2022
"Institute of Medical Biology, Chinese Academy of Medical Sciences",Vaccine,Inactivated virus,Phase III,"Phase III dosed (Malaysia) late January 2021; Phase II began June 2020; Phase I began May 2020, results released October 2020",Inactivated,"NCT04412538, NCT04470609, NCT04659239",Unknown,medRxiv (https://www.medrxiv.org/content/10.1101/2020.09.27.20189548v1),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/31/2021
Sinovac/ Dynavax,Vaccine,Inactivated virus,Pre-clinical,Unknown,Inactivated + adjuvant (CpG 1018),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
Osaka University / BIKEN / NIBIOHN,Vaccine,Inactivated virus,Pre-clinical,Unknown,Inactivated,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Sinovac/ Instituto Butantan/ Bio Farma,Vaccine,Inactivated virus,Phase III," The Egyptian Drug Authority (EDA) granted the Sinovac/VACSERA vaccine an emergency use license on 8/23/2021; Phase I/II clinical trials results in healthy children and adolescents aged 3-17 in China published 6/28/2021; World Health Organization (WHO) granted Emergency Use Listing (EUL) on 6/1/2021; Summary of clinical trial data released on 4/3/2021; Emergency use approval, or conditional marketing authorization, has been granted by over 30 countries as of 4/1/2021; Malaysia granted ""conditional approval"" on 3/2/2021; China's NMPA granted ""conditional marketing authorization"" on 2/8/2021; Phase III results (Brazil, Turkey, Indonesia, Chile) announced on 2/5/2021; Phase I/II safety, tolerability, and immunogenicity data in adults aged 60 years and older published on 2/3/2021; Sinovac filed for ""conditional market authorization"" with China’s National Medical Products Administration (NMPA) on 2/3/2021; Chile granted ""emergency use"" approval on 1/20/2021; Brazil granted ""temporary authorization for emergency use"" on 1/17/2021; Turkey granted ""emergency use authorization"" on 1/31/2021; Indonesia granted ""emergency use approval"" on 01/11/2021; Phase III efficacy results (Brazil) released early January 2021; Phase I/II complete analysis results published 11/17/2020; Phase III trial resumed in Brazil on 11/11/2020, Phase III trial suspended in Brazil on 11/09/2020; Received approval for Phase I/II trial in adolescents and children in September 2020; Phase III trial began end of July 2020; Phase II began June 2020, mid-phase II results released August 2020; Preliminary results from Phase I/II trials released June and September 2020 (aged 60+) 2020; Received early approval for ""emergency use"" in China (Aug 2020)",Inactivated (inactivated + alum); CoronaVac (formerly PiCoVacc); VACSERA in Egypt,"NCT04383574, NCT04352608, NCT04456595,  NCT04551547, NCT04508075, NCT04582344, NCT04617483, NCT04651790, 669/UN6.KEP/EC/2020",Unknown,"Sinovac (http://www.sinovac.com/?optionid=754&auto_id=904), medRxiv (https://www.medrxiv.org/content/10.1101/2020.07.31.20161216v1), http://www.sinovac.com/?optionid=754&auto_id=910, The Lancet (https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30843-4/fulltext), The Lancet (https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30987-7/fulltext), Sinovac (http://www.sinovac.com/?optionid=754&auto_id=922), Sinovac (http://www.sinovac.com/?optionid=754&auto_id=927), The Lancet (https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00319-4/fulltext), Lancet (https://www.thelancet.com/action/showPdf?pii=S1473-3099%2821%2900681-2)",Same platform as vaccine candidates for SARS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/22/2022
"Shenzhen Kangtai Biological Products Co.,Ltd./ Beijing Minhai Biotechnology Co., Ltd.",Vaccine,Inactivated virus,Phase III,"Indonesia granted ""emergency use authorization"" in November 2021; Phase III began June 2021; Received early approval for ""emergency use"" in China in May 2021; Phase I/II results announced April 2021; Phase I/II study began October 2020","Inactivated SARS-CoV-2 vaccine, Vero cell, (KCONVAC)","ChiCTR2000038804, ChiCTR2000039462, NCT04758273, NCT04756323, NCT04852705",Unknown,medRxiv (https://www.medrxiv.org/content/10.1101/2021.04.07.21253850v1),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/10/2022
"National Research Centre, Egypt",Vaccine,Inactivated virus,Pre-clinical,Pre-clinical study results published March 2021,Inactivated; whole virus; (NRC-VACC-01),,Unknown,Vaccines (https://www.mdpi.com/2076-393X/9/3/214),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2021
KM Biologics,Vaccine,Inactivated virus,Phase I/II,Phase I/II study began March 2021,Inactivated (inactivated + alum); (KD-414),jRCT2071200106,Unknown,,"Same platform as vaccine candidates for JE, Zika",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/31/2021
Selcuk University,Vaccine,Inactivated virus,Pre-clinical,Unknown,Inactivated,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/23/2020
Bharat Biotech/ Indian Council of Medical Research/ National Institute of Virology/ Ocugen/ Precisa Medicamentos,Vaccine,Inactivated virus,Phase III,"World Health Organization (WHO) granted Emergency Use Listing (EUL) on 11/3/2021; Phase III efficacy analysis results announced on 7/2/2021; Phase III second interim analysis results announced on 4/21/2021; Authorized for ""emergency use"" in Nepal and Zimbabwe as of March 2021; Phase II interim analysis and Phase I follow-up results published 3/8/2021; Phase III interim analysis results announced 3/3/2021; Neutralization of UK-variant with vaccine-elicited sera announced January 2021; India granted ""permission for emergency use"" on 01/03/2021; Phase I and II safety and immunogenicity data released December 2020 and published January 2021; Phase III began November 2020; Phase I/II study: Phase I began July 2020 and Phase II began September 2020, initial results expected September 2020; Animal study results released September 2020, Approved for intranasal booster dose trials February 2022",Inactivated; whole-virion (COVAXIN) (BBV152),"CTRI/2020/07/026300, NCT04471519, CTRI/2020/09/027674, CTRI/2020/11/028976, NCT04641481",Unknown,"medRxiv (https://www.medrxiv.org/content/10.1101/2020.12.11.20210419v1), medRxiv (https://www.medrxiv.org/content/10.1101/2020.12.21.20248643v1), The Lancet (https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30942-7/fulltext), bioRxiv (https://www.biorxiv.org/content/10.1101/2021.01.26.426986v2), The Lancet (https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00070-0/fulltext), Bharat Biotech (https://www.bharatbiotech.com/images/press/covaxin-phase3-clinical-trials-interim-results.pdf), medRxiv (https://www.medrxiv.org/content/10.1101/2021.06.30.21259439v1)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/10/2022
Erciyes University,Vaccine,Inactivated virus,Phase III,"Phase III began June 2021; Phase II dosed February 2021; Phase I began November 2020, completed on December 14, 2020 ","Inactivated; (ERUCOV-VAC), (TURKOVAC)","NCT04691947, NCT04824391, NCT04942405",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/28/2021
Kocak Farma Ilac ve Kimya San. A.S.,Vaccine,Inactivated virus,Phase III,Phase III began June 2021; Phase I began March 2021,Inactivated,"NCT04838080, NCT04942405, NCT05035238",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/29/2021
Institute of Vaccines and Medical Biologicals (IVAC; Vietnam) / Dynavax / PATH,Vaccine,Inactivated virus,Phase I/II,"Phase I/II began March 2021, Phase I is expected to be completed by end of May 2021","Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) + CpG 1018, (COVIVAC)",NCT04830800,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2021
"Government
  Pharmaceutical Organization (GPO; Thailand) / Dynavax / PATH",Vaccine,Inactivated virus,Phase I/II,Phase I/II began March 2021,"Inactivated, Newcastle Disease Virus (NDV) based chimeric vaccine with or without the adjuvant CpG 1018; (NDV-HXP-S)",NCT04764422,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2021
"Institute
  Butantan (Brazil) / Dynavax / PATH",Vaccine,Inactivated virus,Pre-clinical,Unknown,"Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) + CpG 1018",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/9/2020
Shifa Pharmed Industrial Co,Vaccine,Inactivated virus,Phase II/III,Phase I study in children ages 12-18 began November 2021; Iran granted emergency use authorization on 6/14/2021; Phase II/III trial in adults 18-75 years of age began March 2021; Phase I trial in adults 51-75 years of age began March 2021; Phase I trial in adults 18-50 years of age began December 2020,COVID-19 inactivated vaccine (COVIran Barekat),"IRCT20201202049567N1, IRCT20201202049567N2, IRCT20201202049567N3",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/2/2022
Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products of the Russian Academy of Sciences ,Vaccine,Inactivated virus,Phase III,"Phase III began March 2021; Russia ""registered"" the vaccine in February 2021; Clinical trials began Ocotober 2020","Whole virion inactivated vaccine, CoviVac",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/8/2021
Scientific and Technological Research Council of Turkey (TUBITAK),Vaccine,Inactivated virus,Phase I,Phase I began end of April 2021,Adjuvanted inactivated vaccine,NCT04866069,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/30/2021
"Laboratorio Avi-Mex/ National Council of Science and Technology, Mexico/ Agencia Mexicana de Cooperación Internacional para el Desarrollo (AMEXID)",Vaccine,Inactivated virus,Phase I,Phase I began May 2021,"Recombinant Newcastle disease virus (rNDV), (""Patria"")","NCT04871737, NCT05205746",Unknown,MedRxiv (https://www.medrxiv.org/content/10.1101/2022.02.08.22270676v1),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/11/2022
Indian Immunologicals Ltd/ Griffith University,Vaccine,Live attenuated virus,Pre-clinical,Unknown,Codon deoptimized live attenuated virus,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
Codagenix / Serum Institute of India,Vaccine,Live attenuated virus,Phase I,"Phase I topline safety and immunogenicity data and ongoing acceleration into Phase II/III trials announced September 2021; Pre-clinical research published June 2021; Phase I trial dosed January 2021, initial data expected by mid-2021; Phase I recruitment began December 2020","Single-dose, intranasal, live attenuated vaccine, (COVI-VAC)","NCT04619628, NCT05233826",Unknown,Proceedings of the National Academy of Science (https://www.pnas.org/content/118/29/e2102775118),"Same platform as vaccine candidates for HAV, InfA, ZIKV, FMD, SIV, RSV, DENV ",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/11/2022
Meissa Vaccines ,Vaccine,Live attenuated virus,Phase I,Preliminary clinical data on safety and immunogenicity released October 2021; Pre-clinical data released August 2021; Phase I enrollment began March 2021,"Intranasal live-attenuated chimeric vaccine candidate, (MV-014-212)",NCT04798001,Unknown,"bioRxiv (https://www.biorxiv.org/content/10.1101/2021.07.16.452733v2), Meissa Vaccines (https://www.businesswire.com/news/home/20211028005281/en/Meissa-Announces-Positive-Preliminary-Clinical-Data-on-Safety-and-Immunogenicity-of-Intranasal-COVID-19-Vaccine/)",Same platform as vaccine candidates for RSV,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/28/2021
Mehmet Ali Aydinlar University/ Acıbadem Labmed Health Services A.S.,Vaccine,Live attenuated virus,Pre-clinical,Unknown,Codon deoptimized live attenuated vaccines,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Greffex,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Non-replicating viral vector; Ad5 S (GREVAX™ platform),,Unknown,,"Same platform as vaccine candidates for MERS
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
ReiThera/ Leukocare/ Univercells/ National Institute of Infectious diseases Lazzaro Spallanzani ,Vaccine,Non-replicating viral vector,Phase II/III,"Phase II preliminary data announced July 2021; Phase II/III (COVITAR) study began March 2021; Phase I advanced to second set of three cohorts (aged 65-85 years) in November 2020; Phase I began August 2020, completed the first set of three cohorts (aged 18-55 years), preliminary results announced November 2020",Non-replicating viral vector; replication defective simian adenovirus encoding SARS-CoV-2 S (GRAd-CoV2),"EudraCT 2020-002835-31, EudraCT 2020-005915-39, NCT04528641, NCT04791423",Unknown,ReiThera (https://reithera.com/2021/07/12/reithera-announces-preliminary-phase-2-data-from-its-covid-19-vaccine-candidate/),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/19/2021
iosBIO (formerly Stabilitech Biopharma Ltd),Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Oral Ad5 S; (OraPro-Covid-19),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/28/2021
Bharat Biotech/ Thomas Jefferson University,Vaccine,Non-replicating viral vector,Pre-clinical,Pre-clinical data published October 2020,Recombinant deactivated rabies virus containing S1; (CoraVax),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/27/2021
GeoVax / BravoVax/ NIAID/ NIH/ University of Texas Medical Branch ,Vaccine,Non-replicating viral vector,Pre-clinical,"Awarded a Small Business Innovative Research (SBIR) grant in January 2021 to support the ongoing design, construction, and preclinical testing in preparation for human clinical trials",Non-replicating viral vector; MVA encoded VLP,,National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH),,"Same platform as vaccine candidates for LASV, EBOV, MARV, HIV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/25/2021
CanSino Biologics/ Beijing Institute of Biotechnology/ Petrovax ,Vaccine,Non-replicating viral vector,Phase III,"Authorized for ""emergency use"" in Argentina, Chile, Hungary, Pakistan, and Mexico, and for ""conditional approval"" in China as of June 2021; Filed ""conditional marketing authorization"" with China's National Medical Products Administration (NMPA) on 2/24/2021; Phase III dosed September 2020; Phase II began April 2020, initial results released May 2020, mid-phase results released July 2020; China’s Central Military Commission ""approved the use of the vaccine by the military"" in June 2020","Non-replicating viral vector; Adenovirus Type 5 vector (Ad5-nCoV), (Convidecia™)","ChiCTR2000030906, ChiCTR2000031781, NCT04313127, NCT04341389, NCT04398147, NCT04526990, NCT04540419, NCT04552366, NCT04566770, NCT04568811",Unknown,"The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext), The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31605-6/fulltext)",Same platform as vaccine candidates for EBOV  ,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/5/2022
German Center for Infection Research (DZIF)/ IDT Biologika GmbH/ Universitätsklinikum Hamburg-Eppendorf/ Philipps University Marburg Medical Center/ Ludwig-Maximilians University of Munich,Vaccine,Non-replicating viral vector,Phase I,"Spike protein of the vector vaccine has now been modified and clinical testing will resume as of 7/16/2021; Phase I/II expected to begin July 2021; Clinical testing suspended January 2021, Phase II postponed until further notice; Phase I dosed October 2020",Non-replicating viral vector; MVA-S encoded,"NCT04569383, NCT04895449",Unknown,,Same platform as vaccine candidates for many pathogens,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/29/2021
ImmunityBio/ NantKwest,Vaccine,Non-replicating viral vector,Phase I/II,"Phase I/II/III trial expected to begin Q3 2021 and will study the efficacy, safety, and immunogenicity of ImmunityBio’s T-Cell COVID-19 vaccine as a boost in participants who have already received a spike-only antibody-based vaccine; Expanded trials to test vaccine candidate as a ‘universal boost’ in vaccinated subjects and received approval to test intranasal spray in South Africa as of May 2021; Phase I/II supplemental vaccine boost trial began April 2021; Phase Ib preliminary findings reported on 4/8/2021; Phase I interim safety data announced on 3/15/2021; Phase I dosed in South Africa and the U.S. in March 2021; FDA authorized the expansion of the active Phase I trial and a second trial to test a novel combination of T-cell-based hAd5 subcutaneous prime vaccine with a room-temperature oral or sublingual boost; Phase I interim data announced November 2020; Pre-clinical data released December, November, and July 2020; Phase I trial dosed in the U.S. in October 2020; Selected for US Operation Warp Speed in May 2020","Non-replicating viral vector; [E1-, E2b-, E3-] hAd5-COVID19-Spike/Nucleocapsid; (subcutaneous, oral, and sublingual delivery)","NCT04591717, NCT04710303, NCT04732468, NCT04843722, NCT04845191",Unknown,"ImmunityBio (https://immunitybio.com/immunitybio-announces-positive-interim-phase-i-safety-data-of-had5-t-cell-covid-19-vaccine-candidate-in-oral-and-sublingual-formulations/), medRxiv (https://www.medrxiv.org/content/10.1101/2021.04.05.21254940v1)","Same platform as vaccine candidates for flu, Chik, Zika, EBOV, LASV, HIV/SIV, cancer",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/19/2021
Valo Therapeutics Ltd/ ImmunoScape ,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Adenovirus-based + HLA-matched peptides (Pan-Corona),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/28/2021
Shenzhen Geno-Immune Medical Institute,Vaccine,Non-replicating viral vector,Phase I/II,Phase I/II reportedly began March 2020,LV-SMENP-DC vaccine and antigen-specific CTLs,NCT04276896,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/31/2021
"Centro Nacional Biotecnologia (CNB-CSIC), Spain",Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,"Non-replicating viral vector, MVA expressing structural proteins",,Unknown,,"Same platform as vaccine candidates for HIV, HCV, CHIKV, EBOV, Zika, Malaria, Leishmania",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Janssen Pharmaceutical Companies/ Beth Israel Deaconess Medical Center/ Emergent BioSolutions/ Catalent/ Biological E/ Grand River Aseptic Manufacturing (GRAM)/ Sanofi/ Merck,Vaccine,Non-replicating viral vector,Authorized,"Health Canada fully ""approved"" the vaccine in individuals 18 years of age and older on 11/24/2021; Phase I/IIa sub-study results published 7/14/2021; Johnson & Johnson statement on COVID-19 vaccine released 7/12/2021; Data on neutralizing activity against emerging variants announced 7/1/2021; U.K. MHRA granted ""conditional marketing authorization"" on 5/28/2021; CDC and FDA lift recommended pause on vaccine use in U.S. on 4/23/2021; Phase III ENSEMBLE primary data published on 4/21/2021; CDC and FDA recommended a pause on vaccine use in the U.S. as of 4/13/2021; Phase IIa trial expanded to include adolescents 12-17 years of age as of 4/2/2021; WHO issued ""emergency use listing"" on 3/12/2021; Granted Conditional Marketing Authorization by European Commission on 3/11/2021; Granted ""Interim Order (IO) authorization"" for emergency use by Health Canada on 3/5/2021; U.S. CDC's Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vaccine for individuals 18 years of age and older on 2/28/2021; U.S. FDA issued ""emergency use authorization"" on 2/27/2021; Submitted ""emergency use listing"" to the World Health Organization (WHO) on 2/19/2021; Submitted ""conditional marketing authorisation application"" to the European Medicines Agency (EMA) on 2/16/2021; Janssen submitted application for ""emergency use authorization"" to the U.S. FDA on 2/4/2021; Phase III interim analysis results announced 1/29/2021; Phase I/IIa interim results published 1/13/2021; Phase III trial to study the safety and efficacy of a two-dose regimen began 11/15/2020 (ENSEMBLE 2); Phase III trial (ENSEMBLE) resumed recruitment on 10/23/2020, fully enrolled with ~45,000 participants as of 12/17/2020, interim data expected by the end of January 2021; Janssen Pharmaceutical Companies of Johnson & Johnson voluntarily paused dosing to allow independent review of safety data on 10/12/2020; Phase III trial (ENSEMBLE) began and study protocol released September 2020; Phase I/IIa began end of July 2020, interim results released September 2020; Animal study results published July and September 2020; Selected for US Operation Warp Speed in February 2020 and awarded funding in August 2020","Ad26.COV2-S (or JNJ-78436725), Non replicating viral vector; Ad26 (alone or with MVA boost)","EudraCT 2020-002584-63, ISRCTN14722499, NCT04436276, NCT04505722, NCT04509947, NCT04535453, NCT04614948, NCT04765384",Biomedical Advanced Research and Development Authority (BARDA),"medRxiv (https://www.medrxiv.org/content/10.1101/2020.09.23.20199604v1), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2034201), Johnson & Johnson (https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2101544), Johnson & Johnson (https://www.jnj.com/positive-new-data-for-johnson-johnson-single-shot-covid-19-vaccine-on-activity-against-delta-variant-and-long-lasting-durability-of-response), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMc2108829)","Same platform as vaccine candidates for Ebola, HIV, RSV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/10/2022
Vaxart/ Emergent BioSolutions,Vaccine,Non-replicating viral vector,Phase II,"Phase II dosed October 2021; Phase I preliminary data announced 2/3/2021; Phase I dosed October 2020; FDA clearance for Phase I trial received September 2020, recruiment expected to begin September 2020; Pre-clinical results released September 2020; Data from ongoing animal challenge study released October and November 2020. Phase 2 trials in India begin Feb 2022.","Non-replicating viral vector; Oral Vaccine
 platform","NCT04563702, NCT05067933",Unknown,"Vaxart (https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-positive-preliminary-data-phase-1-clinical), MedRx (https://www.medrxiv.org/content/10.1101/2022.07.16.22277601v1)","Same platform as vaccine candidates for InfA, CHIKV, LASV, NORV, EBOV, RVF, HBV, VEE",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/22/2022
University of Georgia/ University of Iowa,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Non-replicating viral vector; parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein,,Unknown,,Same platform as vaccine candidates for MERS ,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
"University of Oxford, Oxford Biomedica, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA, the Serum Institute, Vaccitech, Catalent, CSL, and AstraZeneca/IQVIA ",Vaccine,Non-replicating viral vector,Authorized,"Phase III safety and efficacy data published September 2021; Tolerability and immunogenicity results after a late second dose or a third dose released on 6/28/2021; Real-world data on vaccine effectiveness against hospitalizations due to the Delta variant released 6/14/2021; Japan granted authorization for ""emergency use"" on 5/21/2021; EMA updated guidance on very rare side effects announced 4/7/2021; Phase II dosing paused in children between the ages of 6 and 17 years pending MHRA review as of 4/6/2021; Phase III primary analysis (U.S. trial) results announced 3/25/2021; Phase III interim analysis (U.S. trial) results announced 3/22/2021; World Health Organization (WHO) granted Emergency Use Listing (EUL) on 2/15/2021; Phase II study in children between the ages of 6 and 17 years expected to begin in February 2021; Phase III (U.K., Brazil) and Phase I/II (U.K., South Africa) analyses data released on 2/3/2021; European Union (EU) granted ""conditional marketing authorisation"" on 1/29/2021; Brazil granted ""temporary authorization for emergency use"" on 1/17/2021; Pakistan granted ""emergency use authorization"" on 1/15/2021; India granted ""emergency use authorisation"" as well as Dominican Republic, El Salvador, Mexico and Morocco as of 1/6/2021; Argentina authorized under ""emergency registration"" on 12/30/2020;  U.K. ""authorised for emergency supply"" on 12/30/2020; Phase I/II data (w/ booster dose) published on 12/17/2020; Phase III trials interim analysis results published 12/8/2020; Phase II/III (COV002) and Phase III (COV003) trial pooled interim analysis results released on 11/23/2020; Phase II/III trial interim results released Nov 2020; Study protocol for late-stage clinical trials released September 2020; AstraZeneca clinical trials resumed globally (in the UK on 9/14/2020, Brazil and South Africa on 9/15/2020, Japan on 10/2/2020, and the US on 10/23/2020); AstraZeneca voluntarily paused vaccination to allow independent review of safety data on 9/8/2020; Phase III trial began Jun 2020 and expanded into US in Aug 2020; Phase II/III began May 2020; Phase I/II trial interim results released Jul 2020; Selected for US Operation Warp Speed in May 2020","Non replicating viral vector; COVID-19 Vaccine AstraZeneca in the U.K. (formerly AZD1222 and ChAdOx1), Covishield in India, (Vaxzevria)"," CTRI/2020/08/027170, EudraCT 2020-001072-15, EudraCT 2020-001228-32, ISRCTN15638344, ISRCTN89951424, NCT04324606, NCT04400838, NCT04444674, NCT04516746, NCT04540393, NCT04568031, NCT04686773, PACTR202005681895696, PACTR202006922165132","Coalition for Epidemic Preparedness Innovations (CEPI)/ UK Government/ Biomedical Advanced Research and Development Authority (BARDA)/ Gavi, the Vaccine Alliance","The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext), The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32466-1/fulltext), AstraZeneca (https://sputnikvaccine.com/newsroom/pressreleases/second-interim-analysis-of-clinical-trial-data-showed-a-91-4-efficacy-for-the-sputnik-v-vaccine-on-d/), The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext), Nature Medicine (https://www.nature.com/articles/s41591-020-01179-4), Nature Medicine (https://www.nature.com/articles/s41591-020-01194-5), Preprints with The Lancet (https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3777268), AstraZeneca (https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/astrazeneca-us-vaccine-trial-met-primary-endpoint.html), AstraZeneca (https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy.html), Public Health England Publishing (https://khub.net/documents/135939561/479607266/Effectiveness+of+COVID-19+vaccines+against+hospital+admission+with+the+Delta+%28B.1.617.2%29+variant.pdf/1c213463-3997-ed16-2a6f-14e5deb0b997?t=1623689315431), Preprints with The Lancet (https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3873839), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2105290), Research Square (https://www.researchsquare.com/article/rs-1792139/v1)","Same platform as vaccine candidates for influenza, TB, Chikungunya, Zika, MenB, plague",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/22/2022
"IDIBAPS- Hospital Clinic, Spain",Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,MVA-S,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/1/2020
"National Center for Genetic Engineering and Biotechnology (BIOTEC)/ GPO, Thailand",Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Inactivated Flu-based SARS-CoV2 vaccine + Adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/1/2020
"Massachusetts Eye and Ear/ AveXis, a Novartis Company/  Viralgen/ Aldevron/ Catalent/ Penn Medicine",Vaccine,Non-replicating viral vector,Pre-clinical,Pre-clinical results released January 2021; Phase I to begin second half of 2020,"AAVCOVID, Adeno-associated viral vector (AAV), spike protein",,Gates Foundation,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/29/2021
Gamaleya Research Institute,Vaccine,Non-replicating viral vector,Phase III,"Final results of trials are expected to be ready by October 2021; Demonstrated efficacy based on the analysis of data from vaccinated persons announced on 4/19/2021; Started rolling review process with the European Medicines Agency (EMA) on 3/4/2021; Authorized for ""emergency use"" in 39 countries as of March 2021; Phase III interim analysis results published on 2/2/2021; ""Registered"" in Belarus in December 2020; Phase III final control point data analysis results released December 2020, interim data analysis results released November 2020; Phase III (post-registration) trial began September 2020; Phase I/2 began June 2020, results published September 2020; Russian Ministry of Health ""registered"" vaccine in August 2020, Mass production expected to begin September 2020",Adeno-based; (Gam-COVID-Vac) (Sputnik V),"NCT04436471, NCT04437875, NCT04530396, NCT04564716, NCT04587219, NCT04640233, NCT04642339, NCT04656613, NCT04713488, NCT04741061",Russian Direct Investment Fund (RDIF),"The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31866-3/fulltext), Gamaleya Center and RDIF (https://sputnikvaccine.com/newsroom/pressreleases/the-first-interim-data-analysis-of-the-sputnik-v-vaccine-against-covid-19-phase-iii-clinical-trials-/), Gamaleya Center and RDIF (https://sputnikvaccine.com/newsroom/pressreleases/second-interim-analysis-of-clinical-trial-data-showed-a-91-4-efficacy-for-the-sputnik-v-vaccine-on-d/), The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext), Gamaleya Center and RDIF (https://rdif.ru/Eng_fullNews/6722/), eClinicalMedicine (https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00090-6/fulltext), American Journal of Therapeutics (https://journals.lww.com/americantherapeutics/Abstract/9900/Plausibility_of_Claimed_Covid_19_Vaccine.47.aspx)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/23/2022
"National
  Research Centre, Egypt",Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Influenza A H1N1 vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
ID Pharma,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Sendai virus vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Ankara University,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Adenovirus-based,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Erciyes University,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Adeno5-based,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/3/2020
"Institut
  Pasteur/ TheraVectys",Vaccine,Non-replicating viral vector,Pre-clinical,Pre-clinical results published December 2020; Animal study results released July 2020 ,Intranasal lentiviral vector vaccine,,Unknown,Cell Host & Microbe (https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(20)30672-7),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/28/2021
"CanSino Biologics/ Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",Vaccine,Non-replicating viral vector,Pre-clinical,Phase I recruitment began end of September 2020,Ad5-nCoV,NCT04552366,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/2/2020
University of Helsinki/ University of Eastern Finland/ Rokote Laboratories Finland Ltd,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Ad 5 vector for intranasal administration,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/28/2021
"Globe Biotech Limited, Bangladesh",Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Adenovirus Type 5 Vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/9/2020
"City of
  Hope Medical Center",Vaccine,Non-replicating viral vector,Phase I,Phase II expected to begin August 2021; Phase I dosed December 2020,MVA-based SARS-CoV-2 vaccine; (COH04S1),"NCT04639466, NCT04977024",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/1/2022
Bharat Biotech International Limited,Vaccine,Non-replicating viral vector,Phase I,Phase I began March 2021,"BBV154; adenovirus vectored, intranasal vaccine",NCT04751682,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/16/2022
Tetherex Pharmaceuticals Corporation,Vaccine,Non-replicating viral vector,Pre-clinical,Phase I expected to begin June 2021,"Adneviral vector vaccine, (SC-Ad6-1)",NCT04839042,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/30/2021
"Gritstone Oncology, Inc.",Vaccine,Non-replicating viral vector,Phase I,Phase I dosed March 2021,"Chimpanzee Adenovirus serotype 68 (chAd) and Self-Amplifying mRNA (SAM) vectors expressing either spike alone, or spike plus additional SARS-CoV-2 T cell epitopes (TCE)",NCT04776317,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/6/2022
AstraZeneca,Vaccine,Non-replicating viral vector,Phase II/III,"Phase II/III dosed end of June 2021, in both previously vaccinated (with two doses of Vaxzevria or an mRNA vaccine) and unvaccinated adults to determine the safety and immunogenicity of AZD2816, a vaccine for the prevention of COVID-19 caused by variant strains of the SARS-CoV-2 virus",Non-replicating viral vector; (AZD2816),NCT04973449,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/14/2022
CyanVac LLC,Vaccine,Non-replicating viral vector,Phase I,Phase I began August 2021,Intranasal PIV5-vectored vaccine expressing SARS-CoV-2 spike protein; (CVXGA1-001),NCT04973449,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/10/2022
BIOCAD,Vaccine,Non-replicating viral vector,Phase I/II,Phase I/II began August 2021,"Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5)-RBD (Receptor Binding Domain)-S Vaccine, (BCD-250)",NCT05037188,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/29/2021
McMaster University/ Canadian Institutes of Health Research (CIHR),Vaccine,Non-replicating viral vector,Pre-clinical,Phase I expected to begin November 2021,"Ad5-triCoV/Mac or ChAd-triCoV/Mac, new experimental adenovirus-based vaccines expressing SARS-CoV-2 spike, nucleocapsid and RNA polymerase proteins",NCT05094609,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/29/2021
Heat Biologics (Zolovax)/ University of Miami/ Waisman Biomanufacturing,Vaccine,Protein subunit,Pre-clinical,Animal data released August 2020,Protein subunit (gp-96 backbone),,Unknown,,"Same platform as vaccine candidates for cancer (NSCLC), HIV, malaria, Zika",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/13/2020
Sanofi Pasteur/ GSK,Vaccine,Protein subunit,Phase III,EMA began rolling review on 7/20/2021; Phase III began end of May 2021; Phase II interim results released May 2021; Phase II with refined antigen formulation began February 2021; Phase I/II interim safety and immunogenicity results released January 2021; Phase IIb expected to begin February 2021; Phase I/II interim results announced December 2020; Phase I/II began September 2020; Selected for US Operation Warp Speed in April 2020 and awarded funding in July 2020 ,"Protein subunit; S protein, baculovirus production; (Vidprevtyn)","NCT04537208, NCT04762680, PACTR202011523101903",Biomedical Advanced Research and Development Authority (BARDA)/ US Department of Health and Human Services (HHS)/ US Department of Defense (DoD),"Sanofi and GSK (https://www.sanofi.com/en/media-room/press-releases/2020/2020-12-11-07-00-00), medRxiv (https://www.medrxiv.org/content/10.1101/2021.01.19.20248611v1.full), Sanofi and GSK (https://www.sanofi.com/en/media-room/press-releases/2021/2021-05-17-07-30-00-2230312)","Same platform as vaccine candidates for Influenza, SARS-CoV (FDA approved vaccine)",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/26/2022
iBio / CC-Pharming,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit; Subunit protein, plant produced",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
ImmunoPrecise/ LiteVax BV,Vaccine,Protein subunit,Pre-clinical,Unknown,Spike-based (epitope screening),,TRANSVAC2,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/15/2020
Novavax/Emergent Biosolutions/ Praha Vaccines/ Biofabri/ Fujifilm Diosynth Biotechnologies/ FDB/ Serum Institute of India/ SK bioscience/ Takeda Pharmaceutical Company Limited/ AGC Biologics/ PolyPeptide Group/ Endo,Vaccine,Protein subunit,Phase III,"Indonesia and the Philippines granted emergency use authorization (EUA) as of November 2021; Announced rolling regulatory submission to the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for authorization on 10/27/2021; Phase III (U.K. trial) final analysis results published 6/30/2021; Phase III efficacy data released 6/14/2021; Updated PREVENT-19 trial protocol released on 5/10/2021; Announced preclinical data from NanoFlu/NVX-CoV2373 combination vaccine study on 5/10/2021; Initiated a pediatric expansion (12-17 years of age) of its Phase III clinical trial on 5/3/2021; Announced participation in Phase II clinical trial called ""Comparing COVID-19 Vaccine Schedule Combinations – Stage 2"" (Com-COV2) on 4/14/2021; Announced the initiation of crossover arms in two ongoing clinical trials on 4/5/2021; Phase III (UK) and Phase IIb ( South Africa) final efficacy results released 3/11/2021; Phase I/II trial dosed in Japan on 2/26/2021; Phase III trial (PREVENT-19) completed enrollment in the US and Mexico on 2/22/2021; Announced the start of the rolling review process with several regulatory agencies worldwide on 2/4/2021, including the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), U.K. Medicines and Healthcare products Regulatory Agency (MHRA), and Health Canada; Phase III (UK) and Phase IIb ( South Africa) interim results released 1/28/2021; Phase III trial (PREVENT-19) initiated in the US and Mexico in December 2020, trial protocol released on website; FDA granted Fast Track Designation on 11/9/2020; Phase III dosed in the UK in October 2020, trial protocol released on website, interim data expected to be released in Q1 2021; Phase IIb trial began Aug 2020; Selected for US Operation Warp Speed July 2020; Phase I/II began end of May 2020, interim data expected to be released on 10/30/2020; Animal study & preliminary Phase I results released Aug 2020, Phase I results published Sept 2020",Protein subunit; Full length recombinant SARs COV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M; (NVX-CoV2373) (SARS-CoV-2 rS),"EudraCT 2020-004123-16, NCT04368988, NCT04533399, NCT04583995, NCT04611802",Coalition for Epidemic Preparedness (CEPI)/ US Department of Defense/ Gates Foundation,"medRxiv (https://www.medrxiv.org/content/10.1101/2020.08.05.20168435v1), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2026920), Novavax (https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3), Novavax (https://ir.novavax.com/news-releases/news-release-details/novavax-confirms-high-levels-efficacy-against-original-and-0), bioRxiv (https://www.biorxiv.org/content/10.1101/2021.05.05.442782v1), Novavax (https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-90-overall-efficacy-and), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2107659), BioRxiv (https://www.biorxiv.org/content/10.1101/2022.04.08.487674v1)","Same platform as vaccine candidates for RSV, CCHF, HPV, VZV, EBOV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/14/2022
Vaxine Pty Ltd/ Flinders University/ Oracle/ Medytox/ Sypharma/ Oxford Expression Technologies,Vaccine,Protein subunit,Phase III,Iran issued an emergency use permit in October 2021; Phase III trial dosed August 2021; Phase II trial dosed June 2021; Phase II and III trials will be initiated in Iran in the coming weeks as of May 2021; Phase I trial dosed July 2020,"Protein subunit; recombinant spike protein with Advax adjuvant (COVAX-19), (SpikoGen)","NCT04453852, NCT04944368, NCT05005559, IRCT20150303021315N23, IRCT20150303021315N24",Innovate UK/ Australian Government,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/29/2021
"Shionogi & Co., Ltd./ National Institute of Infectious Disease, Japan",Vaccine,Protein subunit,Phase II/III,"Phase II/III began October 2021; New Phase I/II clinical trial began in Japan at the end of July 2021, using a new formulation with a modified adjuvant to achieve a higher neutralizing antibody titer; Phase I/II clinical trial began December 2020. Results of 1/2 trial released December 2021. Top line results for Phase 2/3 additional dose released March 2022. ","Recombinant protein vaccine S-268019, baculovirus expression",jRCT2051200092,Japan Agency for Medical Research and Development ,"Shionogi (https://www.shionogi.com/global/en/news/2021/12/e-211207.html)
Shionogi (https://www.shionogi.com/global/en/news/2022/03/e20220304.html)",Same platform as vaccine candidates for Influenza,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/28/2022
ExpreS2ion,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, drosophila S2 insect cell expression system VLPs",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"LakePharma, Inc.",Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, nanoparticle vaccine",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
Axon Neuroscience SE,Vaccine,Protein subunit,Pre-clinical,Pre-clinical results released September 2020,Peptides derived from Spike protein; (ACvac1),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/16/2020
Medigen Vaccine Biologics Corp/ NIAID/ Dynavax,Vaccine,Protein subunit,Phase III,"Announced (10/26/2021) as one of two candidate vaccines to be included in the Solidarity Trial Vaccines with WHO and the Ministries of Health of Colombia, Mali, and the Philippines; Phase III began October 2021; Taiwan began vaccine rollout during the week of 8/23/2021; Phase III expected to complete the recruitment (1,000 participants) by Q3 2021; Taiwan granted EUA approval on 7/19/2021, clinical trials are ongoing; Phase II interim analysis results released 6/10/21; Phase II study in elderly adults (65 years and older) began May 2021; Booster trial with third dose began May 2021; Phase II second dose vaccination completed on 4/28/2021; Phase I interim analysis results announced 4/7/2021; Phase II dosed January 2021; Phase I dosed in early October 2020; Received conditional approval for clinical testing on Aug 31 and was given full approval on Sept 30; Pre-clinical data released August 2020 and published November 2020",MVC-COV1901 vaccine injection; S-2 P protein + CpG 1018,"NCT04487210, NCT04695652, NCT04822025, NCT04951388",Unknown,"medRxiv (https://www.medrxiv.org/content/10.1101/2021.03.31.21254668v1), Medigen (https://www.medigenvac.com/public/en/news/detail/78?from_sort=2)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/30/2022
Baylor College of Medicine,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; S1 or RBD protein,,Unknown,,Same platform as vaccine candidates for SARS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Innovax / Xiamen University / GSK,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; COVID-19 XWG-03 truncated Spike proteins,,Unknown,,"Same platform as vaccine candidates for HPV  
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Quadram Institute Biosciences,Vaccine,Protein subunit,Pre-clinical,Unknown,OMV-based vaccine,,Unknown,,"Same platform as vaccine candidates for Flu A, plaque
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/12/2020
"Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese Academy of Sciences",Vaccine,Protein subunit,Phase III,"China and Uzbekistan granted ""emergency use"" approval in March 2021; Phase III began December 2020; Phase I and II safety and immunogenicity data released December 2020; Phase II began July 2020; Received approval to launch clinical trials in China in June 2020",Adjuvanted recombinant protein (RBD-Dimer); ( ZF2001),"NCT04445194, NCT04466085, NCT04550351, NCT04646590",Unknown,"medRxiv (https://www.medrxiv.org/content/10.1101/2020.12.20.20248602v1), New England Journal of Medicine (https://www.nejm.org/doi/full/10.1056/NEJMoa2202261#:~:text=Conclusions,%3B%20ClinicalTrials.gov%20number%2C%20NCT04646590)",Same platform as vaccine candidates for MERS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/5/2022
Yisheng Biopharma,Vaccine,Protein subunit,Phase I,Phase I clinical trial registered August 2021; Pre-clinical data published March 2021,PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine,ACTRN12621001009808,Unknown,Vaccines (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004863/),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/29/2021
"University of California, San Diego",Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; plant virus nanotechnology formulated as injectable and microneedle patch,,National Science Foundation (Rapid Response Research [RAPID] grant),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
Intravacc/Epivax,Vaccine,Protein subunit,Pre-clinical,Unknown,Outer Membrane Vesicle (OMV)-peptide,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
AJ Vaccines,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; S protein,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"VIDO-InterVac, University of Saskatchewan",Vaccine,Protein subunit,Phase I/II,Phase I/II dosed February 2021; Animal testing results expected in April 2020,"Protein subunit, adjuvanted microsphere peptide, (COVAC-1 & COVAC-2)",NCT04702178,The Government of Saskatchewan and the Canadian Federal Government,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/27/2022
MIGAL Galilee Research Institute,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; oral E. coli-based protein expression system of S and N proteins,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Biological E Ltd/ Dynavax/ Baylor College of Medicine,Vaccine,Protein subunit,Phase III,"Phase III began September 2021; Phase III clinical trial received approval to start by CDSCO in April 2021; CEPI partnership announced December 2020; Phase I/II began November 2020, interim data expected Q1 2021",Protein subunit; (BECOV2),"CTRI/2020/11/029032, CTRI/2021/08/036074",Coalition for Epidemic Preparedness Innovations (CEPI),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/29/2021
OncoGen,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, synthetic long peptide vaccine candidate for S and M proteins",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"Vaxxinity, Inc. (formerly COVAXX and United Neuroscience)/ University of Nebraska Medical Center (UNMC)/ DASA/ United Biomedical Inc. Asia",Vaccine,Protein subunit,Phase II,"Phase I study extended with one booster dose in July 2021; Phase II/III trials expected to begin in Brazil, India, and other countries in Q2 2021; Phase I interim data announced 2/8/2021; Phase II began (Taiwan) February 2021; Phase II clinical trials granted conditional approval by Taiwan's Ministry of Health and Welfare on 1/29/2021; Phase I began (Taiwan) September 2020; Large scale human efficacy clinical trials expected to be conducted in Brazil and the US",S1-RBD-protein; Multitope Peptide-Based Vaccine (MVP); UB-612,"NCT04545749, NCT04683224, NCT04773067, NCT04967742",Ministry of Health and Welfare in Taiwan,COVAXX (https://www.businesswire.com/news/home/20210208005198/en),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/1/2022
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Vaccine,Protein subunit,Pre-clinical,Unknown,Subunit vaccine ,,Unknown,,Same platform as vaccine candidates for Ebola,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/31/2020
"Applied Biotechnology Institute, Inc.",Vaccine,Protein subunit,Pre-clinical,Unknown,"Orally delivered, heat stable subunit",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/12/2020
University of Alberta,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; spike based,,Unknown,,Same platform as vaccine candidates for Hepatitis C,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
St. Petersburg Scientific Research Institute of Vaccines and Serums,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, recombinant protein, nanoparticles (based on S-protein and other epitopes)",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
AdaptVac (PREVENT-nCoV consortium),Vaccine,Protein subunit,Phase II,"Phase I/II (COUGH-1) study began March 2021, initial results expected to be released in July 2021; Pre-clinical data published January 2021","Protein subunit, capsid-like particle (CLP); (ABNCoV2)",,European Commission (Horizon 2020 Program),AdaptVac (•       https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_fcea6eab98ed4cc4bd231e2434ec02ce.pdf),Same platform as vaccine candidates for HPV  ,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/9/2021
Clover Biopharmaceuticals Inc./ Dynavax,Vaccine,Protein subunit,Phase II/III," Phase II/III (SPECTRA) trial succesfully met primary and secondary efficacy endpoints as of September 2021; Phase II/III (SPECTRA) trial with Dynavax adjuvant dosed March 2021, fully enrolled as of July 2021; Clover and GSK discontinued their partnership as of February 2021; Phase I safety and immunogenicity data released December 2020 and published January 2021; Phase II/III trial with Dynavax adjuvant expected to begin during first half of 2021; Phase II/III trial with GSK adjuvant is not expected to move forward; Pre-clinical results released September 2020; CEPI partnership expanded in July and November 2020, Phase I trial began June 2020, preliminary results expected in the near future","Protein subunit, native like trimeric subunit spike protein; (SCB-2019)","NCT04405908, NCT04672395",Coalition for Epidemic Preparedness (CEPI),"Clover Biopharmaceuticals (http://www.cloverbiopharma.com/index.php?m=content&c=index&a=show&catid=11&id=53), medRxiv (https://www.medrxiv.org/content/10.1101/2020.12.03.20243709v1), The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00241-5/fulltext), News Medical (https://www.news-medical.net/news/20220606/Safety-and-efficacy-of-SCB-2019-COVID-vaccine-candidate-as-a-ChAdOx1-S-booster.aspx#:~:text=SCB%2D2019%20is%20a%20novel,SPECTRA%20phase%20II%2FIII%20trial.)","Same platform as vaccine candidates for HIV, RSV, Influenza",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/28/2022
Walter Reed Army Institute of Research (WRAIR) / U.S. Army Medical Research and Development Command,Vaccine,Protein subunit,Phase I,Phase I began recruiting April 2021,Protein subunit; S protein (SpFN),NCT04784767,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2021
Flow Pharma,Vaccine,Protein subunit,Pre-clinical,Pre-clinical study results published May 2021,"Protein subunit, peptide",,Unknown,Vaccines (https://www.mdpi.com/2076-393X/9/5/520),"Same platform as vaccine candidates for Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, Breast Cancer ",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2021
Neovii/Tel Aviv University,Vaccine,Protein subunit,Pre-clinical,Unknown,RBD-based,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
Sorrento Therapeutics,Vaccine,Protein subunit,Pre-clinical,Animal study results released July 2020,Recombinant fusion protein of the SARS-CoV-2 spike protein S1 domain and human IgG Fc (T-VIVA-19),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/17/2020
EpiVax / University of Georgia,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; S protein,,Unknown,,Same platform as vaccine candidates for Inf H7N9,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Generex / EpiVax,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; Ii-Key peptide,,"Beijing Youfeng Biological Technology, Ltd (Youfeng-BI) ",,"Same platform as vaccine candidates for HIV, SARS-CoV, Influenza",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2021
"Emergex Vaccines Holdings/ Center for Primary Care and Public Health (Unisante)/ University of Lausanne, Switzerland/ University of Lausanne Hospitals",Vaccine,Protein subunit,Phase I,Phase I (Stage II of a 2-part adaptive trial) began recruiting in December 2021 and is expected to be dosed in January 2022,"T-Cell Priming Peptide Vaccine Against Coronavirus COVID-19, (naNO-COVID)",NCT05113862,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/29/2021
Vaxil Bio,Vaccine,Protein subunit,Pre-clinical,"Vaxil has put its COVID-19 vaccine work on temporary hold as of May 31, 2021",Protein subunit; peptide,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2021
BiOMVis Srl/ University of Trento,Vaccine,Protein subunit,Pre-clinical,Unknown,OMV-based vaccine,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/12/2020
University of Pittsburgh,Vaccine,Protein subunit,Pre-clinical,Phase I to start as early as June 2020,"PittCoVacc, Protein subunit, microneedle arrays S1 subunit",,Unknown,,Same platform as vaccine candidates for MERS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
SK bioscience/ GSK/ Institute for Protein Design (IPD) at the University of Washington (UW),Vaccine,Protein subunit,Phase I/II,Phase I/II final data announced November 2021; Phase I/II interim data announced August 2021; Phase III IND submitted to the Korean Ministry of Food and Drug Safety in June 2021; Phase I/II began February 2021,"SARS-CoV-2 recombinant protein nanoparticle vaccine, (GBP510)","NCT04742738, NCT04750343",Gates Foundation/ Coalition for Epidemic Preparedness (CEPI),"SK bioscience (https://www.skbioscience.co.kr/en/news/news_01_01?mode=view&id=91&), SK bioscience (https://www.skbioscience.co.kr/en/news/news_01_01?mode=view&id=99&)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/28/2022
"Osaka University / BIKEN / National Institutes of Biomedical Innovation, Japan",Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, VLP-recombinant protein + adjuvant",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Vabiotech,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, recombinant S protein in IC-BEVS  ",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/16/2020
AnyGo Technology,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, recombinant S1-Fc fusion protein",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Vaccine,Protein subunit,Phase III,"Phase I/II interim results published March 2021; Phase III trial began November 2020; ""Registered"" for use in Russia in October 2020; Phase I/II trial began end of July 2020","Peptide vaccine, EpiVacCorona","NCT04527575, NCT04780035",Unknown,Russian Journal of Infection and Immunity (https://www.iimmun.ru/iimm/article/viewFile/1699/1188),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/29/2021
UMN Pharma (Shionogi),Vaccine,Protein subunit,Pre-clinical,Phase I to start by end of 2020,"Protein subunit; recombinant protein vaccine, utilizing baculovirus expression vector system technology",,Japan Agency for Medical Research and Development,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/10/2020
"IMV, Inc., Canadian Center for Vaccinology at Dalhousie University, Izaak Walton Killam Health Center, Nova Scotia Health Authority, Canadian Immunization Research Network, University of Laval, Global Urgent and Advanced Research and Development in Canada",Vaccine,Protein subunit,Pre-clinical,,"Protein subunit; DPX-COVID-19, protein subunit, peptide antigens formulated in LNP",,"National Research Council of Canada Industrial Research Assistance Program (NRC IRAP), Atlantic Canada Opportunities Agency (ACOA), and Next Generation Manufacturing Canada (NGen)",,"Same platform as vaccine candidates for cancer and infectious diseases, including malaria and anthrax",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2021
EpiVax ,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit EPV-CoV-19,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/27/2020
Lomonosov Moscow State University,Vaccine,Protein subunit,Pre-clinical,Unknown,Structurally modified spherical particles of the tobacco mosaic virus (TMV),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/27/2020
Kentucky BioProcessing (British American Tobacco),Vaccine,Protein subunit,Phase I/II,"Phase I/II began recruiting December 2020, results expected mid-2021","RBD-based, (KBP-COVID-19)",NCT04473690,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/16/2022
"Chulalongkorn University/ GPO, Thailand",Vaccine,Protein subunit,Pre-clinical,Unknown,RBD protein fused with Fc of IgG + Adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/1/2020
PDS Biotechnology,Vaccine,Protein subunit,Pre-clinical,Phase I/II is expected to to begin by Q2/3 2021,PDS-0203; Versamune T-cell activating technology ,,"The Ministry of Science, Technology and Innovation of Brazil (MCTI)",,"Same platform as vaccines against cancers, HBV, influenza, and tuberculosis",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2021
"Verndari/ University of California, Davis",Vaccine,Protein subunit,Pre-clinical,"Preliminary pre-clinical results are expected in the second half of 2020, Phase I trial is expected to begin thereafter; Selected by BARDA DRIVe for support in August 2020",Spike protein; VaxiPatch microneedle array dermal patch,,"Biomedical Advanced Research and Development Authority (BARDA) Division of Research, Innovation, and Ventures (DRIVe)",,Same platform as vaccines against influenza,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/27/2020
Max-Planck Institute of Colloids and Interfaces,Vaccine,Protein subunit,Pre-clinical,Unknown,Recombinant S protein,,KHAN-1 Technology Transfer Fund I GmbH & Co KG,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/10/2020
"MOGAM Institute for Biomedical Research, GC Pharma",Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/16/2020
"University of San Martin and CONICET, Argentina",Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/12/2020
Intravacc/Epivax,Vaccine,Protein subunit,Pre-clinical,Pre-clinical data announced April 2021,Outer Membrane Vesicle (OMV)-subunit,,Unknown,Intravacc (https://www.intravacc.nl/news/intravacc-announces-positive-pre-clinical-data-intranasal-sars-cov-2-candidate-vaccine/),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2021
Baiya Phytopharm/ Chula Vaccine Research Center,Vaccine,Protein subunit,Phase I,Phase I began September 2021; Animal trial results announced September 2020,Plant-based subunit (RBD-Fc + Adjuvant),NCT04953078,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/3/2021
"Helix Biogen Consult, Ogbomoso & Trinity Immonoefficient Laboratory, Ogbomoso, Oyo State, Nigeria",Vaccine,Protein subunit,Pre-clinical,Unknown,Subunit,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
"National
  Research Centre, Egypt",Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein Subunit S, N, M & S1 protein",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
University of Virginia,Vaccine,Protein subunit,Pre-clinical,Unknown,S subunit intranasal liposomal formulation with GLA/3M052 adjs.,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
Izmir Biomedicine and Genome Center,Vaccine,Protein subunit,Pre-clinical,Unknown,Recombinant S protein,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Bogazici University,Vaccine,Protein subunit,Pre-clinical,Clinical trials expected to begin summer 2021,Peptide + novel adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2021
InnoMedica,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, TaliCoVax19 ",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Mynvax,Vaccine,Protein subunit,Pre-clinical,Unknown,RBD-protein,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/15/2020
"Research
  Institute for Biological Safety Problems, Rep of Kazakhstan",Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/3/2020
Instituto Finlay de Vacunas,Vaccine,Protein subunit,Phase I/II,Phase I preliminary report released March 2021; Phase I/II began August 2020 ,RBD + Adjuvant (FINLAY-FR-1) (SOBERANA 01),"IFV/COR/04 (RPCEC00000332), IFV/COR/05 (RPCEC00000338)",Unknown,medRxiv (https://www.medrxiv.org/content/10.1101/2021.02.22.21252091v1),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/14/2021
Soligenix/ University of Hawaii at Mānoa,Vaccine,Protein subunit,Pre-clinical,Pre-clinical testing results released in July 2020,CiVax™ COVID-19 vaccine candidate; spike protein + novel adjuvant,,"Soligenix, Inc. ",,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/27/2020
Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana Cayetano Heredia (UPCH),Vaccine,Protein subunit,Pre-clinical,Unknown,RBD protein (baculovirus production) + FAR-Squalene adjuvant,,Unknown,,Same platform as multiple vaccine candidates,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/19/2021
"West China Hospital, Sichuan University",Vaccine,Protein subunit,Phase II,Phase II began November 2020; Phase I began end of August 2020; Animal study data published July 2020,"RBD (baculovirus production
expressed in Sf9 cells)","ChiCTR2000037518, ChiCTR2000039994, NCT04530656, NCT04640402, NCT04718467",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/4/2021
"Adimmune
  Corporation",Vaccine,Protein subunit,Phase I,Phase I/II dose finding study has received approval to begin in Indonesia as of September 2021; Phase I began end of August 2020; Phase II expected to begin November 2020,"Baculovirus-insect cells expression system, spike (S) protein (tAdimrSC-2f)",NCT04522089,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/28/2021
University Hospital Tuebingen,Vaccine,Protein subunit,Phase I,Phase I began December 2020,"SARS-CoV-2 HLA-DR peptides, (CoVAC-1)",NCT04546841,Unknown,Targeted Oncology (https://www.targetedonc.com/view/covac-1-vaccine-demonstrates-potential-to-prevent-severe-covid-19-in-patients-with-cancer),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/2/2022
Instituto Finlay de Vacunas,Vaccine,Protein subunit,Phase III,"Cuba granted ""emergency approval"" on 8/20/2021; Iran began producing the vaccine (as PastuCovac) in August 2021; Phase III efficacy data announced 7/8/2021; Phase III preliminary data announced on 6/19/2021; Phase I/II pediatric study (ages 3-18 years) began June 2021; Cuba began rolling out the vaccine in a mass campaign in May 2021; Phase III began March 2021; Phase II began December 2020; Phase I began October 2020",rRBD produced in CHO-cell chemically conjugate to tetanus toxoid; (FINLAY-FR-2) (SOBERANA 02); PastuCovac in Iran,"IFV/COR/06 (RPCEC00000340), IFV/COR/08 (RPCEC00000347), IFV/COR/09 (RPCEC00000354)",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/31/2021
OSE  Immunotherapeutics/ Cenexi,Vaccine,Protein subunit,Phase I, First positive results announced 11/30/21; Phase I began May 2021; Pre-clinical results  released in August 2020. Positive results released December 2021.,T cell-based vaccine platform (CoVepiT),NCT04885361,Unknown,"OSE Immunotherapeutics (https://www.ose-immuno.com/wp-content/uploads/2021/11/EN_211130_CoVepiT-Update.pdf), OSE Immunotherapeutics (https://www.ose-immuno.com/wp-content/uploads/2021/11/EN_211130_CoVepiT-Update.pdf)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/9/2021
Tampere University,Vaccine,Protein subunit,Pre-clinical,Unknown,Recombinant S protein produced in BEVS,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/10/2020
Ohio State University/ Kazakh National Agrarian University,Vaccine,Protein subunit,Pre-clinical,Unknown,RBD protein delivered in mannose-conjugated chitosan nanoparticle,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/10/2020
Kazakh National Agrarian University,Vaccine,Protein subunit,Pre-clinical,Unknown,Recombinant spike protein with Essai O/W 1849101 adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/10/2020
Neo7Logix,Vaccine,Protein subunit,Pre-clinical,Unknown,Peptides,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/16/2020
"Kazakh National Agrarian University, Kazakhstan/ National Scientific Center for Especially Dangerous Infections",Vaccine,Protein subunit,Pre-clinical,Unknown,Recombinant spike protein with Essai O/W 1849101 adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/10/2020
Nanogen Pharmaceutical Biotechnology,Vaccine,Protein subunit,Phase III,Phase III began June 2021; Phase II began February 2021; Phase I began December 2020,"Recombinant SARS-CoV-2 spike protein, aluminum adjuvanted, (Nanocovax)","NCT04683484, NCT04922788",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/18/2021
University Medical Center Groningen/ Akston Biosciences Corporation/ LakePharma,Vaccine,Protein subunit,Phase I/II,Phase I/II dosed April 2021,SARS-CoV-2-RBD-Fc fusion protein; (AKS-452),NCT04681092,Unknown,https://www.americanpharmaceuticalreview.com/1315-News/587918-Biolexis-and-Akston-Biosciences-Announce-Results-from-Phase-II-III-Trial-of-their-Thermostable-2nd-Gen-COVID-19-Vaccine/ (American Pharmaceutical Review),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/14/2022
"Center for Genetic Engineering and Biotechnology (CIGB), Havana",Vaccine,Protein subunit,Phase I/II,Phase I of Phase I/II (MAMBISA) trial began December 2020,CIGB-669 (RBD-AgnHB),RPCEC00000345,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/31/2021
"Center for Genetic Engineering and Biotechnology (CIGB), Havana",Vaccine,Protein subunit,Phase III,"Cuba began rolling out the vaccine in a mass campaign in May 2021; Phase III began March 2021; Phase II began February 2021, Phase I (ABDALA) trial began December 2020",CIGB-66 (RBD + aluminum hydroxide),RPCEC00000346,Unknown,medRxiv (https://www.medrxiv.org/content/10.1101/2022.03.22.22272739v1),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/30/2022
Razi Vaccine and Serum Research Institute,Vaccine,Protein subunit,Phase III,Iran issued an emergency use license in November 2021; Phase III began September 2021; Phase II began April 2021; Phase I began February 2021,SARS-CoV-2 recombinant Spike protein vaccine (Razi Cov Pars),"IRCT20201214049709N1, IRCT20201214049709N2, IRCT20201214049709N3",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/28/2021
Guangdong Provincial Center for Disease Control and Prevention/ Gaozhou Center for Disease Control and Prevention,Vaccine,Protein subunit,Phase I,Phase I began April 2021,"Recombinant SARS-Cov-2 coronavirus fusion protein vaccine, (V-01)","ChiCTR2100045108, ChiCTR2100045107 ",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/30/2021
"National Vaccine and Serum Institute, China",Vaccine,Protein subunit,Phase I/II,Phase I/II began recruiting April 2021,Recombinant SARS-CoV-2 Vaccine (CHO Cell),NCT04869592,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2021
VaxForm,Vaccine,Protein subunit,Pre-clinical,Phase I expected to begin June 2021,"CoV2-OGEN1, protein-based vaccine",NCT04893512,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2021
Clover Biopharmaceuticals AUS Pty Ltd,Vaccine,Protein subunit,Pre-clinical,Phase II expected to begin August 2021; Pre-clinical data announced May 2021,Adjuvanted recombinant SARS-CoV-2 trimeric S-protein (from B.1.351 variant) subunit vaccine; (SCB-2020S),NCT04950751,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/31/2021
"Shanghai
  Zerun Biotechnology Co., Ltd/ Walvax Biotechnology Co., Ltd",Vaccine,Protein subunit,Phase I,Phase I began July 2021,Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell); (202-CoV ),NCT04982068,Coalition for Epidemic Prepardeness (CEPI),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/31/20
Instituto Finlay de Vacunas,Vaccine,Protein subunit,Phase II,Cuba granted emergency use authorization for use in convalescent individuals (19 years of age and older) on 9/23/2021; Phase I/II study in convalescent pediatric individuals (2-18 years of age) began September 2021; Phase II study in convalescent individuals began April 2021,"RBD + adjuvant booster dose that contains spike-protein fragments, (SOBERANA PLUS)","IFV/COR/11 (RPCEC00000366), IFV/COR/15 (RPCEC00000391)",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/3/2022
"Laboratorios Hipra, S.A.",Vaccine,Protein subunit,Phase I/II,Phase I/II began August 2021, Recombinant Protein RBD,NCT05007509,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/3/2022
Sinocelltech Ltd.,Vaccine,Protein subunit,Pre-clinical,"Phase I/II/III, multicenter, randomized, double-blinded trials (designed to evaluate the safety, tolerability, immunogenicity, and protective efficacy of SCTV01C in healthy population aged ≥18 years previously vaccinated with inactivated, adenovirus vectored, or mRNA COVID-19 vaccine) expected to begin late October 2021","Bivalent Recombinant Trimeric S Protein Vaccine against SARS-CoV-2 Variants, (SCTV01C)","NCT05043311, NCT05043285",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/29/2021
PT Bio Farma,Vaccine,Protein subunit,Pre-clinical,Phase  I/II expected to begin November 2021,SARS-CoV-2 Protein Subunit Recombinant Vaccine,NCT05067894,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/29/2021
HK inno.N Corporation (formerly CJ HealthCare),Vaccine,Protein subunit,Phase I,Phase I began September 2021,"SARS-CoV-2 Vaccine, (IN-B009)",NCT05113849,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/29/2021
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Vaccine,Replicating viral vector,Pre-clinical,Unknown,Replicating viral vector; measles vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/31/2020
DZIF - German Center for Infection Research/ CanVirex AG,Vaccine,Replicating viral vector,Pre-clinical,Unknown,"Measles virus (S, N targets)",,Unknown,,"Same platform as vaccine candidates for Zika, H7N9, CHIKV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
"The Lancaster University, UK",Vaccine,Replicating viral vector,Pre-clinical,Unknown,Avian paramyxovirus vector (APMV),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
Zydus Cadila Healthcare Limited ,Vaccine,Replicating viral vector,Pre-clinical,Unknown,Replicating viral vector; measles vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
The University of Hong Kong/ Xiamen University/ Wantai Biological Pharmacy,Vaccine,Replicating viral vector,Phase I/II,Phase I expected to begin in Hong Kong in April 2021; Phase I/II began in China during Fall 2020; Approved for clinical trials in September 2020,"Replicating viral vector, intranasal flu-based RBD (DelNS1-2019-nCoV-RBD-OPT1)","ChiCTR2000037782, ChiCTR2000039715, NCT04809389",Coalition for Epidemic Preparedness (CEPI),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/12/2021
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Vaccine,Replicating viral vector,Pre-clinical,Unknown,Replicating viral vector; VSV vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/31/2020
Shenzhen Geno-Immune Medical Institute,Vaccine,Replicating viral vector,Phase I,Phase I reportedly began February 2020,Covid-19/aAPC vaccine,NCT04299724,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/31/2021
KU Leuven,Vaccine,Replicating viral vector,Pre-clinical,Unknown,Replicating viral vector; YF17D Vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
BiOCAD/ IEM,Vaccine,Replicating viral vector,Pre-clinical,Unknown,"Replicating viral vector, live viral vectored vaccine based on attenuated influenza virus backbone (intranasal)",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.,Vaccine,Replicating viral vector,Pre-clinical,Unknown,Newcastle disease virus vector (NDV-SARS-CoV-2/Spike),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
University of Wisconsin-Madison / FluGen/ Bharat Biotech,Vaccine,Replicating viral vector,Pre-clinical,Start Phase I trial in fall 2020,M2-deficient single replication (M2SR) influenza vector,,Unknown,,Same platform as vaccine candidates for influenza,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
Tonix Pharma / Southern Research,Vaccine,Replicating viral vector,Pre-clinical,Phase I expected to begin during second half of 2021; Preliminary pre-clinical results reported on 3/17/2021,Replicating viral vector; horsepox vector expressing S protein; (TNX-1800),,Unknown,https://southernresearch.org/news/southern-research-and-tonix-pharmaceuticals-reports-positive-covid-19-vaccine-efficacy-results/,"Same platform as vaccine candidates for smallpox, monkeypox",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2021
University of Western Ontario,Vaccine,Replicating viral vector,Pre-clinical,Unknown,Replicating viral vector; VSV-S,,Unknown,,"Same platform as vaccine candidates for HIV, MERS",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Vaccine,Replicating viral vector,Pre-clinical,Unknown,"Replicating viral vector, recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 (intranasal)",,Unknown,,Same platform as vaccine candidates for influenza,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/31/2020
Fundacao Oswaldo Cruz and Instituto Buntantan,Vaccine,Replicating viral vector,Pre-clinical,Unknown,Attenuated Influenza expressing an antigenic portion of the Spike protein,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/27/2020
"Israel
  Institute for Biological Research/ Weizmann Institute of Science",Vaccine,Replicating viral vector,Phase I/II,Phase IIb/III expected to begin September 2021; Phase III expected to begin October 2021; Phase I began November 2020 and Phase II began December 2020,rVSV-SARS-CoV-2-S vaccine; (BriLife),"NCT04608305, NCT04990466",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/1/2022
Aurobindo,Vaccine,Replicating viral vector,Pre-clinical,Unknown,VSV-S,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/15/2020
Farmacológicos Veterinarios SAC (FARVET SAC),Vaccine,Replicating viral vector,Pre-clinical,Pre-clinical results released March 2021,Intranasal Newcastle disease virus vector (rNDV-FARVET) expressing RBD protein,,Unknown,bioRxiv (https://www.biorxiv.org/content/10.1101/2021.03.07.434276v2),Same platform as multiple vaccine candidates,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2021
University of Manitoba,Vaccine,Replicating viral vector,Pre-clinical,Unknown,Replicating VSV vector-based DC-targeting,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/9/2020
"Cellid
  Co., Ltd./IAVI",Vaccine,Replicating viral vector,Phase I/II,Phase I study of a revised version of the virus vector vaccine began September 2021; Phase IIa is expected to be dosed in early April 2021; Phase I/IIa trial began December 2020,AdCLD-CoV19,"NCT04666012, NCT05047692",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/29/2021
"Farmacológicos
  Veterinarios SAC (FARVET SAC)",Vaccine,Replicating viral vector,Pre-clinical,Pre-clinical results released March 2021,Intranasal Newcastle disease virus vector (rNDV-FARVET) expressing S1 protein,,Unknown,bioRxiv (https://www.biorxiv.org/content/10.1101/2021.03.07.434276v2),Same platform as multiple vaccine candidates,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2021
"Aivita Biomedical, Inc./ National Institute of Health Research and Development, Ministry of Health Republic of Indonesia",Vaccine,Replicating viral vector,Phase II,Phase II began February 2021; Phase I began December 2020,Dendritic cell vaccine AV-COVID-19,"NCT04690387, NCT04685603, NCT04386252, NCT05007496",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/28/2021
Mahidol University/ The Government Pharmaceutical Organization (GPO)/ Icahn School of Medicine at Mount Sinai,Vaccine,Replicating viral vector,Phase I/II,Phase I/II began March 2021,"NDV-HXP-S vaccine, with or without the adjuvant CpG 1018 ",NCT04764422,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/7/2022
Fudan University / Shanghai JiaoTong University / RNACure Biopharma,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; LNP-encapsulated mRNA cocktail encoding VLP,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"Greenlight Biosciences
",Vaccine,RNA-based vaccine,Pre-clinical,Unknown,"mRNA
",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/12/2020
Moderna/ National Institute of Allergy and Infectious Diseases (NIAID)/ Biomedical Advanced Research and Development Authority (BARDA)/ Lonza/ Catalent/ Rovi/ Medidata/ BIOQUAL/ Baxter BioPharma Solutions/ Sanofi/ Recipharm,Vaccine,RNA-based vaccine,Authorized,"Phase II/III KidCOVE study positive interim data announced 10/25/2021; Health Canada has approved the New Drug Submission (NDS-CV) for SPIKEVAX™ (elasomeran mRNA vaccine) in individuals 12 years of age and older as of 9/16/21; India granted ""Emergency Use Authorization"" on 6/29/2021; Clinical update on mRNA-1273's neutralizing activity against emerging variants announced 6/29/2021; Submitted authorization application to Swissmedic for use in adolescents on 6/14/2021; Filed for authorization with U.S. FDA for use in adolescents (12-18 years of age) on 6/10/2021; Filed for authorization with Health Canada for use in adolescents on 6/7/2021; Filed for conditional marketing approval (CMA) with the European Medicines Agency (EMA) for use in adolescents on 6/7/2021; Initiated rolling submission process with the U.S. FDA for a Biologics License Application (BLA) on 6/1/2021; Phase II/III study in adolescents met its primary immunogenicity endpoint as of 5/25/2021, data is expected to be submitted to regulators globally in early June 2021; Phase II initial booster data against variants announced 5/5/2021; World Health Organization (WHO) granted Emergency Use Listing (EUL) on 4/30/2021; Antibody persistence data published 4/6/2021; Phase II/III study (KidCOVE) dosed in pediatric population less than 12 years of age on 3/16/2021; Phase I study of next generation COVID-19 vaccine candidate, mRNA-1283, dosed on 3/15/2021; First participants dosed with modified COVID-19 vaccines, designed to address the potential need for booster vaccine candidates, in an amendment to the ongoing Phase II clinical study on 3/10/21; Provided strategy update for addressing SARS-CoV-2 variants of concern, including a variant-specific booster candidate (mRNA-1273.351) based on the B.1.351 variant first identified in the Republic of South Africa, on 2/24/2021; Results from an in vitro study on neutralization of variants of SARS-CoV-2 by mRNA-1273 vaccine-elicited sera announced January 2021; Phase I/II dosed in Japan (TAK-919) on 01/21/2021; Switzerland ""authorized"" on 01/12/2021; U.K. MHRA granted ""temporary authorization"" on 01/08/2021; European Commission granted a ""conditional marketing authorization"" on 01/06/2021; Israel granted ""authorization to import"" on 01/04/2021; Phase III interim safety and primary efficacy results published on 12/30/2020; Health Canada ""authorized"" on 12/23/2020; U.S. FDA issued ""emergency use authorization"" on 12/18/2020; Phase II/III study in adolescents ages 12 to less than 18 dosed on 12/10/2020; Submitted Emergency Use Authorization (EUA) request to the U.S. FDA on 11/30/2020; Phase III primary efficacy analysis results announced 11/30/2020; European Medicines Agency (EMA) started rolling review on 11/17/2020; Phase III interim analysis results announced 11/16/2020; Swissmedic started rolling review on 11/13/2020; UK Medicines and Healthcare products Regulatory Agency (MHRA) started rolling review on 10/27/2020; EMA confirmed marketing authorization submission eligibility on 10/14/2020; Health Canada rolling submission initiated on 10/13/2020; Study protocol for late-stage clinical trials released September 2020; Phase I interim data from older adult cohorts released Aug 2020 and published Sep 2020; Phase III COVE study began July 2020, completed enrollment on 10/22/2020; Animal study results published July/Aug 2020; Phase I interim results published July 2020; FDA fast track designation granted May 2020; Selected for US Operation Warp Speed in April 2020","RNA; LNP-encapsulated mRNA (mRNA 1273), (TAK-919), (TAK-919), (SPIKEVAX™)","NCT04283461, NCT04405076, NCT04470427, NCT04649151, NCT04677660, NCT04712110, NCT04796896, NCT04847050",Coalition for Epidemic Preparedness (CEPI)/ Biomedical Advanced Research and Development Authority (BARDA),"Moderna (https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2022483), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2028436), Moderna (https://www.businesswire.com/news/home/20201116005608/en/Moderna%E2%80%99s-COVID-19-Vaccine-Candidate-Meets-Primary-Efficacy), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMc2032195), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2035389), bioRxiv (https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMc2103916), medRxiv (https://www.medrxiv.org/content/10.1101/2021.05.05.21256716v1), bioRxiv (https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1), Moderna (https://www.businesswire.com/news/home/20211025005471/en/Moderna-Announces-Positive-Top-Line-Data-from-Phase-23-Study-of-COVID-19-Vaccine-in-Children-6-to-11-Years-of-Age), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2203315)",Same platform as vaccine candidates for multiple candidates,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/18/2022
CanSino Biologics/Precision Nanosystems,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; mRNA lipid nanoparticle (mRNA-LNP),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/21/2020
BiOCAD,Vaccine,RNA-based vaccine,Pre-clinical,Animal studies began April 2020,RNA; liposome-encapsulated mRNA,,Unknown,,Same platform as vaccine candidates for cancer   ,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
GeneOne Life Science / Houston Methodist,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,mRNA; (GLS-3000),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/5/2021
eTheRNA Immunotherapies / EpiVax/ Nexelis/ REPROCELL / Centre for the Evaluation of Vaccination of the University of Antwerp,Vaccine,RNA-based vaccine,Pre-clinical,Start Phase I early 2021,RNA; mRNA in an intranasal delivery system (cross-strain protective COV-2 mRNA) vaccine for high-risk populations,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
China CDC / Tongji University / Stermina,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; mRNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Daiichi-Sankyo/ University of Tokyo's Institute of Medical Science,Vaccine,RNA-based vaccine,Phase I/II,Phase II segment of I/II clinical trial began November 2021; Phase I segment of I/II clinical trial began March 2021,RNA; mRNA (DS-5670),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/7/2022
"Arcturus/Duke-NUS/ Catalent
",Vaccine,RNA-based vaccine,Phase II,"Emergency Use Authorization filing in Vietnam could be as soon as December 2021; Phase IIIb (20,000 participants) dosing planned for first week of October 2021; Phase IIIa (600 participants) on track to initiate by end of September 2021; Phase IIa of Phase I/II trial began recruiting January 2021; Received approval to proceed with Phase II study in Singapore (December 2020) and the US (January 2021); Phase I/II interim data released December 2020; Pre-clinical results released September and December 2020; Phase I/II began August 2020, initial results expected Q4 2020; Received approval to launch clinical trials in Singapore end of July 2020","RNA; mRNA; (LUNAR-COV19), (ARCT-021)","NCT04480957, NCT04668339, NCT04728347, NCT05037097",Unknown,,Same platform as vaccine candidates for multiple candidates,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/27/2022
"Centro Nacional Biotecnologia (CNB-CSIC), Spain",Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; Replicating defective SARS-CoV-2 derived RNAs,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Fudan University / Shanghai JiaoTong University / RNACure Biopharma,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; LNP-encapsulated mRNA cocktail encoding RBD,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"RNAimmune, Inc.",Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; several mRNA candidates,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
BioNTech/ Pfizer/ Fosun Pharma/ Rentschler Biopharma,Vaccine,RNA-based vaccine,Authorized,"Phase III topline results from a longer-term analysis in individuals 12 through 15 years of age announced 11/22/2021; U.S. FDA expanded the EUA of a booster dose to include individuals 18 years of age and older as of 11/19/2021; U.S. FDA Advisory Committee voted on 10/26/2021 to recommend the FDA grant Emergency Use Authorization (EUA) for the companies’ COVID-19 vaccine in children 5 to <12 years of age; Phase III topline results of the efficacy and safety of a 30-µg booster dose announced on 10/21/2021; Initial results from Phase II/III study (in participants 5 to 11 years of age) submitted to the U.S. FDA for the Agency’s initial review on 9/28/2021; U.S. FDA  granted EUA for a booster dose in individuals 65 years of age and older, and individuals ages 18 through 64 within certain high-risk groups as of 9/22/2021; Phase II/III study (in participants 5 to 11 years of age) topline results announced 9/20/2021; U.S. FDA approved the Biologics License Application (BLA) for COMIRNATY® to prevent COVID-19 in individuals 16 years of age and older on 8/23/2021; U.S. FDA granted Priority Review designation for the Biologics License Application (BLA) on 7/16/2021 and the Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is in January 2022; Vietnam granted ""emergency use"" approval on 6/12/2021; European Union expanded Conditional Marketing Authorization (CMA) to include individuals 12-15 years of age on 5/28/2021; U.S. FDA expanded Emergency Use Authorization (EUA) to include individuals 12-15 years of age on 5/10/2021; Announced initiation of Biologics License Application (BLA) with the U.S. FDA on 5/7/2021; Phase III updated topline results announced 4/1/2021; Phase III trial in adolescents (12-15 years) topline results announced 3/31/2021; Phase I/II/III continuous study in children 11 years to 6 month old dosed March 2021; Real-world data gathered by the Israel Ministry of Health announced on 3/11/2021; Evaluation of the safety and immunogenicity of a third dose (30 µg booster of the current vaccine) 6 to 12 months after receiving initial two-dose regimen began 2/25/2021; New stability data at standard freezer temperature was submitted to the U.S. FDA as of 2/19/2021; Phase II/III study in healthy pregnant women 18 years of age and older dosed 2/18/2021; Results from in vitro studies on neutralization of variants of SARS-CoV-2 by BNT162b2 vaccine-elicited sera announced January 2021; Phase I (China) preliminary safety and immunogenicity data released January 2021; World Health Organization (WHO) granted Emergency Use Listing (EUL) on 12/31/2021; Argentina authorized under ""emergency registration"" on 12/22/2020; European Commission granted a ""conditional marketing authorisation"" (CMA) on 12/21/2020, following European Medicines Agency (EMA) recommendation to grant CMA; U.S. FDA issued ""emergency use authorization"" on 12/11/2020; Mexico COFEPRIS granted ""emergency use authorization"" on 12/11/2020; Saudi Food and Drug Authority (SFDA) ""approved the registration"" of the vaccine on 12/10/2020; Health Canada ""authorized"" on 12/9/2020; Bahrain granted ""emergency use authorization"" on 12/4/2020; U.K. MHRA granted ""temporary authorization for emergency use"" on 12/2/2020; Submitted Emergency Use Authorization (EUA) request to the U.S. FDA on 11/20/2020; Phase III complete analysis results announced 11/18/2020, interim analysis results announced 11/09/2020; Phase I data published October 2020; FDA approved late-stage trial enrollment of children 12 years and older in October 2020; EMA rolling submission initiated on 10/6/2020; Study protocol for late-stage clinical trials released Sept 2020; Amended protocol to FDA to expand trial enrollment to 44,000 participants; Phase IIb/III trial began Jul 2020; FDA granted Fast Track designation for BNT162b1 and BNT162b2 in Jul 2020; Selected for US Operation Warp Speed in Jul 2020; Phase I/II began Apr 2020; preliminary data released Jul 2020, additional data published Aug, Sept, and Dec 2020; Pre-clinical data released Sept 2020 and Dec 2020","3 LNP-mRNAs; BNT162 
","ChiCTR2000034825, EudraCT 2020-001038-36, EudraCT 2020-003267-26, NCT04368728, NCT04380701, NCT04523571, NCT04537949, NCT04588480, NCT04649021, NCT04713553, NCT04754594",Unknown,"Pfizer (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-early-positive-data-ongoing-0), medRxiv (https://www.medrxiv.org/content/10.1101/2020.06.30.20142570v1), medRxiv (https://www.medrxiv.org/content/10.1101/2020.07.17.20140533v1), Nature (https://www.nature.com/articles/s41586-020-2639-4), medRxiv (https://www.medrxiv.org/content/10.1101/2020.08.17.20176651v1), Nature (https://www.nature.com/articles/s41586-020-2814-7), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2027906?query=featured_home), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2034577?query=featured_home), medRxiv (https://www.biorxiv.org/content/10.1101/2020.12.11.421008v1), medRxiv (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1), Pfizer (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-data-german-phase-12-study), bioRxiv (https://www.biorxiv.org/content/10.1101/2021.01.07.425740v1), bioRxiv (https://www.biorxiv.org/content/10.1101/2021.01.18.426984v1), Research Square (https://www.researchsquare.com/article/rs-137265/v1), BioNTech (https://investors.biontech.de/news-releases/news-release-details/real-world-evidence-confirms-high-effectiveness-pfizer-biontech), Pfizer (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-announce-positive-topline-results-pivotal), Pfizer and BioNTech (https://www.businesswire.com/news/home/20210401005365/en/Pfizer-and-BioNTech-Confirm-High-Efficacy-and-No-Serious-Safety-Concerns-Through-Up-to-Six-Months-Following-Second-Dose-in-Updated-Topline-Analysis-of-Landmark-COVID-19-Vaccine-Study); Pfizer and BioNTech (https://www.businesswire.com/news/home/20210920005452/en/), Pfizer (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-phase-3-trial-data-showing), Pfizer (https://www.pfizer.com/news/press-release/press-release-detail/follow-data-phase-3-trial-pfizer-biontech-covid-19-vaccine)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/28/2022
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; mRNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/31/2020
Ziphius Therapeutics/ Ghent University,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,"RNA; ZIP-1642, vaccine consists of a combination of mRNA molecules, encoding multiple SARS-CoV-2 antigens",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
"IDIBAPS- Hospital Clinic, Spain",Vaccine,RNA-based vaccine,Pre-clinical,Unknown,mRNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/1/2020
Max-Planck Institute of Colloids and Interfaces,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,LNP-encapsulated mRNA encoding S,,KHAN-1 Technology Transfer Fund I GmbH & Co KG,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/9/2020
Chimeron Bio/ George Mason University's National Center for Biodefense and Infectious  Disease,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,"Self amplifying RNA, self-assembling delivery system",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
Chulalongkorn University/ Chula Vaccine Research Center/University of Pennsylvania,Vaccine,RNA-based vaccine,Phase I/II,Phase II began August 2021; Phase I began June 2021,LNP-mRNA; (ChulaCov19),NCT04566276,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/3/2021
People's Liberation Army (PLA) Academy of Military Sciences/ Walvax Biotech,Vaccine,RNA-based vaccine,Phase II,Phase III expected to begin late May 2021; Phase II began January 2021; Phase Ib began end of October 2020; Pre-clinical results published September 2020; Phase I trial began end of June 2020,mRNA (ARCoV),"ChiCTR2000034112, ChiCTR2000039212, ChiCTR2100041855, NCT04847102",Unknown,"Cell (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377714/#__ffn_sectitle), Lancet (https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00280-9/fulltext)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/27/2022
Selcuk University,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,mRNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Gennova/ HDT Biotech Corporation,Vaccine,RNA-based vaccine,Phase I/II,Mid-stage trials expected to begin September 2021; Phase I/II began April 2021,Self-amplifying mRNA vaccine; (HGCO19),CTRI/2021/04/032688,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/16/2022
Elixirgen Therapeutics/ Fujita Health University,Vaccine,RNA-based vaccine,Phase I/II,Entered into an exclusive licensing agreement with a global pharmaceutical company (currently undisclosed) in October 2021; Phase I/II began at Fujita Health University Hospital in May 2021,srRNA (EXG-5003),NCT04863131,Japan Agency for Medical Research and Development (AMED),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/27/2021
"Globe Biotech Limited, Bangladesh",Vaccine,RNA-based vaccine,Pre-clinical,Pre-clinical study published June 2021; Phase I/II protocol submitted to Bangladesh Medical Research Council (BMRC) on 1/17/2021 for approval to begin clinical trials; Pre-clinical data released September 2020,"D614G variant LNP-encapsulated mRNA; (BANCOVID), (BANGAVAX)",,Unknown,"bioRxiv (https://www.biorxiv.org/content/10.1101/2020.09.29.319061v1), Vaccine (https://www.sciencedirect.com/science/article/pii/S0264410X21006071)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2021
"Infectious Disease Research Institute/ Amyris, Inc.",Vaccine,RNA-based vaccine,Pre-clinical,Phase I expected to begin mid-2021,saRNA formulated in a NLC,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/16/2020
GlaxoSmithKline/CureVac,Vaccine,RNA-based vaccine,Pre-clinical,"Pre-clinical data published 11/18/2021; Pre-clinical data released 5/13/2021; CureVac and GSK aim to develop a multi-valent candidate vaccine to address emerging variants for pandemic and endemic use; Development to begin immediately (February 2021) targeting vaccine availability in 2022, subject to regulatory approval",Next-generation multi-valent mRNA-based vaccine; (CV2CoV),,Unknown,"bioRxiv (https://www.biorxiv.org/content/10.1101/2021.05.13.443734v1), Nature (https://www.nature.com/articles/s41586-021-04231-6)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/29/2021
CureVac/UK Government (Vaccines Taskforce),Vaccine,RNA-based vaccine,Pre-clinical,Collaboration to develop and manufacture variant vaccines for commercial supply and distribution in the UK and its territories was entered in February 2021,Multiple mRNA vaccine candidates against SARS-CoV-2 variants ,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/5/2021
Providence Therapeutics Holdings Inc.,Vaccine,RNA-based vaccine,Phase I,Phase II expected to begin June 2021; Pre-clinical results released May 2021; Phase I interim data announced May 2021; Phase I dosed January 2021,PTX-COVID19-B vaccine,NCT04765436,Unknown,"Providence Therapeutics (https://www.providencetherapeutics.com/providence-therapeutics-announces-very-favorable-interim-phase-1-trial-data-for-ptx-covid19-b-its-mrna-vaccine-against-covid-19), bioRxiv (https://www.biorxiv.org/content/10.1101/2021.05.11.443286v1)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/21/2021
SENAI CIMATEC/ HDT Bio Corp,Vaccine,RNA-based vaccine,Pre-clinical,Phase I expected to begin July 2021,"Lipid-Inorganic Nanoparticle (LION™) formulated replicating RNA-based vaccine, (HDT-301)",NCT04844268,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/6/2021
Moderna/National Institute of Allergy and Infectious Diseases (NIAID),Vaccine,RNA-based vaccine,Phase I,Initial booster data announced May 2021; Phase I began March 2021,RNA; LNP-encapsulated mRNA (mRNA 1273.351),"NCT04785144, NCT04405076",Unknown,Moderna (https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-initial-booster-data-against-sars-cov),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/19/2022
"ModernaTX,
  Inc.",Vaccine,RNA-based vaccine,Phase I,"Phase I study of next generation COVID-19 vaccine candidate, mRNA-1283, dosed March 2021",RNA; LNP-encapsulated mRNA (mRNA 1283),NCT04813796,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/6/2021
"ModernaTX,
  Inc.",Vaccine,RNA-based vaccine,Phase II/III,Phase II/III began May 2021,RNA; LNP-encapsulated mRNA (mRNA 1273.211), NCT04927065,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2021
Monash Institute of Pharmaceutical Sciences (MIPS)/ Peter Doherty Institute for Infection and Immunity (Doherty Institute),Vaccine,RNA-based vaccine,Pre-clinical,Phase I expected to begin October 2021; Preliminary trial results are expected in the first half of 2022,mRNA second generation COVID-19 vaccine ,,"mRNA Victoria, the agency of the Australian State of Victoria Government",,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/29/2021
"ModernaTX, Inc.",Vaccine,RNA-based vaccine,Pre-clinical,Rapidly advancing an Omicron-specific booster candidate (mRNA-1273.529) as of 11/26/2021,RNA; LNP-encapsulated (mRNA-1273.529),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/3/2021
University of Manitoba,Vaccine,Virus-like particle,Pre-clinical,Unknown,Virus-like particle-based dendritic cell-targeting vaccine,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/9/2020
Medicago Inc./ GlaxoSmithKline,Vaccine,Virus-like particle,Phase II/III,Phase II interim results released May 2021; Health Canada initiated review of the Interim Order (IO) rolling submission on 4/19/2021; Phase III portion of the ongoing Phase II/III trial began March 2021;Phase II portion of the Phase II/III trial dosed December 2020; Phase II/III began recruiting November 2020; Phase I interim results released November 2020; Phase I began July 2020,VLP; plant-derived VLP adjuvanted with GSK or Dynavax adjuvants; (CoVLP),"NCT04450004, NCT04636697, NCT04662697",Unknown,"medRxiv (https://www.medrxiv.org/content/10.1101/2020.11.04.20226282v1.full), medRxiv (https://www.medrxiv.org/content/10.1101/2021.05.14.21257248v1), New England Journal of Medicine (https://www.nejm.org/doi/pdf/10.1056/NEJMoa2201300?articleTools=true), New England Journal of Medicine (https://www.nejm.org/doi/full/10.1056/NEJMoa2201300#:~:text=The%20CoVLP%2BAS03%20vaccine%20was,moderate%2Dto%2Dsevere%20disease)","Same platform as vaccine candidates for flu, rotavirus, norovirus, West Nile virus, and cancer",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/3/2022
"ARTES Biotechnology
",Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP; eVLP,,Unknown,,"Same platform as vaccine candidates for malaria
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
University of Sao Paulo,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLPs peptides/whole virus,,Unknown,,,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
VBI Vaccines / National Research Council of Canada/ Therapure Biomanufacturing,Vaccine,Virus-like particle,Pre-clinical,"Phase I/II trial of VBI-2902a expected to begin March 2021; Phase I trial of VBI-2905, targeting the B.1.351 variant, expected to begin mid-year 2021","Enveloped virus-like particle (eVLP): Pan-coronavirus vaccine candidate, targeting COVID-19, SARS, and MERS, spike protein (VBI-2900)",NCT04773665,Coalition for Epidemic Preparedness (CEPI),,"Same platform as vaccine candidates for glioblastoma, cytomegalovirus, and Zika",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/14/2021
Saiba GmbH,Vaccine,Virus-like particle,Pre-clinical,Unknown,"VLP; virus-like particle, based on RBD displayed on virus-like particle",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Doherty Institute,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP; unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
Imophoron Ltd / Bristol University's Max Planck Centre,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP; ADDomerTM multiepitope display,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
OSIVAX,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP (COVID-19 and SARS1),,European Innovation Council (EIC),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Mahidol University/ The Government Pharmaceutical Organization (GPO)/ Siriraj Hospital,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP + Adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
"Navarrabiomed, Oncoimmunology group",Vaccine,Virus-like particle,Pre-clinical,Unknown,"Virus-like particles, lentivirus, and baculovirus vehicles",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/1/2020
IrsiCaixa AIDS Research/ IRTA-CReSA/ Barcelona Supercomputing Centre/ Grifols,Vaccine,Virus-like particle,Pre-clinical,Unknown,S protein integrated in HIV VLPs,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/23/2020
Scientific and Technological Research Council of Turkey (TÜBITAK)/ Middle East Technical University/ Bilkent University,Vaccine,Virus-like particle,Phase I,Phase II expected to begin early June 2021; Phase I dosed end of March 2021,VLP,NCT04818281,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2021
Medicago Inc./ Dynavax,Vaccine,Virus-like particle,Pre-clinical,Phase I to start mid-July 2020,VLP (CoVLP)+ Adjuvant (CpG 1018),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/10/2020
"Medicago
  Inc./ GSK",Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP (CoVLP)+ Adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/14/2020
Bezmialem Vakif University,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/21/2020
Serum Institute of India/ Accelagen Pty/ SpyBiotech,Vaccine,Virus-like particle,Phase I/II,Phase I of follow up Phase I/II clinical trial adjuvanted with CpG 1018 dosed December 2020; Phase I/II began September 2020,RBD SARS-CoV-2 HBsAg VLP vaccine,"ACTRN12620000817943, ACTRN12620001308987",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/17/2021
Tampere University,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLPs produced in BEVS,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/9/2020
Max-Planck Institute for Dynamics of Complex Technical Systems,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/9/2020
Icosavax,Vaccine,Virus-like particle,Phase I/II,"Phase I/II began June 2021; Pre-clinical results published October 2020, Topline results published March 2022. ",VLP displaying the SARS-CoV-2 receptor-binding domain (RBD); (IVX-411),,Unknown,"BioSpace (https://www.biospace.com/article/releases/icosavax-announces-topline-interim-phase-1-2-results-for-ivx-411-against-sars-cov-2/), Icosavax (https://investors.icosavax.com/news-releases/news-release-details/icosavax-announces-topline-interim-phase-12-results-ivx-411)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/28/2022
Arizona State University ,Vaccine,Virus-like particle,Pre-clinical,Unknown,"Myxoma virus co-expressing S, M, N and E proteins ",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/12/2021
Arizona State University ,Vaccine,Virus-like particle,Pre-clinical,Unknown,"Plasmid driven production of virus like particles (VLPs) containing S, M, N and E proteins of SARS-CoV-2",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/12/2021
Radboud University,Vaccine,Virus-like particle,Phase I,Phase I of I/II study began March 2021,"ABNCoV2 capsid virus-like particle, formulated with and without the adjuvant MF59","NCT04839146, NCT05329220",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/15/2022
"Catholic University/ Millennium Institute of Immunology and Immunotherapy/ Technological Consortium in Clinical Molecular Biomedicine, Chile",Vaccine,Unknown,Pre-clinical,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/23/2020
Tulane University,Vaccine,Unknown,Pre-clinical,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
ISR Immune System Regulation,Vaccine,Unknown,Pre-clinical,"Animal study results expected in Q2 2020, Phase I begins Q4 2020",ISR-50,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
HaloVax (Voltron Therapeutics) / The Vaccine & Immunotherapy Center at the Massachusetts General Hospital,Vaccine,Unknown,Pre-clinical,Animal study results by October 2020,"Self-assembling vaccine (fusion protein of a heat shock protein and Avidin, with biotinylated immunogenic peptides)",,Analog Devices Foundation,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/21/2020
Vir Biotechnology / GSK,Vaccine,Unknown,Pre-clinical,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
AbVision,Vaccine,Unknown,Pre-clinical,Unknown,AVI-205,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/13/2020
Precision Vaccines Program at Boston Children's Hospital,Vaccine,Unknown,Pre-clinical,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"Oragenics (Noachis Terra)/ Aragen Bioscience
",Vaccine,Unknown,Pre-clinical,Phase I expected to start in early 2021,"TerraCoV2
",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/28/2020
Vivaldi Biosciences/ Esco Aster Pte Ltd,Vaccine,Unknown,Pre-clinical,Unknown,Chimeric vaccine (coronavirus and influenza),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/2/2020
Adeleke University,Vaccine,Unknown,Pre-clinical,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
Codiak BioSciences/ Ragon Institute,Vaccine,Unknown,Pre-clinical,Unknown,exoVACC exome platform,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/4/2020
Vault Pharma/ University of California Los Angeles,Vaccine,Unknown,Pre-clinical,Unknown,nanoparticles (vaults) as second-line defense of infection,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
NidoVax,Vaccine,Unknown,Pre-clinical,Unknown,unknown; IMT504 technology,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/18/2020
"United
  Biomedical (UBI)/ c19",Vaccine,Unknown,Pre-clinical,,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/2/2020
"University of California, Los Angeles (Horwitz Lab)",Vaccine,Replicating bacterial vector,Pre-clinical,Unknown,Recombinant LVS ΔcapB – vectored vaccine expressing multiple SARS-CoV-2 antigens,,Unknown,,Same platform as vaccines against select agents and emerging pathogens,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/10/2020
Farmacológicos Veterinarios SAC (FARVET SAC),Vaccine,Replicating bacterial vector,Pre-clinical,Unknown,Oral Salmonella enteritidis (3934Vac) based protein expression system of RBD,,Unknown,,Same platform as multiple vaccine candidates,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/19/2021
Altimmune / University of Alabama at Birmingham/ Summit Biosciences,Dormant / Discontinued,Dormant / Discontinued,Phase I,"Discontinued further development of AdCOVID as of June 29, 2021; Phase I data expected to be released June 2021; Additional pre-clinical data released March and May 2021; Phase I commenced enrollment on 2/25/2021; FDA issued clinical hold for planned Phase I trial on 12/22/2020; Pre-clinical data released October 2020","AdCOVID; single-dose, intranasal vaccine; non replicating viral vector; adenovirus-based NasoVAX expressing spike protein",NCT04679909,Unknown,"bioRxiv (https://www.biorxiv.org/content/10.1101/2020.10.10.331348v1), Altimmune (http://www.globenewswire.com/news-release/2021/03/15/2192650/0/en/AdCOVID-Altimmune-s-Single-Dose-Intranasal-COVID-19-Vaccine-Candidate-Prevents-SARS-CoV-2-induced-Disease-and-Blocks-Viral-Replication-in-Preclinical-Studies-of-SARS-CoV-2-Infectio.html), Altimmune (https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-new-preclinical-data-adcovidtm-demonstrating)",Same platform as vaccine candidates for influenza,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2021
Institut Pasteur/ Themis/ University of Pittsburgh CVR/ Merck Sharp & Dohme,Dormant / Discontinued,Dormant / Discontinued,Phase I/II,Development discontinued following review of Phase I findings on 1/25/2021; Phase I results to be submitted for publication; Phase I/II began September 2020; Animal testing began April 2020,Replicating viral vector; measles vector (V591); formerly (TMV-083),"NCT04497298, NCT04498247",Coalition for Epidemic Preparedness (CEPI),,"Same platform as vaccine candidates for West nile, CHIKV, Ebola, Lassa, Zika, MERS",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/25/2021
IAVI/ Merck,Dormant / Discontinued,Dormant / Discontinued,Pre-clinical,Development discontinued following review of Phase I findings on 1/25/2021; Phase I results to be submitted for publication; Phase I enrollment began November 2020; Selected for US Operation Warp Speed in April 2020; clinical studies to start in 2020,"Replicating viral vector, replication-competent VSV chimeric virus technology (VSVdeltaG) delivering the SARS-CoV-2 Spike (S) glycoprotein; (V590)",NCT04569786,Biomedical Advanced Research and Development Authority (BARDA); Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DoD),,"Same platform as vaccine candidates for Ebola, Marburg, Lassa (including FDA-licensed Ebola vaccine, ERVEBO®)",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/25/2021
Wuhan Jinyintan Hospital,Dormant / Discontinued,Dormant / Discontinued,Clinical,"No trial updates since February 2020
","AiRuiKa (camrelizumab), anti-programmed cell death protein (PD-1) antibody",ChiCTR2000029806,Unknown,,Treatment of certain cancers,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/27/2020
CureVac/Bayer/Novartis,Dormant / Discontinued,Dormant / Discontinued,Phase III," CureVac announced its decision to withdraw its first-generation COVID-19 vaccine candidate (CVnCoV) from the current approval process with the European Medicines Agency (EMA) as of 10/12/2021; Phase IIb/III final analysis results released 6/30/2021; Phase IIb/III second interim analysis results released 6/16/2021; Initiated rolling submission with Swissmedic on 4/19/2021; Initiated rolling submission with European Medicines Agency (EMA) on 2/12/2021; Phase III trial began December 2020; Phase IIb/III (HERALD) trial began recruiting December 2020; Phase IIa trial began end of September 2020; Phase I trial began June 2020, interim results reported November 2020; Pre-clinical data released October 2020",RNA; mRNA (CVnCoV),"EudraCT 2020-004066-19, NCT04449276, NCT04515147, NCT04652102, NCT04674189, PER-054-20",Coalition for Epidemic Preparedness (CEPI); European Commission; Gates Foundation; Defense Advanced Research Projects Agency (DARPA); German Government; European Investment Bank (EIB); German Federal Ministry of Education and Research (BMBF),"CureVac (https://www.curevac.com/en/2021/06/16/curevac-provides-update-on-phase-2b-3-trial-of-first-generation-covid-19-vaccine-candidate-cvncov/), CureVac (https://www.curevac.com/en/2021/06/30/curevac-final-data-from-phase-2b-3-trial-of-first-generation-covid-19-vaccine-candidate-cvncov-demonstrates-protection-in-age-group-of-18-to-60/)","Same platform as vaccine candidates for RABV, LASV, YFV, MERS, InfA, ZIKV, DengV, NIPV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/26/2021
Sanofi / Regeneron; Feinstein Institutes; REMAP-CAP global trial,Dormant / Discontinued,Dormant / Discontinued,Clinical,"Phase III (US) results released July 2020 and US trial stopped, Phase III (ex-US in severe and critical hospitalized patients continues) results expected 3Q 2020; trials outside of US stopped","Kevzara (sarilumab), interleukin-6 receptor antagonist","NCT04315298, NCT04321993, NCT04341870, NCT04324073, NCT04327388, NCT04322773, NCT04345289, NCT02735707, NCT04357808, NCT04357860, NCT04359901, EudraCT 2020-001246-18, EudraCT 2015-002340-14 (REMAP-CAP), EudraCT 2020-001367-88, EudraCT 2020-001854-23, EudraCT 2020-001246-18, EudraCT Number: 2020-001745-40, EudraCT Number: 2020-001275-32, EudraCT Number: 2020-001531-27, EudraCT Number: 2020-001290-74, EudraCT Number: 2020-001634-36, EudraCT Number: 2020-001162-12, EudraCT Number: 2020-001255-40, EudraCT Number: 2020-002037-15, NCT04386239, NCT04380519, NCT04366206",Biomedical Advanced Research and Development Authority (BARDA),"medRxiv (https://doi.org/10.1101/2020.04.23.20076612)Regeneron (https://newsroom.regeneron.com/index.php/news-releases/news-release-details/regeneron-and-sanofi-provide-update-us-phase-23-adaptive)ChinaXiv (http://www.chinaxiv.org/abs/202003.00026)medRxiv (https://doi.org/10.1101/2020.05.14.20094144), Regeneron (https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-provide-update-kevzarar-sarilumab-phase-3)",,"FDA-approved since 2017, approved to treat rheumatoid
 arthritis",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/2/2020
Imperial College London/ VacEquity Global Health,Dormant / Discontinued,Dormant / Discontinued,Phase I/II,"Not advancing to late-stage clinical trials, but the saRNA technology is being modified to produce a more consistent and strong response, even at very low dose levels, and will pursue trials with updated vaccine candidates; Phase I data released July 2021; Pre-clinical results published July 2020; Phase I/II trial began June 2020",RNA; LNP-nCoVsaRNA,ISRCTN17072692,UK Government,,"Same platform as vaccine candidates for EBOV, LASV, MARV, Inf (H7N9), RABV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/29/2020
"Hu'nan Haiyao hongxingtang Pharmaceutical Co., Ltd (Novaferon) 
",Dormant / Discontinued,Dormant / Discontinued,Clinical,Unknown,"Novaferon, Nova, interferon, licensed in China for Hepatitis B","ChiCTR2000029573       

ChiCTR2000029496",Unknown,medRxiv (https://doi.org/10.1101/2020.04.24.20077735),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/27/2020
Sanofi Pasteur/ Translate Bio,Dormant / Discontinued,Dormant / Discontinued,Phase I/II,"Phase I/II study interim results announced September 2021; Phase I/II began March 2021, interim results expected in 3Q 2021; Pre-clinical results released October 2020","LNP-mRNA
",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/28/2021
The First Affiliated Hospital of Fujian Medical University/Novartis,Dormant / Discontinued,Dormant / Discontinued,Clinical,,"Gilenya (fingolimod), sphingosine 1-phosphate receptor modulator",NCT04280588,Unknown,,,"FDA-approved since 2010, approved to treat multiple sclerosis",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/27/2020
University of Queensland/CSL/Seqirus,Dormant / Discontinued,Dormant / Discontinued,Phase I,Phase I results released February 2021; Phase II/III trials will not proceed following Phase I completion (announced 12/11/2020); Phase I trial began July 2020,Protein subunit; molecular clamp stabilized Spike protein with MF59 adjuvant,"ACTRN12620000674932p,  ISRCTN51232965, NCT04495933",Coalition for Epidemic Preparedness (CEPI)/Queensland Government/Federal Government (Australia)/Paul Ramsay Foundation,Preprints with The Lancet (https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3769210),"Same platform as vaccine candidates for Nipah, influenza, Ebola, Lassa",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/16/2021
The First Affiliated Hospital of Guangzhou Medical University,Dormant / Discontinued,Dormant / Discontinued,Clinical,,Recombinant ACE2 (angiotensin-converting enzyme 2),NCT04287686 ,,Study stopped before recruitment,,Unknown,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
The Second Hospital of Nanjing Medical University,Dormant / Discontinued,Dormant / Discontinued,Clinical,,Washed microbiota transplantation,NCT04251767,,Study stopped before recruitment,,Unknown,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"Mianyang Central Hospital 
",Dormant / Discontinued,Dormant / Discontinued,Clinical,"Chinese trial site last updated March 30, 2020
","Combination of ebastine, lopinavir, and interferon alpha
",ChiCTR2000030535,,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/7/2020
Numerous trials with Chinese research sponsors,Dormant / Discontinued,Dormant / Discontinued,Clinical,"Chinese trial site last updated February 16, 2020 - March 4, 2020 for various trials ","azvudine, reverse transcriptase inhibitor
","ChiCTR2000030487

ChiCTR2000030424

ChiCTR2000029853",,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/7/2020
"Roche/the First Hospital Affiliated to Zhejiang University's Medical School
",Dormant / Discontinued,Dormant / Discontinued,Clinical,"Chinese trial site last updated February 12, 2020 
","Xofluza (baloxavir marboxil), polymerase acidic endonuclease inhibitor
","ChiCTR2000029544

ChiCTR2000029548",,medRxiv (https://doi.org/10.1101/2020.04.29.20085761) (ChiCTR2000029544),,"FDA-approved since 2018, approved to treat influenza
",https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/10/2020